The role of TAF proteins during early zebrafish development by Zaucker, Andreas
  
 
THE ROLE OF TAF PROTEINS DURING EARLY 
ZEBRAFISH DEVELOPMENT 
 
by 
ANDREAS ZAUCKER 
 
A thesis submitted to 
The University of Birmingham 
for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
 
College of Medicine & Dentistry 
The University of Birmingham 
April 2011 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third parties. 
The intellectual property rights of the author or third parties in respect of this work 
are as defined by The Copyright Designs and Patents Act 1988 or as modified by 
any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission of 
the copyright holder.  
 
 
 
I 
 
Abstract 
Replacement of the prototype promoter recognition factor (PRF) TFIID by alternative PRFs or 
changes in its subunit composition have recently been implicated in differentiation processes 
during development. TFIID is composed of TBP (TATA-binding protein) and 13 TAFs (TBP-
associated factors). I comprehensively studied the roles of Tafs during vertebrate development 
using zebrafish model. 
Taf knock down (kd) phenotypes generated in an antisense morpholino oligonucleotide (MO) 
screen suggest differential functions of Tafs during zebrafish development. The kd phenotypes 
also propose a special requirement of DNA-binding Tafs during zebrafish development. 
In conjunction with zygotic mutant phenotype analysis of zebrafish taf8-mutants compared to 
taf6-mutants I investigated a potential coactivator function of Taf8 for Pparγ, which has been 
suggested by in vitro data. Oil Red O (ORO) stainings of 5 dpf (days post fertilisation) taf8- and 
taf6-mutant larvae revealed a specific lipogenesis defect in liver and intestine of taf8-mutant 
larvae. The results from treatments with a PPARγ inhibitor suggest that this lipogenic process is 
Pparγ-dependent. To convincingly establish a coactivator function of Taf8 for Pparγ during early 
zebrafish development, future work has to link the 5 dpf lipogenesis phenotype of taf8-mutants to 
defects in Pparγ-dependent transcription. 
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1 Introduction 
1.1 Transcriptional regulation on the core promoter level 
1.1.1 Overview of transcriptional regulation 
The first step in the utilisation of the information encoded by the DNA (deoxyribonucleic acid) is 
its transcription into RNA (ribonucleic acid). This process ultimately results in macromolecules 
(gene products), RNAs and proteins, which determine the identity and behaviour of the cell. 
Transcription of genomic DNA in eukaryotes is carried out by three different DNA-dependent 
RNA-polymerases (Pol I, II, or III), each of them responsible for the production of different types 
of transcripts (rRNA, mRNA and small RNAs respectively). If not stated otherwise, the 
transcription of protein coding genes by Pol II is discussed in this thesis. The genomic DNA not 
only encodes for proteins (genomic code) but also contains a code for the spatiotemporal control 
of transcription, the regulatory code. The regulatory code is contained in sequences controlling 
the transcription of their target genes mostly in cis. Those sequences are therefore called cis-
regulatory elements (CREs). The cis-regulatory elements are recognised and interpreted by trans-
acting factors. Trans-acting factors are mostly proteins and protein-complexes, but RNAs can 
also be involved. Some of these proteins, so called transcription factors (TF), can directly bind to 
small sequence motifs within CREs. CREs can be classified into three categories, based on 
distance to the transcription start site (TSS): 
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1. Core promoter elements (or motifs) are located within the core promoter of genes. The 
core promoter is defined as the minimal sequence required for directing accurate 
transcription initiation by Pol II in vitro. The core promoter encompasses the sequences 
40 bp (base pairs) upstream and downstream of the TSS. 
2. Proximal Elements are CREs within several hundreds of base pairs upstream of the TSS. 
3. Distal Elements are CREs located further away from the TSS. They can be several 
kilobases (kb) up to megabases (Mb) away from the TSS of their target genes. There is no 
clear functional distinction between distal and proximal promoter. 
CREs and trans-acting factors are embedded in so called gene regulatory networks, which control 
the expression of the genes within the network. 
Transcription is to a great extent regulated at the step of transcription initiation. However, the 
transcription of many genes, up to one third, might also to be regulated at the elongation step 
(Levine, 2011). The regulation of transcription initiation is a very complex process, involving 
various multiprotein complexes and CREs (Figure 1.1). Some of the multiprotein complexes, e.g. 
the chromatin modifying and the chromatin remodelling complexes, control if the chromatin 
template is in a state, which is accessible for the transcription machinery. The order and the cause 
effect relationship of the events are not fully understood, but all these regulatory inputs converge 
on the core promoter, to either block or facilitate the formation of a preinitiation complex (PIC). 
The PIC recruits and activates Pol II for transcription of the downstream gene. 
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Figure 1.1 – Multiprotein complexes involved in transcriptional regulation 
Schematic representation of protein complexes and cis-regulatory elements involved in the 
regulation of transcription initiation. The regulatory code embedded in distal elements (DE), 
proximal elements (PE), the core promoter and also the chromatin, is interpret by transacting 
protein complexes. There is an extensive interplay of the components involved, represented by 
the arrows in the figure. This interplay and the order of these regulatory events are not fully 
understood. But generally can be said that the formation of a preinitiation complex on the core 
promoter is either stimulated or blocked, depending on the protein-protein interactions on the cis-
elements. Figure modified from (Hochheimer and Tjian, 2003). 
1.1.1.1 Chromatin as a regulator of transcription 
In vivo the template for Pol II is not DNA, but chromatin, which is a complex of DNA and 
proteins. The principal subunit of chromatin is the nucleosome. A nucleosome consists of ≈146 
bp of DNA wrapped around a histone-octamer, which is a complex of a histone H3/H4-tetramer 
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sandwiched between two histone H2A/H2B-dimers. The site where the DNA enters and leaves 
the octamer is covered by histone H1. Chromatin plays a major role in transcriptional regulation, 
as it can switch between states which do, or do not favour transcription. It can be in an open, 
nucleosome depleted state, which is accessible for the transcription machinery and recruits 
factors with an activating effect on transcription. The opposite, silenced state is characterised by 
densely packed nucleosomes. This chromatin is less accessible for the transcription machinery 
and recruits factors with a silencing effect on transcription. 
Many of the changes between the two states are associated with posttranslational modifications of 
the N-terminal domains (histone tails) of the histones in nucleosomes. Postranslational 
modifications described for histones are: Acetylation, methylation, phosphorylation, 
monoubiquitination, sumoylation and ADP-ribosylation ((Smith and Shilatifard, 2010) and 
references therein)). A histone modifications which is associated with transcriptionally active 
chromatin is H3K4me3 (histone H3 tri-methylated at lysine K4), whereas the H3K27me3 
modification is indicative of a repressed state (Mikkelsen et al., 2007, Rosenfeld et al., 2009). 
Both marks can be found together in the promoter regions of a set of genes in ESCs (Embryonic 
Stem Cells) which is enriched for developmental regulators (Bernstein et al., 2006). It has been 
hypothesised that bivalent promoters facilitate the rapid activation of genes in certain lineages 
during development. However, the significance of bivalent domains is under debate (B. M. Lee 
and Mahadevan, 2009). Histone acetylation, in particular H3K9ac, is associated with an open 
chromatin state on regulatory regions and with transcription (Roh et al., 2005). Proteins involved 
in transcriptional regulation often contain domains which can bind to modified residues of 
histones. Bromodomains for example bind to acetylated lysines (Mujtaba et al., 2007), whereas 
chromodomains, MBT (mid-blastula transition) repeats and PHD-fingers (plant homeodomain) 
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bind to methylated lysines (Bonasio et al., 2010, Champagne and Kutateladze, 2009, Yap and 
Zhou, 2011). 
1.1.1.2 Proteins and complexes on enhancers 
Enhancers are cis-regulatory sequences with stimulating effect on the transcription rate of their 
target genes. Accordingly, they contain binding sites for so called (transcriptional) activators. 
Activators are transcription factors, a class of proteins which bind to DNA to regulate 
transcription of a subset of genes, which are regarded as the TF’s target genes. The structure of 
TFs is modular, comprising a DNA-binding domain (DBD) and a (trans)activation domain (AD). 
The TF uses the DBD to bind to short (6-12 bp) sequence motifs. The sequence motifs are called 
transcription factor binding sites (TFBS). The DBD is not unique for each TF. Only a limited 
number of DBDs seem to have evolved in nature, some of them are found only in certain 
branches of the tree of life, like the Dof domain proteins in plants (Yanagisawa, 2004). 
Accordingly most of the TFs in a given organism share their DBD with other TFs and the DBD 
can be used to classify TFs. The DNA-binding domain is the hallmark of a TF and the sequence 
motif encoding for it can be used to identify TFs in a sequenced genome. The AD, as the name 
suggests, is a domain responsible for the activating function of the activator on the transcription 
rate of its target genes. This domain provides surfaces for protein-protein interactions with either 
co-regulators or the PIC on the core promoter. A reoccurring principle is that TFs often bind to 
enhancers in combination with other activators, to form a complex on the enhancer called 
enhanceosome (Panne, 2008). The specific combination of TFs in the enhanceosome is thought to 
define the specific function of the enhancer. 
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1.1.1.3 Co-regulators and protein complexes linking enhancers to 
promoters 
How do activators bound to distal sites influence the transcription rate of their target genes? The 
current view is that they do this in two ways: 
1. Activators recruit co-regulators with enzymatic activities which render the chromatin into 
an open state, which is accessible for the transcription machinery (Visel et al., 2009). 
2. Activators directly, or indirectly via co-regulators, interact with general transcription 
factors (GTFs) to stabilise the PIC. GTFs and their subunits are all the proteins within the 
PIC, which do not belong to Pol II (Wright and Tjian, 2009). 
Both principles require that the enhancer and promoter come in close proximity to each other, 
which would result in a looping of the DNA. Indeed DNA-loops have been demonstrated (Carter 
et al., 2002). The higher order organisation of chromatin defines which sequences can potentially 
interact with each other. Factors which are shaping the higher order organisation of chromatin, 
like CTCF (CCCTC-binding factor) and cohesin, have accordingly been implicated in 
transcriptional regulation (Kagey et al., 2010, Phillips and Corces, 2009). 
One mechanism for the regulation of transcription by co-regulators lies within their histone 
modifying activities. Histone actylation and deacytylation have been shown to have an inverse 
effect on transcription. Histone acetylation weakens the interaction of histones with DNA. This 
resolves the repressive effect of chromatin on transcription. The opposite is the case for histone 
deacetylation. Accordingly, many transcriptional co-regulators are themselves HATs (histone 
acetyl transferases), or they recruit HATs. The inverse is the case for co-reppressors, which often 
are HADCs (Anamika et al., 2010, Viswakarma et al., 2010). 
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Figure 1.2 – Coactivators of transcription 
The figure depicts the various types of coactivators which have been described in the literature. 
Some of those coactivators are mediating interactions between transcriptional activators and the 
basal transcription machinery (TAFs, Mediator, TFIIA and SAGA). Others have a chromatin 
modifying activity (HAT) which opens up the chromatin to facilitate transcription (SAGA, 
TAFs). Modified from (Martinez, 2002). 
 
One complex mediating the indirect interaction of enhancers with promoters is called Mediator 
Complex. The Mediator complex interacts with numerous activators and Pol II, such forming a 
bridge between the enhancer and the basal transcription machinery on the core promoter. Another 
class of such complexes is the SAGA complex (Spt-Ada-Gcn5-Acetyltransferase). SAGA first 
has been described in yeast, followed by the discovery of complexes (TFTC, STAGA, PCAF), 
with an overall very similar subunit composition, in other organisms. Therefore, it has been 
suggested to collectively refer to them as SAGA, or SAGA-like complexes (Pijnappel and 
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Timmers, 2008). Furthermore these complexes harbour the yeast histone acetyl transferase Gcn5 
(general control nonderepressable 5), or homologs of it. 
1.1.1.4 Promoter recognition factors 
Pol II itself does not recognise promoters and requires accessory factors for site-specific 
transcription initiation. Those accessory factors ( TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH) 
have been biochemically purified in human HeLa cells. They are collectively referred to as GTFs. 
Their naming uses following nomenclature: TF (transcription factor) II (Pol II-driven 
transcription) X (chromographic fraction of isolation). All GTFs, except TFIIE, are themselves 
multiprotein complexes. One component of a PIC has to be able to distinguish promoters from 
the rest of the genome, based on sequence motifs and/or histone marks, and to nucleate PIC 
assembly (promoter recognition factor). The classical promoter recognition factor is TFIID, 
which is composed of TATA-binding protein and up to 13-14 TAFs. In the classical model of 
PIC formation TFIID, bound to core-promoters via its subunit TBP, nucleates the assembly of a 
stereotypic set of GTFs and Pol II into a PIC. There are two models for the precise order of PIC 
assembly (Thomas and Chiang, 2006): 
The sequential assembly pathway suggests a stepwise assembly of the PIC. TFIID nucleates PIC 
assembly via binding to the promoter, followed by entry of TFIIB and TFIIA. A TFIID/A/B-
TFIIF/Pol II complex forms on the promoter, which then recruits TFIIE and finally TFIIH. 
The Pol II holoenzyme pathway (two component pathway) suggests that a preassembled Pol II 
holoenzyme complex (various compositions described), containing a subset of GTFs, associates 
with a second complex, containing the rest of the GTFs, to form a PIC. 
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1.1.2 Diversity of the core Pol II promoter binding machinery 
 
Figure 1.3 – Diversity of core promoter binding machinery 
This figure illustrates the variety of PRFs which have been described in the literature. A) shows 
the three TBP-containing complexes, which are involved in the initiation of transcription from 
Pol I, Pol II and Pol III-dependent promoters, respectively. A) is taken from (Hochheimer and 
Tjian, 2003). B) is taken from (Muller and Tora, 2004). It illustrates the dynamic composition of 
TFIID, which differs between cell-types and might change upon exogenous stimuli (e.g. 
apoptotic stimuli). C) depicts the conservation of TBP-family proteins from yeast to humans. The 
figure is taken from (Bartfai et al., 2004). D) taken from (Hochheimer and Tjian, 2003) and (Hart 
and Green, 2008), depicts some of the various TBP-paralog containing complexes described in 
the literature. 
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1.1.2.1 TBP family of proteins 
TBP can be seen as the central transcription factor in eukaryotic transcription, as it is involved in 
transcription catalysed by all three major eukaryotic RNA-polymerases, Pol I, II and III. It 
associates with different sets of other proteins to form specific complexes for the recruitment of 
the different Polymerases to the promoters of the specific types of genes they transcribe (Figure 
1.3). Those TBP containing complexes are SL1 for Pol I, TFIID for Pol II and TFIIIB for Pol III. 
TBP is highly conserved from yeast to humans. TBP got its name from the fact that it was found 
to bind to the common eukaryotic promoter motif called TATA-box, which carries its consensus 
sequence (not the exact one) in its name. The DBD of TBP (C-terminal), also called the core-
domain, has a saddle-shaped structure. It binds to DNA with its inner, concave side and binding 
forces the DNA double strand to kink in 90°. This is thought to assist in opening up the double 
strand for transcription initiation. The outer convex side is thought to provide interaction surfaces 
for other GTFs and proteins. TBP also carries a N-terminal domain. TBP is not required for all 
Pol II transcribed genes (Ferg et al., 2007, Jacobi et al., 2007, Martianov et al., 2002, Muller et 
al., 2001, Veenstra et al., 2000). In line with that finding, only a minority of ≈10-20% of Pol II 
core promoters appears to carry a TATA-Box (Ohler and Wassarman, 2010). 
Numerous biochemical and genetic studies have been carried out on yeast TBP and TFIID. More 
recently, paralogs of TBP have been discovered in several metazoan species. The first one was 
TBP-related factor 1 (TRF1) in Drosophila (Crowley et al., 1993). It is an insect specific factor 
(or possibly Diptera-specific). Besides in Drosophila it only has been found in Anopheles. TRF1 
interacts with TFIIA and B and directs TATA-dependent transcription in vitro (Hansen et al., 
1997). TRF1 is ubiquitously expressed during embryogenesis and in adults, with higher 
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expression levels in the adult nervous system and in the male germline (Hansen et al., 1997). A 
TRF1 containing complex directing transcription from an alternative, TFIID-independent, 
promoter of the tudor gene has been described (Holmes and Tjian, 2000). However, on a global 
scale, ChIP-chip experiments suggest that TRF1 plays only a minor role in Pol II dependent 
transcription. The more important role of TRF1 seems to be in replacing TBP for Pol III 
dependent transcription (Isogai et al., 2007b, Takada et al., 2000). 
A metazoan-specific factor called TBP-like factor (TLF) has been described nearly 
simultaneously by several authors (Dantonel et al., 1999, Maldonado, 1999, Moore et al., 1999, 
Rabenstein et al., 1999), causing a little bit of confusion with the naming. TRF2, TBP-related 
protein (TRP), TBP-related factor 2 (TRF2) and TBP-like protein 1 (TBPL1), all are synonyms 
for this factor. The core domain of human TLF shows only 42% sequence identity with the core 
domain of human TBP. Critical residues for the interaction with the DNA of the TATA-box are 
altered, so that TLF neither binds to the TATA-box, nor does it direct TATA-dependent 
transcription. Its biological role has been studied in several model organisms, revealing 
significant differences between mammals (mouse) and lower vertebrates (Xenopus, fish) and 
organisms. It seems to be essential for early development of lower vertebrates (Muller et al., 
2001, Veenstra et al., 2000), as well as C. elegans (Kaltenbach et al., 2000) and Drosophila 
(Kopytova et al., 2006) In mouse it is dispensable for early development and plays a role in 
spermiogenesis. In Drosophila TLF interacts with DREF (DNA replication-related element 
binding factor). The DREF/TLF-complex can direct transcription from an alternative promoter of 
the PCNA gene (Proliferating cell nuclear antigen). This complex seems to play a significant role 
for Pol II transcription in Drosophila (Isogai et al., 2007a). In Xenopus and in C. elegans TLF is 
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required for the transcription of many genes during development (Jacobi et al., 2007, Kaltenbach 
et al., 2000). 
The newest member of the TBP family is the vertebrate-specific TBP2 (TRF3, 
TBPL2)(Persengiev et al., 2003). Its core domain in humans is nearly identical to the one of TBP 
(91% identity). Accordingly it binds to the TATA-box, directs TATA-dependent transcription 
and interacts with TFIIA and B. This suggests redundant functions between TBP and TBP2. And 
indeed TBP2 substitutes TBP for Pol II dependent transcription in Xenopus oocytes (Akhtar and 
Veenstra, 2009). But there is a significant difference between TBP and TBP2. TBP2 lacks the N-
terminal domain, suggesting roles of TBP2 beyond redundancy with TBP. Indeed specific 
functions of TBP2 have been described. A TBP2/TAF3 has been found to replace TFIID during 
myogenesis in vitro (Deato and Tjian, 2007). Also, the expression of TBP2 in Xenopus and 
zebrafish during gastrulation is restricted to the ventral half, which may contribute to the 
observed hematopoietic role of a TBP2/TAF3-complex in zebrafish and mouse embryonic stem 
cells (Hart et al., 2007, Hart et al., 2009). Similar to what has been described for TLF, TBP2 is 
essential during development in lower vertebrates (Bartfai et al., 2004, Hart et al., 2007, Jallow et 
al., 2004) but not in mouse. TBP2 ko mice show no obvious phenotype except of defects in 
oogenesis (Gazdag et al., 2009). TBP2’s specific role in oocytes is supported by the observation 
that TBP2 is the predominantly expressed TBP-family member in vertebrate oocytes (Bartfai et 
al., 2004, Gazdag et al., 2007, Xiao et al., 2006). The mouse ko phenotype contradicts the 
findings about the role of TBP2 for the myogenic and hemtopoietic differentiation of mouse cells 
in vitro and caused an ongoing controversy about that issue. The reason for different observations 
might be due to different antibodies and protein extraction methods used in different laboratories 
(Goodrich and Tjian, 2010). 
13 
 
The two TBP paralogs in mouse seem to control transcriptional programmes in the context of 
meiosis, with TLF in the male and TBP2 in the female germline. While in lower vertebrates those 
two factors are also is essential during early development. 
Table 1.1 – Specific functions of TBP family members 
adapted from (Goodrich and Tjian, 2010) 
Factor System studied Functions discussed References 
TBP 
HeLa cells Mitotic bookmarking (Xing et al., 2008) 
zebrafish 
Key regulator of maternal to 
zygotic transition (Ferg et al., 2007) 
TRF1 Drosophila Pol III-dependent transcription (Crowley et al., 1993), (Hansen et al., 1997) 
TLF 
C. elegans, Xenopus, 
zebrafish 
Early embryogenesis 
(Kaltenbach et al., 2000), 
(Veenstra et al., 2000), (Muller 
et al., 2001) 
Drosophila Germ cell differentiation, 
metamorphosis 
(Kopytova et al., 2006), 
(Bashirullah et al., 2007), 
Drosophila S2 cells Transcription (e.g. histone H1) (Hochheimer et al., 2002), 
(Isogai et al., 2007a) 
mouse Spermatogenesis (Zhang et al., 2001), (Martianov 
et al., 2001) 
TBP2 
Xenopus Gastrulation (Jallow et al., 2004), (Xiao et al., 
2006) 
zebrafish Embryogenesis, haematopoiesis 
(Bartfai et al., 2004), (Hart et al., 
2007) 
mouse ESCs Haematopoiesis (Hart et al., 2009) 
mouse C2C12 cells Myogenesis (Deato and Tjian, 2007), 
mouse Oogenesis 
(Xiao et al., 2006), (Gazdag et 
al., 2009) 
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1.1.2.2 Structural function of TAFs in TFIID 
All proteins in TFIID other than TBP are so called TBP-associated factors, TAFs. They were first 
described as “coactivators associated with the TATA-binding protein that mediate transcriptional 
activation”(Dynlacht et al., 1991). The set of TAFs within TFIID is highly conserved from yeast 
to human and a unified nomenclature system exists, numbering them from 1-15 (Tora, 2002). 
Exceptions are Taf14, which is only found in yeast, and TAF15, which is also not found in all 
organisms. So the actual set of TAFs within TFIID in different organisms ranges between 13 and 
14. TAFs are a quite heterogeneous group of proteins. However, 9 out of the 13 TAFs in TFIID 
carry a region with striking similarity to core histones, the histone fold domain (HFD). Via their 
HFDs TAFs form five pairs of heterodimers: TAF3/10, TAF4/12, TAF6/9, TAF8/10 and 
TAF11/13. Interestingly, all HFD-containing TAFs are present in more than one copy within 
TFIID, while HFD-less are present in single copies. The exception is the HFD-less TAF5. Our 
structural knowledge about TFIID is limited to low resolution (23-32Ǻ) structures elucidated by 
electron microscopy (EM) of human and yeast TFIID. The structure of TFIID seems to resemble 
a horseshoe-shaped molecular clamp. The combination of EM with immunolabelling facilitated 
the localisation of individual TAFs within this structure. The TAFs within TFIID form a 
complicated network of protein-protein interactions resulting in its assembly and organisation. 
The current model suggests a modular assembly of TFIID. In this model a stable core complex, 
composed of most, if not all, of the TAF heterodimers and a TAF5 homodimer, associates with a 
TAF1-TAF7-TBP module and TAF2 to form TFIID. Several versions of this core complex have 
been described, comprising either 5 TAFs (Wright et al., 2006), 7 TAFs (Demeny et al., 2007) or 
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9 Tafs (yeast). However, the homo-dimerisation of TAF5 is under discussion and also whether 
the TAF3/10 heterodimer is really part ofTFIID (Cler et al., 2009). 
The relative contribution of the subunits to the stability of TFIID has not been thoroughly 
investigated for all TAFs. There is some evidence that TAF4, TAF5 and TAF10 are each crucial 
for the assembly and the integrity of TFIID. 
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Figure 1.4 – Structure of TAFs and model of TFIID-assembly 
In A) the domain structures of human TAFs, TAF paralogs (TAFb) and TAF-like proteins (TAFL) are 
depicted. Known domains are highlighted in different colours and their names are given in the according 
legend. TAFs which are part of the 7 TAF core complex are labelled with an asterisk. B) shows the current 
model of TFIID assembly. A core complex module associates with a TAF1-TAF7-TBP module and TAF2 
to form full TFIID. Modified from (Cler et al., 2009).  
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1.1.2.3 Molecular and biological functions of TAFs 
As a promoter recognition factor nucleating PIC-assembly, TFIID needs to be able to bind to 
promoter chromatin. It is well established that TBP binds to the TATA-box, but most of the 
promoters lack a detectable TATA-box. 
The current view is that TFIID binds to TATA-free promoters via interactions of its TAF-
subunits with other promoter elements and/or histone marks enriched around promoters. TAF2, 
alone or in a subcomplex with TAF1, binds to the Initiator (Inr) promoter element found around 
the TSS of many genes (Papai et al., 2009). Furthermore an interaction of the TAF6/9-
heterodimer with the downstream promoter element (DPE) has been demonstrated (Burke and 
Kadonaga, 1997). Several of the TAFs contain structural domains for interactions with 
chromatin. TAF1, itself a HAT, interacts with actylated histone H4 via its tandem (double) 
bromodomain (Jacobson et al., 2000). TAF3 was shown to bind the histone mark H3K4me3, 
which is enriched at promoters of actively transcribed genes, via its PHD-finger (Vermeulen et 
al., 2007). 
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Figure 1.5 – Promoter recognition by subunits of TFIID 
The figure shows a summary of what is known about promoter recognition by TFIID subunits. 
Binding of TAF2 together with TAF1 to the Inr has been demonstrated. The TAF6/9 heterodimer 
binds to the DPE. TAF3 was found to bind to the H3K4me3 histone mark and TAF1 binds to 
acetylated histone tails. These mechanisms might be essential for promoter recognition of TATA-
less promoters. The figure is modified from (Goodrich and Tjian, 2010). 
 
TAFs have initially been identified as coactivators required together with TBP for activated 
transcription. For some of the TAFs direct interactions with activators have been reported. 
Human TAF4 interacts with several activators like SP1 and CREB, via a well conserved domain 
(TAFH), which binds to a short hydrophobic motif often present in transcriptional regulators (X. 
Wang et al., 2007). TAF3, as part of a TBP2/TAF3 complex has been shown to be a coactivator 
for the myogenic factor MyoD in cultured mouse cells (Deato et al., 2008). For the Drosophila 
orthologs of TAF4 and TAF3 different coactivator functions have been described. TAF4 has been 
placed at the end of protein-protein interactions leading to activated transcription of a Wnt target 
gene (Wright and Tjian, 2009). TAF3 interacts with the hox gene Antennapedia (Antp) (Prince et 
al., 2008). For TAF7 interactions with numerous activators, including SP1, YY1, USF and CTF, 
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have been reported (Chiang and Roeder, 1995). Also in yeast interactions of Tafs with activators 
have been observed. Yeast TFIID serves as a coactivator for Rap1, via interactions of several of 
its subunits, the two Taf4/12 heterodimers and the two Taf5 molecules, with Rap1 (Garbett et al., 
2007). Furthermore Taf12 has been shown to interact with the acidic activators Gal4 and Gcn4 
(Reeves and Hahn, 2005). 
Emerging from what is discussed above is the following picture of the general transcription factor 
TFIID: TFIID is a promoter recognition factor, recruited to core promoters via interactions of its 
subunits with core promoter motifs and with histone marks. Specific interactions of its numerous 
subunits with other transcriptional regulators enable TFIID to serve as an integration point for the 
various regulatory and signalling events acting on the regulation of transcription initiation on the 
core promoter. 
But roles of TFIID subunits beyond the above described principle have been reported. In early 
embryos of C. elegans, transcription is globally repressed by sequestration of TAF-4 into the 
cytoplasm via interactions with OMA proteins (Guven-Ozkan et al., 2008). This principle, that 
the localisation of a TAF is controlled by its interaction partners is not new. The nuclear import 
of TAF10, which lacks a nuclear import signal (NLS), is dependent on its interactions with the 
NLS bearing TAF8 or TAF3 (Soutoglou et al., 2005). TAF12 has been implicated in an active 
DNA demethylation mechanism of promoter DNA (Schmitz et al., 2009). A splice variant of 
TAF6 called TAF6δ seems to be induced and incorporated into TFIID upon apoptotic stimuli 
(Wilhelm et al., 2008). 
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Table 1.2 – Specific functions proposed for TAFs and homologs 
Principle process Specific process discussed Factor References 
 
Promoter 
Recognition 
Binding to 
promoter 
motifs 
Binding to initiator element (Inr) TAF1, TAF2 
(Chalkley and 
Verrijzer, 1999) 
Binding to downstream promoter 
element (DPE) 
TAF6/9 
heterodimer 
(Burke and Kadonaga, 
1997) 
Binding to downstream core-promoter 
element (DCE) 
TAF1 (D. H. Lee et al., 2005) 
Binding to 
histone marks 
Binding to acetylated histone H4 tails TAF1 (Jacobson et al., 2000) 
Binding to H3K4me3 TAF3 
(Vermeulen et al., 
2007) 
Coactivator 
Indirect coactivator for Wnt TAF4 
(Wright and Tjian, 
2009) 
Fuctional interaction with ANTP TAF3 (Prince et al., 2008) 
Differentiation process 
Myogenesis 
TAF3 
(Deato and Tjian, 2007) 
Hematopoiesis (Hart et al., 2009) 
Adipogenesis TAF8 (Guermah et al., 2003) 
Gametogenesis 
Mouse gametogenesis TAF4b (Falender et al., 2005) 
Spermatogenesis TAF7L (Pointud et al., 2003) 
Drosophila spermatogenesis Several (V. C. Li et al., 2009) 
Others 
Active promoter DNA demethylation TAF12 (Schmitz et al., 2009) 
Suppression of transcription in early 
embryos by sequestration of TAF-4 into 
the cytoplasm 
TAF-4 
(Guven-Ozkan et al., 
2008) 
1.1.3 TAF8 
TAF8 protein is conserved from yeast to humans. The human protein is a 43 kDa (kilo Dalton) 
protein. It contains a histone fold domain at  its N-terminus. The histone fold domain provides 
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surfaces for protein-protein interactions with other histone fold containing TAFs and proteins. 
Less is known about the function of the proline-rich domain. 
The role of TAF8 during development has been investigated in mouse model, where a mutant 
allele has been generated by an insertion of a gene trap cassette, which disrupts the protein after 
66 amino acids. The investigation of the mouse Taf8 mutant phenotype revealed a specific 
requirement of TAF8 for the survival of the inner cell mass (ICM) of E3.75 blastocysts. Late 
blastocysts appear empty because of the lacking ICM. This resemblance of an empty nut, 
properly prompted the investigators to call the mouse phenotype of TAF8 “Taube Nuss”, which 
is a german idiom for “empty nut” without a core (or someone with an empty head). The gene 
trap cassette used for the insertional mutagenesis also contained a LacZ reporter gene, which 
expression patterns should resemble the one of TAF8. Using the LacZ reporter gene the authors 
of that study found that TAF8 was ubiquitously expressed at very low levels throughout 
embryonic mouse development. The reporter gene appeared to be expressed a little bit higher in 
the inner cell mass, the developing heart and adult hippocampus. 
Within TFIID TAF8 is present as a heterodimer with TAF10. TAF8 is not part of SAGA, where 
it is replaced by SPT7 as a hetero-dimerisation partner for TAF10. Recently a small TAF 
complex (SMAT) containing all three factors (TAF8, TAF10, SPT7L) has been described, which 
might be a storage complex to scavenge unincorporated TFIID and SAGA subunits (Demeny et 
al., 2007). 
Very little is known about zebrafish Taf8. The gene is present as a single copy in the genome. 
The HFD is present in the protein but not the TAF8 proline-rich domain. Amongst the scarce 
experimental data specifically about Taf8 are the expression patterns of taf8 determined by 
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whole- mount in situ hybridisation (Thisse, 2004) and analysis of the expression of a Ptaf8:EGFP 
reporter gene in transgenics (Burket et al., 2008). 
1.1.4 Hypothesis of transcriptional regulation on the core 
promoter 
Research carried out during the last decade has revealed a substantial diversity of core promoter 
structures and of complexes forming on them. This phenomenon is thought to reflect 
transcriptional regulation on the core promoter. Transcriptional regulation on the core promoter 
level is based on the concept that the set of promoter recognition factors present in a given cell-
type, to a certain extent restricts the transcriptional programmes, which can be carried out in that 
cell-type. The set of PRFs defines which promoters are used and how responsive those promoters 
are to regulatory input from other regulatory sites like enhancers. This differential responsiveness 
is thought to be based on the compatibility of complexes forming on enhancers and promoters. 
1.1.4.1 Developmental transcription on the core promoter level 
Several lines of evidence point towards a differential requirement of GTFs during development. 
Prototype TFIID seems to be required for transcription in early embryos. During lineage 
specification and differentiation this requirement of prototype (full) TFIID gradually diminishes. 
The reduction or entire depletion of the protein levels of TFIID-subunits has been observed in 
several differentiation processes: During the all-trans retinoic acid induced differentiation of F9 
embryonal carcinoma cells into primitive endodermal cell-types (Perletti et al., 2001), the 
differentiation of 3T3-L1 preadipocytes into adipocytes (Guermah et al., 2003), the 
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differentiation of myoblasts into myotubes (Deato and Tjian, 2007) and the differentiation of 
hepatoblasts into hepatocytes (D'Alessio et al., 2011). In extreme cases, like during meiosis and 
myogenesis in mammals, an entire replacement of the basal transcription machinery has been 
reported (Deato and Tjian, 2007, Gazdag et al., 2009). One possible explanation for the observed 
phenomena is that full TFIID is required for transcriptional activation in mitotically dividing cells 
(Cler et al., 2009). TFIID is required for the activation (transcription initiation) of a gene during 
ontogeny, by providing an integration point for all the possible regulatory inputs, but is 
dispensable for reinitiation in certain differentiated cell-types. 
 
Figure 1.6 – Decrease of taf transcript levels during zebrafish development 
Expression profile of taf transcripts during zebrafish development, from 0 hpf (hours post fertilisation) to 
90 dpf. Most of the tafs show an expression profile where the transcript levels are steadily decreasing 
during development. The data is derived from single color experiments using an Affimetrix zebrafish 
array. Modified from web-tool ZF-Espresso (Max-Planck-Institute for Developmental Biology, Marc 
Saric, Robert Geisler, 2005).  
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Figure 1.7 – Regulation of developmental transcription on the core promoter level 
A) Early zygotic transcription in the pluripotent state largely follows the classical model of 
transcription initiation by canonical TFIID. B) With the appearance of enhancer-activated, 
spatially and temporally restricted transcription, differential roles of TAFs and TAF homologs 
have been demonstrated. This is paralleled by a decrease of TFIID components. C) In terminally 
differentiated cells an alternative promoter recognition factor replacing TFIID (TBP2/TAF3-
complex) and partial TFIID complexes have been found. D) A highly specialised general 
transcription machinery seems to be acting in germ cells, in the context of meiosis. In the mouse 
gonads, TBP is replaced by TBP2 in oocytes and by TLF in spermatocytes. Figure is taken from 
(Muller and Tora, 2004). 
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1.2 Zebrafish Model 
Zebrafish has been introduced as a model for developmental genetics by George Streisinger at the 
University of Oregon in the early 1980s (Chakrabarti et al., 1983, Streisinger et al., 1981, C. 
Walker and Streisinger, 1983). Zebrafish is a vertebrate model organism and its body plan and 
organ-systems therefore closer resemble the one of humans than do non-vertebrate models like 
Drosophila and C. elegans. Its major advantage over mammalian models is its ex utero 
development combined with optical transparency of the developing embryo. This allows studying 
complex processes like organogenesis or gene expression during development, in situ, in a whole 
developing organism, with single cell resolution. The embryo lacks membranes obscuring the 
view, which makes it possible to follow its development using simple light microscopy and to do 
experimental manipulations early on. Its development is rapid. After hatching between 2 to 3 
days post fertilisation most organs are present at least as primordia and at 5 dpf the larva starts 
feeding. Furthermore the small fish can be maintained relatively cheap in high numbers under 
laboratory conditions. This model provides high numbers of embryos for experiments, as healthy 
females lay 200-300 eggs on a weekly basis throughout the year. A further advantage, which also 
renders zebrafish suitable for genetics, is the short generation time of zebrafish of around three 
months. 
Because zebrafish is amenable for large scale mutagenesis screens it later became a very 
successful model for developmental genetics. A wealth of mutants has been generated in big 
mutagenesis screens, using either ENU to generate point mutations (Haffter et al., 1996), or 
pseudotyped retroviruses, to generate insertional mutants (Amsterdam et al., 1999). With the 
availability of the first assemblies of the zebrafish genome (1.9 Giga bases on 25 chromosomes) 
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and a powerful method to block the translation of mRNAs using morpholino oligonucleotides 
(MO, or just morpholino), zebrafish also became amenable for studying gene function by reverse 
genetics. Today there is a wealth of resources available, all accessible via the zebrafish model 
organism database ZFIN (zebrafish information network) and links therein: The genomic 
sequence via genome browsers (Ensembl, UCSC); genes, their transcripts and expression 
patterns; mutant, transgenic and wildtype lines; zebrafish anatomy and methodology. 
Zebrafish is an excellent model to study the function of cis-regulatory elements in vivo, partly 
because transgenesis is relatively easy achievable (Abe et al., 2011). Reporter constructs, where 
the CRE is controlling the expression of a fluorescent reporter gene, can be used for transient or 
stable transgenesis. The way the CRE controls reporter gene expression can then be analysed by 
fluorescent microscopy in living zebrafish larvae, providing spatiotemporal resolution. CREs 
often function in a modular fashion and transgenesis using BACs, containing the full set of CREs 
controlling the expression of a gene, can yield transgenic lines recapitulating the full expression 
patterns of a gene. The labelling of certain cell-lineages with fluorescent reporter genes combined 
with time lapse confocal microscopy is a powerful tool to perform lineage tracing experiments 
and to study organogenesis in great spatiotemporal resolution (J. Y. Bertrand et al., 2010). 
Zebrafish experiments can be performed in well-plate formats, what predestines this model as the 
vertebrate model of choice for high throughput screens (HTS). 
1.2.1 General LOF-phenotype for cell-essential genes 
Early embryogenesis in animal models is driven by cellular components, which have been 
deposited in the egg during oogenesis. These maternal products (RNAs, proteins, mitochondria) 
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are collectively called maternal factors. During embryogenesis there is a transition phase during 
which the zygotic genome is activated and embryonic development gradually becomes controlled 
by factors produced by the embryo itself. This transition event is synonymously called MZT 
(maternal-to-zygotic transition) or ZGA (zygotic gene activation). In some animals (e.g. zebrafish 
and Xenopus) it is accompanied with another developmental event, the MBT. MZT and ZGA 
solely describe transcriptional phenomena, while the MBT also comprises phenomena like 
lengthening of the cell cycle and loss of synchrony of cell divisions. The extent to which 
embryogenesis is reliant on maternal factors differs between animal models. In mouse the zygotic 
genome becomes transcribed already at the two cell stage, whereas in zebrafish, the MZT 
happens around the 1000 cell stage. Obviously there is a significant difference in the number of 
cell divisions controlled by maternal factors in mouse and zebrafish. Interestingly, taking a 
different scale, zebrafish MZT happens much earlier than in mouse. The zebrafish genome 
becomes activated around 3.5 hpf, the mouse genome 18 hpi (hours post insemination) (Kimmel 
et al., 1995). The maternal impact on embryonic development in zebrafish is substantial and it 
has been shown that maternal factors contribute to embryonic development at least up to 3 dpf 
(Ryu et al., 2005). At least 8 000 maternal transcripts have been identified in zebrafish (Aanes et 
al., 2011) and maternally controlled processes include axis-specification and specification of the 
germline (Marlow, 2010). 
In line with a substantial contribution of maternal gene products to early zebrafish development is 
the fact, that zygotic zebrafish mutants of supposedly cell-essential genes, often show 
surprisingly mild phenotypes (see http://web.mit.edu/hopkins/). The mutation still is lethal, but 
the mutants survive till 5 dpf and beyond. Those mutants display very similar, pleiotropic 
phenotypes, which I would like to call “general phenotype”. In the general phenotype most, if not 
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all of the structures and organs are underdeveloped comparing mutants to wildtypes. Due to the 
substantial maternal contribution to embryonic development in zebrafish, many mutant 
phenotypes and morphants (MO-induced phenotypes) probably do not reflect the full loss of 
function (LOF) phenotype for that gene. To achieve a LOF-phenotype, where the gene product is 
completely lacking in the embryo, maternal zygotic mutants for the gene need to be generated. 
This very rarely is done because in many cases it is not trivial to generate a maternal mutant, as a 
prerequisite to study maternal zygotic phenotypes. 
Many zygotic phenotypes studied in zebrafish in fact might be partial LOF-phenotypes, where 
maternal supply of the respective gene product compensates for loss of the zygotic gene. This is 
not necessarily a disadvantage. It enables investigators to study late functions of genes in 
downstream processes which couldn’t be studied in more drastic null mutant phenotypes. 
Zebrafish mutants can be used to study the function of genes in organogenesis, whose mouse 
mutant counterparts die during or before gastrulation. The role of hdac1 in liver development 
could for example only be revealed by studying the zebrafish mutant and not the more drastic 
mouse mutant phenotype for Hdac1 (Noel et al., 2008). 
1.2.2 MO-mediated knock down technology 
Morpholino oligonucleotides are synthetic analogues of nucleic acids, containing the same 
nucleobases, but differing in the structure of the backbone. The backbone of MOs is composed of 
morpholine rings (which carry the nucleobases) connected by phosphorodiamidate groups. This 
synthetic backbone renders MOs resistant to enzymatic degradation, because it is not recognised 
by any natural nucleases. However, they hybridise to complementary sequences just like their 
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natural counterparts. This hybridisation to complementary sequences is the basis for the use of 
MOs for a very efficient antisense-mediated knock down technique using MOs. Especially in 
research using zebrafish model, where the alternative RNAi (RNA interference) not could be 
established, the use of MOs for gene knock downs is very popular. 
The target of MOs is usually a single stranded RNA molecule, where it can hybridise to 
complementary target sequences. Depending on the nature of the target sequence, the MO can 
interfere with various aspects of RNA biology. With the target sequence laying upstream or 
covering the start codon (AUG), MOs are used to block translation. Targeting splice donor or 
splice acceptor sites can induce aberrant splice products of the pre-mRNA (precursor mRNA), 
which are instable or do not encode for a functional protein (Morcos, 2007). The target sequence 
does not have to lie in a transcript of a protein-coding gene. MOs can also be used to target non-
coding RNAs, like miRNAs (micro RNAs), or snRNAs (small nuclear RNAs) (Flynt et al., 2007, 
Konig et al., 2007). 
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Figure 1.8 – MO-mediated block of mRNA translation 
A) MOs are nucleic acid mimics, containing the same nucleobases, but with a different, nuclease-
resistant backbone. B) Only MO-sequences targeting sequences upstream, or including the start 
codon AUG (first 25 nucleotides) are efficiently blocking the translation of the targeted mRNA. 
C) The reason for that lies within the mechanism of MO-mediated block of translation. The MO 
blocks the movement of the small ribosomal subunit, which is scanning for the start codon from 
the 5’-Cap. Adapted from (Seyffert, 2003). 
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Relevant for this thesis is only the use of MOs to block translation of mRNA, thereby generating 
LOF-phenotypes for the gene of the targeted transcript. The gold standard for controlling the 
specificity of morphant phenotypes is the following: 
• Two targeting MOs inducing the same morphant phenotype. 
• A MO, with 5 mismatches in its sequence, compared to one of the targeting MOs. These 
MOs will serve as a negative control MO and should not induce a morphant phenotype. 
• The morphant phenotype should, at least partially, be rescued by co-injection of mRNA 
encoding for the wildtype protein. Best is it to use a mRNA, which is resistant to being 
targeted by the MO, for the rescue experiments. 
If all the above mentioned criteria are fulfilled, the morphant phenotype is well controlled and 
therefore specific. The actual kd of the gene, the loss of the protein, has to be validated by 
western blot. This requires an antibody for the protein, which, especially for zebrafish, is not 
always available. Because of the other, stringent, methods to control the specificity of the 
morphant phenotypes, the validation of the kd is not mandatory. However, MO-induced aberrant 
splicing can be validated by RT-PCR (reverse transcription polymerase chain reaction). If 
primers are used for the RT-PCR, framing the aberrantly spliced part of the transcript, then the 
amplicon sizes on an agarose gel will differ between wildtype and mis-spliced transcript. This is 
for example the case if introns are included, or exons are excluded from the transcript. What also 
can be observed using MOs targeting splice sites is the loss or reduction of transcript levels, 
because a substrate for non-sense mediated decay is produced by the mis-splicing event. 
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1.3 Potential coactivator function of TAF8 for PPARγ 
The lab of Laszlo Tora at the IGBMC Strasburg, a close collaborator of our group, is studying the 
role of TBP-type factor- and TAF-containing complexes in initiation Pol II-depending 
transcription. The studies of the Tora group include work on the identification of interaction 
partners of TAF proteins. During his time in the Tora lab Mate Demeny was working on 
interaction partners of TAF8. TAF8 was found to be a positive regulator of adipogenesis based 
on following observations: 
1. TAF8 is dramatically and selectively (relative to other TAFs) induced and sequestered 
within TFIID upon in vitro differentiation of 3T3-L1 preadipocytes into adipocytes 
2. The histone fold domain of TAF8 acts as a dominant-negative mutant and selectively 
inhibits the adipogenic differentiation of 3T3-L1 preadipocytes 
3. Over-expression of wildetype TAF8 rescues the phenotype caused by its histone fold 
domain. 
This suggests TAF8 as a potential interaction partner for the master regulator of adipocyte 
biology, PPARγ. Indeed, work carried out by Mate Demeny suggests a functional interaction of 
TAF8 with the nuclear receptor PPARγ. Flag-tagged human TAF8 can be co-immunoprecipitated 
together with PPARy and vice versa (Figure 1.9). Furthermore overexpressed TAF8 can 
potentiate the expression of a PPARγ responsive reporter gene in a dose dependent manner 
(Figure 1.10). 
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Figure 1.9 – Interaction of human TAF8 with PPARγ demonstrated by CoIP (co-
immunoprecipitation) 
A) Flag-tagged PPARγ co-immunoprecipitates with TAF8 when co-expressed in SF9 cells 
B) Flag-tagged TAF8 co-immunoprecipitates with PPARγ when co-expressed in Cos-1 cells 
These experiments have been performed at the IGBMC Strasburg by Mate Demeny. 
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Figure 1.10 – Luciferase assays suggests functional interaction between TAF8 and PPARγ 
Shown in the bar chart are the results from luciferase assays after the co-transfection of 
expression vectors for PPARγ, TAF8 and a PPARγ-responsive reporter (shown below). The 
PPARγ-responsive luciferase reporter is stimulated by TAF8 overexpression in a dose-dependent 
manner. These experiments have been performed by Mate Demeny. 
1.3.1 NRs (nuclear receptors) 
Nuclear Receptors are ligand regulated transcription factors. They link transcriptional regulation, 
and thereby cellular behaviour, to extracellular signals, like hormones and compounds with 
hormone like function. The central role in physiology and organismal homeostasis, together with 
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the fact that their activity can be modulated with endogenous and synthetic ligands, makes them 
excellent drug targets. Nuclear receptors have a modular structure: 
A/B in Figure 1.11 is the N-terminal regulatory domain. The A/B domain is highly variable in 
sequence between nuclear receptors and contains activation function 1 (AF1), which itself 
produces only a weak transcriptional activation, but synergises with activation function 2 (AF2) 
in the E domain. The activity of the AF1 can be modulated by signalling pathways, which target 
certain phosphorylation sites within the A/B domain. C in Figure 1.11 is the DNA binding 
domain. It is a highly conserved domain, which is binding to DNA-sequences called hormone 
response elements (HRE) via two zink fingers. D in Figure 1.11 is the hinge region. The hinge 
region is a flexible domain linking domains C and E. The hinge region of some nuclear receptors 
binds to DNA sequences upstream of the HRE (Chandra et al., 2008). E in Figure 1.11 is the 
ligand binding domain (LBD). The LBD of nuclear receptors is moderately conserved in its 
primary structure but highly conserved in its tertiary structure. As the name suggests, this domain 
contains a ligand binding cavity. It also harbours activation function 2 (AF2), which is modulated 
by the presence of bound ligand. Furthermore it contributes to the dimerisation interface and 
interacts with co-regulators. F in Figure 1.11 is C-terminal domain. The C-terminal domain varies 
a lot between NRs. 
Nuclear receptors form a so called superfamily of proteins and there are 48 genes which encode a 
nuclear receptor encoded by the human genome. There are several ways to classify this large 
group of proteins. Mechanistically they can be grouped into two major classes. One class is in the 
absence of ligand trapped in the cytoplasm, in a complex with heat shock proteins. Upon ligand 
binding the heat shock proteins dissociate and the NR is translocated into the nucleus, where it 
binds to its HRE as a homodimer. A second class is bound to its response element even in the 
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absence of ligand, as a heterodimer with RXR (retinoid x receptor). In this state it is associated 
with corepressor complexes and binding of ligand causes the replacement of these corepressor 
complexes with coactivator complexes, thereby leading to activated transcription of its target 
genes. 
An alternative historical classification of NRs is based on the knowledge about their ligands. One 
class, the endocrine receptors, comprises the classical NRs, which are regulated by endocrine 
hormones like adrenal and gonadal steroids. Then there are the orphan receptors, which have 
been identified as a NR based on homology, without any knowledge about their ligands. Once a 
ligand for these orphan receptors has been found it is reclassified as a so called adopted orphan 
receptor. One interesting aspect of the adopted orphan receptors is the fact that they respond to 
exogenous compounds as ligands, e.g. dietary lipids. This links organismal physiology to 
environmental factors. 
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Figure 1.11 – Nuclear receptors 
A) The five classical domains of a NR from N-terminus (NH2) to C-terminus (COOH). 
B) Classification of nuclear receptors according to the history of their identification and 
knowledge about their ligands. Endocrine receptors are the classical receptors and bind to 
hormonal lipids of the endocrine system. Orphan receptors can be identified as nuclear receptors 
based on homology, but their ligands are unknown. They are taken out of orphanage when their 
ligand is found and then become adopted orphan receptors. Figure modified from (Evans, 2004). 
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1.3.1.1 PPARs 
In 1990 one of the orphan NRs was found to bind chemicals known to induce peroxisome 
proliferation (Issemann and Green, 1990). It was named peroxisome proliferator-activated 
receptor (PPAR) and later, after two closely related receptors have been discovered, PPARα 
(Nicolakakis and Hamel, 2010). The other two members of the family are called PPARβ (also 
called PPARδ) and PPARγ. Following the nomenclature for NRs the PPARs belong to nuclear 
receptor subfamily 1, group C. There is a wealth of published data about PPARs. A search in the 
pubmed database with PPAR as search term yields 12780 hits, while PPARγ alone as query 
retrieves 9812 publications (pubmed 10.02.2011). The reason why PPARs gain so much attention 
is certainly because they are regarded as extremely valuable drug targets, also against disorders 
associated with Metabolic Syndrome (Syndrome X). In the affluent societies of the industrialised 
nations obesity is an ever growing problem. Obesity is a risk factor to suffer from disorders like: 
Insulin resistance, which can progress into type 2 diabetes mellitus; dyslipidemia (high 
triglycerides and low high density lipoproteins); hypertension; atherosclerosis. 
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Figure 1.12 – The role of PPARs in lipid-physiology 
This figure depicts the role of the three PPAR subtypes in three central tissues of lipid- and 
glucose-metabolism. The activities of PPARα and PPARβ lead to an increase in fatty acid 
catabolism for the production of energy equivalents (fat burning). Activation of PPARγ, in 
contrast, leads to an increase of intracellular neutral lipids, particularly in adipocytes (fat cells). 
All three NRs are drug targets for drugs against disorders associated with the metabolic 
syndrome, like the lipid-lowering fibrates and the insulin-sensitising TZDs. Recently also drugs 
targeting PPARβ became available (GW1516). Figure modified from (Evans et al., 2004). 
1.3.1.2 PPARα 
PPARα is the name giving member of this subgroup of NRs. Its activation leads to peroxisome 
proliferation in rodent livers. This effect is not observed in humans. PPARα is predominantly 
expressed in liver and to a lesser extend in heart and muscle. Its target genes are involved in fatty 
acid catabolism for energy production via β-Oxidation. Accordingly, PPARα knockout mice 
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suffer from hyperlipidemia and fatty liver. PPARα is the drug-target of the lipid-lowering fibrates 
(clofibrate, ciprofibrate). 
1.3.1.3 PPARβ (PPARδ) 
PPARβ, like PPARα, plays a role in energy expenditure via fatty acid catabolism (β-Oxidation). 
PPARβ is ubiquitously expressed, with low levels in liver. In contrast to PPARα, it also has been 
implicated in adaptive thermogenesis. Mice, in which PPARβ has been knocked out, show 
reduced energy uncoupling and are prone to obesity. 
1.3.1.4 PPARγ 
This member of the PPAR family plays a somewhat opposing role in lipid metabolism to the 
other two subtypes. Where PPARα and PPARβ are playing a role in fatty acid catabolism, in fat 
burning, PPARγ plays a role in fat storage. Accordingly it is predominantly expressed in adipose-
tissue. PPARγ exists in two major isoforms in mammals, PPARγ1 and PPARγ2. PPARγ1 is 
broadly expressed, including liver, skeletal muscle, heart and adipocyte tissue. PPARγ2, which 
contains an extended N-terminus compared to PPARγ1, is mainly expressed in adipocytes In 
humans two more isoforms, called PPARγ3 and 4, encoding for the same protein like PPARγ1 
have been found (Desvergne and Wahli, 1999). There is plenty of evidence that PPARγ is a 
master regulator of adipocyte biology (white fat tissue). It is essential for the formation 
(adipogenesis) and the function (lipid-handling, adipokine production) of white fat tissue. With 
the 3T3-L1 cell line an excellent in vitro model for adipogenesis is available. This preadipocyte 
cell line can be hormonally (adipogenic inducers) stimulated to differentiate into mature 
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adipocytes, which accumulate triglycerides in lipid droplets and express marker genes typical for 
mature adipocytes. From this model, it is known that PPARγ plays a major role during 
adipogenesis together with members of the CCAAT/enhancer binding protein (C/EBP) family. It 
appears that hormonal stimulation leads to the induction of a central regulatory loop in mature 
adipocytes, where PPARγ and C/EBPα mutually are keeping up their expression levels, leading 
to a robust high expression of those two factors. C/EBPβ and C/EBPδ are involved in the 
initiation of this regulatory loop and can be considered as early markers for adipogenesis, 
although a role for C/EBPβ in mature adipocytes has been described recently. There is a 
substantial overlap of genomic sites co-occupied be PPARγ and C/EBP members, suggesting that 
these factors cooperatively regulate the expression of adipocyte target genes. Indeed, around half 
of the genes induced during adipogenesis appear to be regulated by PPARγ, highlighting its role 
as master regulator of this differentiation process. 
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Figure 1.13 – The 3T3-L1 model for adipogenesis 
A) Light microscopy pictures of 3T3-L1 cells at different days post hormonal stimulation for 
adipogenic differentiation. The cells have been stained with the red lipid stain ORO to reveal the 
accumulation of lipids in mature adipocytes (days 7 and 10). Note the change of the fibroblast 
like morphology to the roundish shape of mature adipocytes during the differentiation. The time 
course experiment shown in A) has been performed by Mate Demeny. 
B) Shown on the left is the order of cell biological events during the differentiation process. 
Hormonal stimulation of 3T3-L1 preadipocytes leads to several rounds of clonal expansion, 
followed by growth arrest and terminal differentiation into mature adipocytes. Shown on the right 
is the order of molecular events leading to establishment of the mature adipocyte transcriptional 
programme. These molecular events involve PPARγ and C/EBP family members. 
 
The biological role of PPARγ in vivo extensively has been studied using mouse-model. PPARγ 
null mice revealed essential functions for PPARγ during pre-natal and post-natal development. 
During mouse development substantial expression of PPARγ is first detected in the placenta at 
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E8.5. The first expression in the embryo is observed around E14.5 in the interscapular brown fad 
pad. Mice lacking PPARγ die around E9.5 because of a placental pathology. The placental 
trophoblast fails to differentiate properly and the placenta does not become vascularised. The 
fetus in turn, where PPARγ is not expressed at that stage, displays cardiomyopathies (premature 
cardiomyocyte differentiation and ventricular hypoplasia). This early phenotype can be rescued 
by placental reconstitution with tetraploid chimeras. PPARγ does not seem to be essential for 
further embryonic development. However, a knockout mouse surviving to term dies within one 
week and displays lipodystrophy, fatty liver and haemorrhages (Barak et al., 1999). 
Tissue-specific KOs of PPARγ in mouse made clear that not only the adipocyte PPARγ, but also 
PPARγ in other tissues plays an important role in lipid- and glucose-homeostasis (see Figure 
1.12). Interestingly, an adipocyte-specific KO revealed that PPARγ is essential for maintenance 
of the adipocyte-phenotype and for the survival of adipocytes. Humans with one PPARγ mutant 
allele display partial lipodystrophy and insulin resistance. 
PPARγ in mammals is expressed in macrophages, where it is involved in a certain aspect of 
cholesterol metabolism. The lipid transport system of fish, like the one of mammals, consists of 
an exogenous (dietary) loop as well as an endogenous loop. The lipids are transported as 
lipoprotein (particles). Chylomicrons are the lipoproteins of the exogenous loop. They are 
composed of triacylglycerols (TAGs), cholesterol, cholesterol-esters and apolipoprotein B-48 
(Apob-48). Nascent chylomicrons bypass the liver via lymphatic vessels but later enter the blood 
circulation. After they have delivered their TAG-content to peripheral tissues (skeletal muscle, 
adipose tissue) the chylomicron remnants are taken up by the liver. In the liver, lipids are 
packaged into particles of similar composition like chylomicrons, except for a different 
apolipoprotein component, Apob-100. This lipoprotein, released from the liver into the 
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circulation, is called very low density lipoprotein (VLDL). While delivering its TAG-cargo (low 
density) to peripheral tissues the density of this lipoprotein successively increases. The VLDL 
goes over IDL (Intermediary Lipoprotein) to LDL (Low Density Lipoprotein). Macrophage 
PPARγ is involved in a process by which macrophages convert oxLDL (bad cholesterol), which 
contains ligands for PPARγ, into HDL (good cholesterol). HDL, high density lipoprotein, is 
considered as good cholesterol, because it transports cholesterol to the liver, where it can be 
secreted together with the bile. This is one of the few processes by which excess cholesterol, 
which has been associated with artheromatous diseases, can be removed from the body. 
 
Figure 1.14 – PPARγ and cholesterol transport 
Depicted is a schematic of the lipid transport system, with emphasis on cholesterol transport and 
the role of PPARγ in clearance of “bad” cholesterol. Dietary cholesterol reaches the liver in 
chylomicron remnants. In the liver it is repacked into VLDL and released into the circulation. As 
TAGs (triacyl glycerols) are lost to peripheral tissues VLDL becomes the denser LDL. LDL 
components can become oxidised with time. Macrophages can take up oxidised LDL (oxLDL, 
bad cholesterol) and release it as HDL (good cholesterol). This process involves PPARγ, which is 
activated by certain components of oxLDL (Evans, 2004). 
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1.3.2 Transcriptional regulation by PPARγ 
PPARs form a heterodimer with members of the RXR-family (nuclear receptor subfamily 2, 
group B). Especially the interaction with RXRα seems to be important for PPARγ-regulated 
transcription (Chawla et al., 2001, Lefterova et al., 2008). The principal mechanism for ligand-
dependent transcriptional regulation by PPARs is the following: 
In the unliganded state the PPAR/RXR-heterodimer, bound to the PPRE (peroxisome proliferator 
response element) is associated with a corepressor complex containing HDACs. Upon ligand-
binding the corepressor complex is replaced with coactivator complexes like Mediator and 
complexes containing HATs (Viswakarma et al., 2010). 
The PPRE consists of two hexameric half sites, direct repeats of an AGGTCA consensus, 
separated by one nucleotide. Such a HRE is called DR1-element (Heinaniemi et al., 2007). 
PPARγ occupies the 5’ half site and the RXR the 3’ half site, while the hinge region of PPARγ 
makes additional contacts with the AAACT element found up-stream of some PPREs (Chandra et 
al., 2008). 
Several mechanisms for transrepression by PPARγ (PPARγ/RXR-heterodimer) have been 
described in the literature (Schmidt et al., 2010): 
1. PPARγ directly binds to other TFs like AP-1 and NFκB, which prevents them from 
binding to their response elements (P. Wang et al., 2001). 
2. PPARγ interferes with transcriptional regulation by competing for general coactivators 
with other TFs which rely on those coactivators (Kodera et al., 2000). 
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3. Sumoylated PPARγ has been connected to transrepression of NFκB-dependent 
transcription by preventing the removal of the NCoR/SMRT corepressor complex from 
the promoter region of pro-inflammatory genes (Jennewein et al., 2008). 
4. PPARγ inhibits the phosphorylation of JNK and p38 in the MAPK pathway by an 
unknown mechanism. Thereby, PPARγ indirectly represses the transcription of pro-
inflammatory genes (Desreumaux et al., 2001). 
It is increasingly being recognised that the activity of PPARγ is regulated by post translational 
modifications (PTMs) (van Beekum et al., 2009). PPARγ contains two known phosphorylation 
sites, Serine 112 and Serine 273 (number of residues is for PPARγ2). Serine 112 lies within AF1 
and is a target of MAPKs and the CDKs (cyclin-dependent kinases) CDK7 and CDK9. 
Phosphorylation of Serine 112 by MAPKs seems to predominantly decrease the transcriptional 
function of PPARγ, while phosphorylation of the same residue by CDK7/9 has the opposite 
effect. Serine 273 is a target of CDK5. Phosphorylation of Ser273 by CDK5 causes dysregulation 
of a subset of PPARγ target genes, including genes which are dysregulated in obesity, like the 
insulin-sensitising adiponectin. Some of the PPARγ-targeting insulin-sensitising drugs, e.g. 
Rosiglitazone, block the phosphorylation of Ser273 by CDK5. Two sumoylation sites have been 
found in PPARγ. Sumoylation of K107 has a repressive effect on transcription, while 
sumoylation of K395 is connected to transrepression of NFκB target genes (Pascual et al., 2005, 
van Beekum et al., 2009). 
 
47 
 
 
Figure 1.15 – Transcriptional regulation by PPARγ 
A) Schematic representation of the PPARγ2 protein structure. The positions of known post 
translational modifications of this protein (Ser112/Ser273 phosphorylation and K107/K395 
sumoylation) are shown. These PTMs influence the transcriptional activity of PPARγ. 
B) Principle mechanism of transcriptional regulation by PPARs. Upon ligand binding HDAC-
containing corepressor complexes are replaced with HAT-containing coactivator complexes and 
complexes linking PPAR/RXR to the basal transcription machinery (Mediator). A) was taken 
from (van Beekum et al., 2009) and B) from (Viswakarma et al., 2010). 
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1.3.3 Zebrafish as model for lipid-metabolism and adipocyte 
biology 
1.3.3.1 PPARγ in zebrafish 
The zebrafish genome contains orthologs for all three PPAR subtypes. Due to the whole genome 
dublication event in the teleost lineage, there are two copies for pparα (pparαa, pparαb) and 
pparβ (pparβa, pparβb). Zebrafish pparγ is a single copy gene, like its mammalian ortholog. So 
far, no splice variants for pparγ have been described. The spatiotemporal expression patterns of 
zebrafish NRs together with their most important co-regulators during embryonic development 
have been comprehensively studied (S. Bertrand et al., 2007). The study revealed that NRs are 
often more specifically expressed than their co-regulators. There is hardly any expression of 
pparα during embryonic zebrafish development. Pparβa is highly expressed in the liver, whereas 
its dublicate pparβb is weakly expressed throughout the body and stages. Pparγ shows a broad 
expression during embryonic stages, but in early larvae becomes more restricted to endodermal 
organs like gut, intestinal bulb, liver and swim-bladder. 
The expression of Ppars has also been comprehensively studied in adult zebrafish (Ibabe et al., 
2002). In this study the expression patterns of the Ppars only partly resembled the ones observed 
in mammals. Zebrafish Pparα is expressed mainly in liver, kidney, intestine and pancreas. Pparβ 
is ubiquitously expressed and for Pparγ weak expression in pancreas, intestine and gonads has 
been observed. 
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1.3.3.2 Zebrafish as a model for adipocyte research 
The best studied biological function of PPARγ is its role in fat cells. Models mainly used in 
adipocyte research are rodents and in vitro models. The preadipocyte cell line 3T3-L1 can in vitro 
be stimulated to differentiate into adipocytes and is used as an in vitro model for adipogenesis. 
Zebrafish model only recently has been established as a model for adipocyte research. 
Adipogenesis during early zebrafish development has been studied by several investigators using 
slightly different approaches. They also used different criteria for the identification of adipocytes 
and the stage, where the first adipocytes are observed, differs between the studies. 
In one study Li et al. investigated the role of the RA (retinoic acid) and PPARγ signalling 
pathways acting on CNC (cephalic neural crest). Their findings indicate that cephalic osteoblasts 
and adipocytes share a common precursor, CNC. Modulating the activity of both pathways using 
respective ligands, they observed a reciproke relationship between cephalic adipogenesis and 
osteogenesis, where increased adipogenesis goes at an expense of osteogenesis and vice versa. In 
this study the first cephalic adipocytes were observed at 5 dpf using marker gene expression 
(pparγ, cebpa) and lipid accumulation (ORO) as criteria to identify adipocytes (N. Li et al., 
2010). Flynn et al. monitored the appearance of adipocytes during early zebrafish development. 
They used lipid accumulation (nile red), marker gene expression (pparγ and fabp11a) and 
histological criteria to identify mature adipocytes. In this study the first adipocytes were observed 
in close proximity to the pancreas at 8 dpf. Another finding of that study was that exogenous 
nutrition seems to be required for the appearance of the first preadipocytes close to the pancreas 
at 6 dpf (Flynn et al., 2009). Finally Imrie et al. studied the development of WAT (white adipose 
tissue) in zebrafish. They determined the position of the WAT-depots in zebrafish and their 
50 
 
appearance during development. The authors of this study used similar criteria for the 
identification of adipocytes like Flynn et al. but additionally checked for the expression of the 
adipokines adipsin and adiponectin. They found that the first WAT-depot in zebrafish appears 
around 12 dpf in the pancreas (Imrie and Sadler, 2010). 
1.3.3.3 Zebrafish as model for hepatobiliary diseases 
Like other organs in zebrafish the liver develops rapidly and is fully functional by 5 dpf (Chu and 
Sadler, 2009). Zebrafish liver development can be subdivided into two principal phases, budding 
and growth (Field et al., 2003). Unlike in mammals hepatic vasculature and hematopoiesis are not 
essential for hepatogenesis in zebrafish (Chu and Sadler, 2009). However, a functional blood-
circulation is required for late stages of liver development, during the growth phase (Korzh et al., 
2008). Furthermore, endothelial cells seem to contribute to the establishment of properly 
separated vascular and biliary networks by assisting in apicobasal polarisation of hepatocytes 
(Sakaguchi et al., 2008). A single layer of hepatocytes lies between those two networks, their 
apical membranes facing the biliary network, their basal membranes facing the vascular network. 
The anatomical architecture, the arrangement of cells and vasculature, differs between 
mammalian and teleost livers (Hinton and Couch, 1998, Lorent et al., 2004). The subdivision of 
this organ into functional units differs, but the function of the hepatic cell-types and the overall 
function of the organ is the same (Sadler et al., 2005). Also the biliary tree resembles its 
mammalian counterpart and is composed of extra- and intrahepatic ducts and ductules. However, 
in teleosts, a specialised branch of the biliary tree, the preductular epithelial cell, analogous to the 
Canal of Hering, seems to connect canaliculi and ductules (Sadler et al., 2005). 
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Table 1.3 – Zebrafish as a model for hepatobiliary diseases 
The table is adapted from (Chu and Sadler, 2009). 
Gene LOF-phenotype 
Defects observed (model for disease, 
syndrome) Reference 
vps33b Morphant Cholestasis (ARC-Syndrome) (Matthews et al., 2005) 
foie gras Mutant Hepatic steatosis (fatty liver disease) 
(Sadler et al., 2005) nf2 Mutant Choledochal cysts 
vps18 Mutant Hepatomegaly, biliary paucity 
dtp Mutant Hepatic steatosis and degeneration (Matthews et al., 2009) 
Jagged 
and 
notch 
Morphants 
(compound 
knock downs) 
Biliary paucity (Alagille-Syndrome) (Lorent et al., 2004) 
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1.4 Objectives 
1.4.1 Distinct roles of TAFs in development 
In chapter 1.1.4 I introduced the concept of transcriptional regulation on the core promoter level. 
Although there is accumulating evidence suggesting a participation of the core promoter binding 
machinery in transcriptional regulation also during development , only a few studies have shown 
how changes in the core promoter binding machinery lead to the establishment of cell-type 
specific transcriptional programmes. TBP- and TAF-paralog containing complexes for example 
seem to drive transcriptional programmes in the context of meiosis. Also replacement of the 
canonical TFIID complex during myogenesis has been described (Deato and Tjian, 2007). 
However, this finding was not confirmed by the mouse ko (knock out) phenotype of TBP2, which 
only displays defects in gametogenesis in females. Therefore, there is a need to study the function 
of components of the basal transcription machinery in vivo, in the context of a whole developing 
organism. 
I chose zebrafish as an in vivo model to study the role of Taf proteins during early zebrafish 
development due to the advantages of this model for that purpose. LOF-phenotypes can be easily 
generated and analysed in this model (chapter 1.2) using MO-mediated kd technology. 
The systematic study of Tafs would, to our knowledge, be the first comprehensive analysis of the 
role of TAF-proteins during development of a vertebrate organism. I hypothesised, that besides 
the relative contribution of the distinct Taf-subunits to early zebrafish development, the study 
might reveal some interesting specific phenotypes for certain Tafs, similar to the implication of 
Taf3 in hematopoiesis (Hart et al., 2009). Furthermore it will be interesting to analyse the Taf-
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morphants in the light of the knowledge about structure and composition of the different TAF-
containing complexes. 
1.4.2 Exploring the potential role of Taf8 in Pparγ-dependent 
gene regulation 
The advantages of zebrafish as a model organism, especially the possibility to visualise and study 
complex developmental and physiological processes in vivo, are increasingly utilised for lipid 
research. Staining methods to visualise the distribution of neutral lipids in living embryos/larvae 
(Nile Red, (Jones et al., 2008)) or in fixed embryos/larvae (ORO, (Schlegel and Stainier, 2006)) 
can be deployed in zebrafish. Importantly a collection of lipids conjugated with the fluorochrome 
BODIPY are available to study their distribution and conversion in vivo by live imaging (Holtta-
Vuori et al., 2010). Utilising its advantages and the available resources, zebrafish has successfully 
been established as a model for various lipid-related diseases: Atherosclerosis (Stoletov et al., 
2009), obesity (Song and Cone, 2007), diabetes (Elo et al., 2007, Gleeson et al., 2007), 
cholesterol metabolism (Schlombs et al., 2003), acute alcoholic liver disease (Passeri et al., 2009) 
and non-alcoholic fatty liver disease (Sadler et al., 2005). 
I want to study the phenotype of the zebrafish taf8-mutant with focus on in vivo evidence for a 
potential coactivator function of Taf8 for Pparγ, a key-regulator of lipid-metabolism. This might 
provide valuable information about the mechanism of PPARγ-regulated transcription, by further 
linking PPARγ to the basal transcription machinery, additionally to its known interactions with 
the Mediator complex (Ge et al., 2002, Grontved et al., 2010). TAF8 has been implicated in 
adipogenesis, a differentiation process for which PPARγ is essential. In vivo evidence of a 
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functional interaction of Taf8 with Pparγ in the context of adipogenesis would strengthen the role 
of TAF8 as a pro-adipogenic factor. 
1.4.3 Zebrafish as a genetic model for studying metabolic 
disorders involved in ARC-syndrome 
Macrophage PPARγ is linked to cholesterol metabolism via a process by which oxLDL is cleared 
from the circulation. Zebrafish becomes increasingly used as a model for disorders related to 
lipid-metabolism. Cholestasis and malabsorption of lipids are lipid-related features of the 
multisystem disorder ARC-syndrome (arthrogryposis renal dysfunction and cholestasis-
syndrome). The kd phenotype for the zebrafish ortholog of the gene which is mutated in the 
majority of the cases of classical ARC-syndrome (vps33b) shows some resemblance to the lipid-
related defects found in ARC-syndrome (Matthews et al., 2005). We want to compare the kd 
phenotype of the zebrafish ortholog of the gene which is mutated in the remaining cases of 
classical ARC-syndrome (vipar, VPS33b Interacting Protein involved in Apical protein 
Restriction) to the vps33b kd phenotype. Similarities and differences between the phenotypes 
would allow conclusions on the question if the two genes act in the same pathway. 
The studies on analysing the taf8-mutants and vipar-morphants for lipid-metabolism related 
defects might contribute to the establishment of zebrafish as a model for lipid research. 
1.4.4 New methods to interfere with maternal effect genes 
Many zebrafish phenotypes of supposedly cell-essential genes show a surprisingly mild general 
phenotype (chapter 1.2.1). This phenotype might reflect a mixture of a general cellular defect, 
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which is attenuated by the substantial maternal supply of the gene product, and a specific 
phenotype, reflecting specific functions of the respective gene. I want to explore if detailed 
analysis of general phenotypes can reveal distinct, non-general features, which may indicate 
specific functions. Given the modest nature of phenotype observed for numerous cell-essential 
genes, the maternal contribution needs to be addressed. 
In collaboration with Zsolt Csenki we want to develop a method which circumvents the need of a 
zygotic mutant as a prerequisite to study maternal gene function by direct manipulation of 
isolated early stage oocytes. This requires the reintroduction of the oocytes into the ovary of 
surrogate mothers to allow for normal oogenesis. We explored if a novel transplantation method 
for early stage oocytes may allow the development of fertilisable eggs. 
  
56 
 
2 Material and Methods 
2.1 Material 
2.1.1 Chemicals 
If not otherwise stated chemicals were ordered from Sigma-Aldrich (Poole, UK) or Fisher 
Scientific (Loughborough, UK). Commonly used chemicals, like salts and organic solvents, are 
not listed. 
Chemical Catalogue Number Supplier 
Ampicillin  Sigma-Aldrich, Poole, UK 
Albumin, bovine serum, Fraction 
V, ≈ 99% 
A3059-10G Sigma-Aldrich, Poole, UK 
dNTPs  5Prime, Nottingham, UK 
37% Formaldehyde Solution  Sigma-Aldrich, Poole, UK 
Nuclease-Free Water 9914G Applied Biosystems, Warrington, 
UK 
Nuclease-Free Water P1193 Promega, Southampton, UK 
Paraformaldehyde  Sigma-Aldrich, Poole, UK 
Phenol red solution  Sigma-Aldrich, Poole, UK 
N-Phenylthiourea  Sigma-Aldrich, Poole, UK 
Kanamycin  Sigma-Aldrich, Poole, UK 
Hydrogen peroxide, 30 
wt.%solution in water 
21, 676-3 Sigma-Aldrich, Poole, UK 
TRIzol Reagent 15596-018 Invitrogen, Paisley, UK 
Phenol:Chloroform:Isoamyl 
Alcohol 25:24:1 Saturated with 10 
P3803-100ML Sigma-Aldrich, Poole, UK 
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mM Tris, pH 8.0, 1mM EDTA 
Phenol:Chloroform 5:1, Acid-
equilibrated: pH 4.7 
P1944-400ML Sigma-Aldrich, Poole, UK 
GW9662 (PPARγ antagonist) M6191-5MG Sigma-Aldrich, Poole, UK 
Troglitazone (PPARγ agonist) T2573-5MG Sigma-Aldrich, Poole, UK 
Gentamycin Sulfate BP918-1 Fisher Scientific, Loughborough, UK 
10x DPBS without CaCl2 and 
MgCl2 
14200-083 Invitrogen, Paisley, UK 
Phosphate Buffered Saline 
(Dulbecco A) 
BR0014G Oxoid Limited, Basingstoke, UK 
Guanidine Thiocyanate G9277 Sigma-Aldrich, Poole, UK 
Alizarin Red S A5533-25G Sigma-Aldrich, Poole, UK 
Alcian Blue 8GX A5268-10G Sigma-Aldrich, Poole, UK 
N-Phenylthiourea, Grade I, ≈ 98% P7629-10G Sigma-Aldrich, Poole, UK 
Phenol red Solution, 0.5% in DPBS P0290 Sigma-Aldrich, Poole, UK 
Citric Acid (Monohydrate) C-1909 Sigma-Aldrich, Poole, UK 
Formamide F5686-1L Sigma-Aldrich, Poole, UK 
TWEEN 20 P1379 Sigma-Aldrich, Poole, UK 
Dimethyl sulfoxide DMSO D8418 Sigma-Aldrich, Poole, UK 
pH indicator sticks FB33003 Fisher Scientific, Loughborough, UK 
3.0 ml Graduated Pasteur Pipette E 1414-0300 Starlab, Milton Keynes, UK 
3.0 ml Fine Tip Pasteur Pipette E 1414-1300 Starlab, Milton Keynes, UK 
Ethyl 3-aminobenzoate, 
methanesulfonic acid salt, 98% 
MESAB 
E10521-50G Sigma-Aldrich, Poole, UK 
Ribonucleic acid, transfer, Type V, 
From Wheat Germ 
R7876-10KU Sigma-Aldrich, Poole, UK 
1 kb DNA Ladder N3232S New England Biolabs, Hitchin, UK 
100 bp DNA Ladder N3231S New England Biolabs, Hitchin, UK 
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Optical 96-Well Reaction Plate N801-0560 Applied Biosystems, Warrington, 
UK 
Optical Adhesive Film 4311971 Applied Biosystems, Warrington, 
UK 
Oil Red O 00625-25G Sigma-Aldrich, Poole, UK 
Oligo (dT)15 Primer 500 μg/ml C110A Promega, Southampton, UK 
rRNasin RNase Inhibitor 40 u/μl N251B Promega, Southampton, UK 
Gel Loading Dye Blue (6x) B7021S New England Biolabs, Hitchin, UK 
Gel Loading Buffer II 8546G Applied Biosystems, Warrington, 
UK 
Ampicillin sodium salt A9518-25G Sigma-Aldrich, Poole, UK 
TURBO DNase 2 u/µl with 
Ammonium Acetate Stop Solution 
2238G2, 9075G Applied Biosystems, Warrington, 
UK 
DIG RNA Labeling Mix, 10x, 
Digoxigenin-UTP 
11 277 073 910 Roche Diagnostics, Burgess Hill, UK 
Trypsin from bovine pancreas T9201-100MG Sigma-Aldrich, Poole, UK 
BCIP (5-Bromo-4-chloro-3-
indolyl-phosphate), 3 ml (150 mg) 
11 383 221 001 Roche Diagnostics, Burgess Hill, UK 
NBT (4-Nitro blue tetrazolium 
chloride)  
11 383 213 001 Roche Diagnostics, Burgess Hill, UK 
Random Hexamers 100 µl 50 μM N808-0127 Applied Biosystems, Warrington, 
UK 
Heparin 100 mg H3400-100MG Sigma-Aldrich, Poole, UK 
2.1.2 Enzymes 
Enzyme Catalogue Number Supplier 
Pfu Polymerase   
Protease, Type XIV: Bacterial,  Sigma-Aldrich, Poole, UK 
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From Streptomyces griseus 
(pronase) 
Proteinase K  Sigma-Aldrich, Poole, UK 
Restriction Enzymes  Invitrogen, Paisley, UK 
New England Biolabs, Hitchin, UK 
Promega, Southampton, UK 
RNaseA  Sigma-Aldrich, Poole, UK 
Power SYBR Green PCR Master 
Mix 
4367659 Applied Biosystems, Warrington, 
UK 
M-MLV RT, RNase H(-) Point 
Mutant 200 U/μl with 
M-MLV RT 5x Buffer 
M368B, M531A Promega, Southampton, UK 
RQ1 RNase-Free DNase 1 u/μl 
with 10x Reaction Buffer and Stop 
Solution 
M610A, M198A, 
M199A 
Promega, Southampton, UK 
GoTaq DNA Polymerase 5 u/μl 
with 
5x Green GoTaq Reaction Buffer 
M830A, 
M791B 
Promega, Southampton, UK 
T7 RNA Polymerase 10881767001 Roche Diagnostics, Burgess Hill, UK 
SP6 Polymerase 114 876 710 01 Roche Diagnostics, Burgess Hill, UK 
2.1.3 Equipment and Consumables 
Equipment for microinjections 
Equipment Catalogue Number Supplier 
Analogue gas microinjector  Tritech Research, Los Angeles, USA 
Borosilicate glass capillaries  
(OD 1 mm, ID 0.78 mm) 
300035 Harvard Apparatus, Kent, UK 
Flaming-Brown needle puller  Sutter Instruments, Novato, USA 
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Nanosep Centrifugal Devices 
(modified nylon membrane) 
516-8554 VWR, Lutterworth, UK 
Microloader Filling Tips 524 295 6003 Eppendorf, Hamburg, Germany 
 
Equipment for microarray 
Equipment Catalogue Number Supplier 
Unrestricted AMADID Release GE 4x44K 
60mer, 1X244K features, sold in multiples of 1-
1'x3' slides per kit, 1 micrroarray per slide 
G2519F Agilent, Waldbronn, 
Germany 
LRILAK PLUS, two-Colour Low RNA Input 
Linear Amplification Kit PLUS 
5188-5340 
Pack of 5 Backings, 4 Arrays/Slide G2534-60011 
Gene Expression Hybridization Kit 5188-5242 
Two Color RNA Spike-in Kit 5188-5928 
Gene Expression Wash Buffer Kit 5188-5327 
Stabilization and Drying Solution 5185-5979 
RNeasy mini kit 74106 Quiagen, Crawley, UK 
 
Equipment Supplier 
Stereomicroscope SMZ800 
with digital camera DXM1200 controlled by 
ACT-1 Version 2.70 software 
Nikon 
Stereoscopic Zoom Microscope SMZ 1500 
with Epi-fluorescence Attachment and digital camera DS-Qi1Mc 
controlled by NIS Elements software 
Nikon 
Stereomicroscope SMZ645 Nikon 
Heraeus Megafuge 11R Centrifuge  Thermo Scientific 
Heraeus Incubator (used for zebrafish embryos/larvae) Thermo Scientific 
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Milli-QPLUS 185, Ultra Pure Water System Millipore, Watford, UK 
Multi Genius, Bio Imaging System 
controlled by GeneSnap sofware 
Syngene, Cambridge UK 
NanoDrop ND-1000 Peqlab, Erlangen, Germany 
 
Equipment for PCR (polymerase chain reaction) 
Equipment  Supplier 
iQ5 Multicolor Real-Time PCR Detection 
System 
BIO-RAD, Hemel Hempstead, UK 
DNA Engine Tetrad 2 Peltier Thermal Cycler BIO-RAD, Hemel Hempstead, UK 
iQ5 software BIO-RAD 
Optical well plates Applied Biosystems, Warrington, UK 
Optical films Applied Biosystems, Warrington, UK 
PCR strips  
Single PCR tubes  
Optical well plates Applied Biosystems, Warrington, UK 
TripleMaster PCR System  Eppendorf, Hamburg, Germany 
2.1.4 Kits 
Kit Catalogue 
Number 
Supplier 
Plasmid Maxi Kit  Quiagen, Crawley, UK 
First Choice RLM-RACE AM1700 Applied Biosystems, 
Warrington, UK 
TOPO TA Cloning Kit (with pCR2.1-TOPO) K4500-01 Invitrogen, Paisley, UK 
Wizard SV Gel and PCR Clean-Up System A9282 Promega, Southampton, UK 
nMESSAGE mMACHINE SP6 AM1340 Applied Biosystems, 
Warrington, UK 
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TURBO DNA-free AM1907 Applied Biosystems, 
Warrington, UK 
Wizard Plus SV Minipreps DNA Purification 
System 
 Promega, Southampton, UK 
 
2.1.5 Morpholino oligonucleotides 
Targeted Gene Morpholino Morpholino type Sequence 
taf1 
taf1ATG targeting TCATCACTGTCCGAGTCTGACATTC 
taf1ATGmm mismatch control GCATCCCTGTCAGAGTATGACTTTC 
taf1UTR targeting CTCTCCTCTTGAAGTAAACCGGCAC 
btaf1 btaf1ATG targeting AGATAAAGAGACGTTCTAACCGCAT btaf1mm mismatch control AGAaAAAcAcACcTTCTAACCcCAT 
taf2 
taf2ATG targeting CCCTTGTCTTTCTTGCGGTTCATTC 
taf2ATGmm mismatch control ACCTTTTCTTTATTGCTGTTCCTTC 
taf2UTR targeting CCCTTAAGTCCATTTCGTCATGTCC 
taf3 
taf3ATG targeting GCGCGAAGCTCTCACACATCTCTCC 
taf3ATGmm mismatch control TCGCGACGCTCGCACAAATCTATCC 
taf3UTR targeting GGGCTTTGTTTTGGCCACTCACATC 
LOC100149942 
(taf4l) 
taf4lATG targeting ACGTCCCGATCAAAGTAGTTACCAT 
taf4lmm mismatch control ACcTCCCcATgAAAcTAcTTACCAT 
taf5 taf5ATG targeting CCATCCTGCACAGCCGCCATTTTTC taf5ATGmm mismatch control ACATCATGCAAAGCCTCCATTTTTC 
taf5l 
taf5lATG targeting GGACACGCTTCATCTCTGCATAATC 
taf5lUTRmm mismatch control AGTGAAGGCCTTTCCTTGAGACAAG 
taf5lUTR targeting CGTGAATGCCTGTCCTGGAGAAAAG 
taf6 
taf6ATG targeting TCTGTCTGCGTTCCTCTGCCATTTC 
taf6ATGmm mismatch control GCTGTATGCGGTCCTATGCCCTTTC 
taf6UTR targeting CAGCTATGTCTATTTAAAGCTGCCG 
taf6l taf6lATG targeting GCCGTTCCTCCCTCTCGGTCATCTT taf6lATGmm mismatch control GCCcTTgCTgCCTCTgGcTCATCTT 
taf7 
taf7ATG targeting TCCCACTTTTGTTTTTGAGGTCATC 
taf7ATGmm mismatch control NA 
taf7UTR targeting ATCAGAGAACAGCTAAATTGAGCAC 
taf8 taf8ATG targeting ATCATTACCGAGTCTGCCATTTTAG 
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taf8ATGmm mismatch control ATCATTAGCGACTGTGCGATTTTAC 
taf9 
taf9ATG targeting TTCGGAGACGCCATTTTTCACTCCT 
taf9ATGmm mismatch control TTCcGAcACGCgATTTTTgACTgCT 
taf9UTR targeting AGCGAGCGATCAGCCTTACCCAGAC 
si:dkey-72l14.8 
(taf10) 
taf10ATG targeting CGGTCTGCGTGAGATCCACGTTCAT 
taf10ATGmm mismatch control CGcTCTcCGTGAcATCCACcTTgAT 
taf10UTR targeting TTCCCGGCTTAGTTTATGTATTGCA 
taf11 
taf11ATG targeting GGGTCTGCCATGATTTCAGCTCAGA 
taf11ATGmm mismatch control TGGTCGGCCATTATTTAAGCTAAGA 
taf11UTR targeting CGACAACCGCGTTGAAAATAATGTT 
taf12 
taf12ATG targeting GCTGGATACTGGGTCATACTATGCT 
taf12ATGmm mismatch control TCTGGCTACTTGGTCCTACTCTGCT 
taf12UTR targeting TGTCAAATGTCACAAGCCTCTTCAG 
taf13 
taf13ATG targeting CGGGATCATCTTCTTCCTCGACCAT 
taf13ATGmm mismatch control AGGGAGCATCGTCTTACTCGCCCAT 
taf13UTR targeting ACACAAACAAACCAGCAGGAAACGC 
zgc:158363 
(taf15) 
taf15ATG targeting GTAGCCTGAATCTGAGGCCATCGTT 
taf15ATGmm mismatch control TTAGCATGAAGCTGAGTCCATAGTT 
taf15UTR targeting ATTAAAAACCCGGCACGAGCGAAAC 
2.1.6 PCR Primers (oligonucleotides) 
AZ: Andreas Zaucker. 
(1): from Adam Amsterdam (MIT, personal communication). 
(2): taken from (Jones et al., 2008). 
(3): taken from (McCurley and Callard, 2008). 
Primer name Gene Sequence 5’-3’ TM in °C Amplicon in bp Design 
(gDNA)       
Taf8 fw taf8 CTCTTTCCTTCACCCTGCTG 60 396 
AZ 
(gDNA)       
Taf8 rev taf8 GCTAACCCAATTCTCCATGC 58 AZ 
(gDNA)        
Taf6 fw taf6 TAGCGGTAACGCACAGACAA 58 390 
AZ 
(gDNA)       
Taf6 rev taf6 CTTTCAGGCAACAACCCATC 58 AZ 
Insert rev gtvirus, t5virus CTGTTCCATCTGTTCCTGAC 58 
186/148 (with Taf8 fw) 
246 (with Taf6 fw) (1) 
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Primer Name Gene Sequence 5'-3' TM in°C Amplicon from 
cDNA/gDNA in bp 
Design 
Taf8 fw 
taf8 
TGATAGCGCTGAGAAAGCTG 58 
187/953 
AZ 
Taf8 rev TTTGGCGTACACTGGAAGAG 58 AZ 
Taf6 fw 
taf6 
TCGGAACTAAATGGGCTGTG 58 
188/ (N/A) 
AZ 
Taf6 rev GCTTCTGTCTGCGTTCCTCT 60 AZ 
Bactin1 fw 
bactin1 
TCTTCACTCCCCTTGTTCAC 58 
198/1565 
AZ 
Bactin1 rev GGAGTCTTTCTGTCCCATGC 58 AZ 
Bactin1 II fw CGAGCAGGAGATGGGAACC 62 
102/102 
(3) 
Bactin1 II rev CAACGGAAACGCTCATTGC 58 (3) 
Fabp11a fw 
fabp11a 
CACCTTCAAAACCACCGAGA 58 203/(1781 and 
1772) 
AZ 
Fabp11a rev CCACATCACCCATCTTGCAT 58 AZ 
Fabp11b fw 
fabp11b 
TGAGCAGGGCGTCATCACTATGAA 65 
176/1121 
(2) 
Fabp11b rev TTGTGGTCTTTCCTTCCCAGGTCT 65 (2) 
Cd36 fw 
cd36 
GAACAGCTTGGTTGGAGCTT 58 
318/4847 
AZ 
Cd36 rev GCATCAACAGGCAGCAAGTA 58 AZ 
Lpl fw 
lpl 
TTACCCAACATCAGCCTCCT 58 
249/1173 
AZ 
Lpl rev GCGTCGTCTGGAGAAAGAGT 60 AZ 
Pparγ fw 
pparγ 
TGCCGCATACACAAGAAGAG 58 
240/11029 
AZ 
Pparγ rev GGCTTTGGTCAGAGGGAAGT 60 AZ 
Slc27a1a fw 
slc27a1a 
TCAGCAAGCTCTTCCTCCAT 58 
188/7941 
AZ 
Slc27a1a rev GCTCCTCGTTGACAAGTTCG 60 AZ 
Ef1a fw 
ef1a 
CTTCTCAGGCTGACTGTGC 59 
358/(N/P) 
(3) 
Ef1a rev CCGCTAGCATTACCCTCC 58 (3) 
Fabp2 fw 
fabp2 
ATTCTCTGGCAGACGGCACT 61 
166/2368 
AZ 
Fabp2 rev TTGGCCTCGACTCCATCATA 58 AZ 
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2.1.7 Zebrafish lines 
Line Description 
AB Wildtype line 
taf8hi3079Tg Mutant line generated by insertional mutagenesis. The foreign 
sequence (GT transgenic construct) inserted into the first intron. 
taf8hi4055Tg Mutant line generated by insertional mutagenesis. The foreign 
sequence (GT transgenic construct) inserted into the first intron. 
taf6hi80aTg Mutant line generated by insertional mutagenesis. The foreign 
sequence (F5 transgenic construct) inserted into the first intron. 
fli1a:EGFP gata1:dsRed Double transgenic line with fli1a:EGFP driven expression of 
enhanced GFP (green fluorescent protein) in the blood 
vasculature, the dorsal aorta, the posterior cardinal vein and the 
thoracic duct . The gata1:dsRed transgene drives expression of 
dsRed in the dorsal aorta, the erythroid cell lineage and in the 
posterior cardinal vein (Rampon et al., 2009, Yaniv et al., 2007). 
 
The taf8-mutants used in this thesis were a mix of the two taf8-mutant lines. The difference 
between the two mutant alleles (taf8hi3079Tg and taf8hi4055Tg) is negligible. The two independent 
insertions occurred in very close proximity in the first intron of the taf8 gene. There are only 38 
bp between the insertion sites. Both alleles are mutant alleles, it shouldn’t matter for the 
experiments in this thesis, which combination of two taf8-mutant alleles generates the mutant 
phenotype as long as it is a taf8 LOF phenotype. Because this is the case for all combinations the 
term taf8-mutant in this thesis refers to taf8-mutants irrespective of the exact combination of 
mutant alleles. 
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Figure 2.1 – Insertion sites of the hi4055 and hi3079 alleles 
Shown are the insertion sites of the two nearly identical taf8-mutant alleles, taf8hi3079Tg and 
taf8hi4055Tg. The information is taken from the Hopkins lab web page 
(http://web.mit.edu/hopkins/). 
2.1.8 Web-based databases and bioinformatic tools 
Ensembl   http://www.ensembl.org/index.html 
NCBI    http://www.ncbi.nlm.nih.gov/ 
UCSC    http://genome.ucsc.edu/ 
DAVID   http://david.abcc.ncifcrf.gov/home.jsp 
OligoCalc   http://www.basic.northwestern.edu/biotools/oligocalc.html 
Primer3   http://frodo.wi.mit.edu/primer3/ 
BioVenn   http://www.cmbi.ru.nl/cdd/biovenn/ 
ZFIN    http://zfin.org/cgi-bin/webdriver?MIval=aa-ZDB_home.apg 
KEGG    http://www.genome.jp/kegg/kegg2.html 
ZF-Espresso   http://zf-espresso.tuebingen.mpg.de/ 
Nancy Hopkins web page http://web.mit.edu/hopkins/ 
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2.1.9  Software 
SigmaStat for Windows Version 3.5 (Systat Software, Inc) 
Serial Cloner 1.3-11 
Bio-Rad iQ5 
ImageJ software 
Microsoft Excel 2007 
2.2 Zebrafish methodology 
2.2.1 Production of embryos 
Zebrafish embryos can be easily obtained by crossing adult fish. Females and males can be 
distinguished by body-shape and colour. Healthy, egg-producing females, have a big white belly 
and their colour is bluish grey. Males are slender and their colour is more yellowish golden. A 
female needs three stimuli to lay: Light (in the wild zebrafish lay in the morning), males and a not 
to low water temperature <20°C. If zebrafish are pair-wise put together directly from their 
communal tanks in the morning they lay with a big delay, or they do not lay at all. Both is not 
desired for experiments, where the time of the production of fertilised eggs needs to be 
controlled. If the pairs are put together in small crossing cages the day before, their laying 
behaviour is much better and they will start to mate as soon as there is light on the next morning. 
The crossing cages contain neatly fitting inlays with a mesh bottom, which separates the adult 
zebrafish from the eggs. This is necessary, because the adult zebrafish would eat the eggs. 
Furthermore, the inlay itself can be subdivided into two compartments using a divider. If female 
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and male were kept in separate compartments over night (O/N), they only can mate if the divider 
is removed. The experimentator thereby can control when eggs (embryos) are produced. This is 
especially important for experiments where synchronised and/or early (zygote, one cell stage) 
embryos are required, like microinjections. 
2.2.2 Rearing zebrafish larvae 
The cages used for crossings of adults fit in the top of small fish tanks such a way, that most of 
the cage is submerged into the water of the tank, but the fringe of the cage still stays above the 
surface level of the water in the tank. Thereby the temperature for egg incubation in the cages is 
controlled by the system. In those cages zebrafish embryos are reared. It is critical to rear 
embryos in a container with a low surface level of the medium. This allows early larvae to reach 
the surface for swallowing air, to initially inflate their swim bladders. The inflation of the swim-
bladder allows larvae to stay at the surface for feeding. After approximately one month, they are 
then released from the cages into the communal tanks. 
2.2.3 Microinjections 
Microinjection of early zebrafish embryos was carried out manually, without micromanipulator. 
The embryos are readily accessible and there are no obstacles, like strong envelops or shells. The 
chorion is relatively weak until 2 cell stage. Thus, injection is carried out through the chorion into 
the cytoplasm, or into the unsegregated ooplasm 10-15 min after fertilisation. The embryos can 
be immobilised prior to injection by complete removal of the medium from the Petri dish. 
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2.2.3.1 Injection solutions 
The injection solutions for the MO-screen were prepared the following way:  
A 5% rhodamin solution was prepared dissolving the powder in nuclease free water. The 5% 
rhodamin solution was filtered through a microspin column to remove all undissolved rhodamin 
powder. Similarly, a 0.5% phenol red solution was prepared, spinning the stock solution through 
a microspin column to remove un-dissolved phenol red. Prior to use the 1 mM MO (in nuclease-
free water, NFW) stock solutions were heated to 65°C for 5 min to bring any precipitated MO 
back into solution. 
MO injection solutions 
Stock solution, concentration Volume in µl Final concentration 
MO, 1 mM 1 100 µM 
Rhodamin, 5% 1 0.5% 
Phenol red, 0.5% 2 0.1% 
NFW 6  
Final Volume 10  
2.2.3.2 Dechorionation of embryos and larvae 
Early zebrafish embryos <1 hpf can be easily dechorionated by pronase digestion of the chorion, 
which is composed of glycoproteins. Later the chorion hardens and during gastrulation stages it is 
impossible to digest the chorion by pronase without damaging the embryos. From 24 hpf on the 
embryos can again be efficiently digested using pronase. An alternative to enzymatic 
dechorionation with pronase is manual dechorionation with forceps, which can be done from late 
somitogenesis stages onwards. 
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Dechorionated embryos ≤30 hpf are fragile and should not be kept in plain Petri dishes, where 
they might stick to the plastic and break when moved. Instead, they have to be kept in agarose 
gel-coated Petri dishes (agarose-plates). Agarose-plates are made by heating a 1% suspension of 
agarose in Hank’s medium (140 mM NaCl, 5.4 mM KCl, 4.2 mM NaHCO3, 1.3 mM CaCl2, 1 
mM MgSO4, 440 μM KH2PO4, 250 µM Na2HPO4) till it forms a gel. The hot gel can then be 
poured into Petri dishes. When the gel has solidified the Petri dish is coated with an agarose gel. 
 
Dechorionation of early embryos (zygote, 1 cell stage) 
If dechorionated embryos younger than Prim-5 stage were needed for experiments, the embryos 
were dechorionated right after fertilisation. Freshly laid eggs are opaque and their chorion is not 
inflated. In this stage they can be easily damaged. When they had cleared up and their chorion 
had swollen up they were collected and put into non-coated small Petri dishes (Ø 6 cm). Extant 
liquid above the chorions was removed. Then 500 µl (for ≤500 embryos) or 1 000 μl (for more 
than 500 embryos) of pronase (10 mg/ml in Hank’s) were added and the pronase evenly 
distributed by shaking. The pronase was preheated in hand warm water from the tap. The Petri 
dish then was left standing under the microscope till the first embryos (approximately5) can be 
seen, which have left the chorion. This should happen within the first 5 min after adding the 
pronase. Keeping the embryos for to long in pronase carries the risk to over-digest them. The 
Petri dish then was carefully submerged into a 500 ml beaker containing clean water from the 
system. Because the embryos break at the surface-tension, they have to stay submerged 
throughout. The water was decanted as far as possible and fresh water was added letting it run 
down the wall of the tilted beaker. The movement of the embryos generated by this stream helps 
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to dechorionate them. This washing step to remove the pronase was repeated two more times. 
After the last washing the embryos were transferred into agarose gel coated Petri dishes using 
plastic Pasteur pipettes. 
 
Dechorionation of embryos at 1 dpf 
Embryos around or older than Prim-5 stage were either dechorionated manually using forceps, or 
by pronase digest. The 1 dpf embryos usually were digested in a similar way to the early 
embryos, but in large Petri dishes (Ø 9 cm), by adding 1 ml of pronase (10 mg/ml). In contrast to 
the early embryos the 1 dpf embryos were not kept standing under the microscope but were 
vigorously shaken approximately every minute till most had left the chorion. The washing steps 
again were the same like the ones for early embryos. Embryos younger than or in Prim-5 stage 
were transferred into agarose-plates, because they still are fragile. Embryos around or older than 
Prim-15 stage were transferred into plain Petri dishes. 
2.2.3.3 Injections 
To ensure an optimal, homogenous distribution of the injected material, it is critical to inject 
zebrafish embryos at the earliest possible time point. In the egg the cytoplasm (ooplasm) is mixed 
with the yolk. After fertilisation the cytoplasm separates from the yolk and forms the first 
blastomere (cell) at the animal pole. Structures called axial streamers are involved in this 
transport process of the ooplasm to the animal pole. In my experience, it is optimal to microinject 
the embryos as early as possible, at a time point before the beginning of separation of ooplasm 
and yolk (zygote), or while the first blastomere just begins to form. The injected material then 
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together with the ooplasm is transported into the first cell (blastomere). Because the first 
blastomere is fully formed already around 12 min after fertilisation, there is little time to 
dechorionate the embryos before injections. The microinjections performed for this thesis 
therefore all were done with non-dechorionated embryos, between zygote and 1 cell stage. 
An alternative to the strategy described above is to inject the material directly into the first 
blastomere. Furthermore, axial streamers are still present at least up to the 8 cell stage (Fuentes 
and Fernandez, 2010) and the blastomeres  are not completely separated from the yolk cell by a 
plasma membrane until the 8 cell stage (marginal cells even cycle 10) (Kimmel et al., 1995). 
Small molecules therefore can reach the cytoplasm of the blastomeres also when injected at later 
stages, by diffusion. 
For microinjections through the chorion, embryos are collected with a net, right after the eggs 
have cleared up and the chorion has swollen up. The collected embryos then were placed into a 
small Petri dish. If the embryos are collected too early, they will be damaged during the 
microinjection process, because they are attached to the chorion. The embryos were collected in 
the middle of the Petri dish and the liquid was removed completely. This is necessary to prevent 
the embryos from rolling away while trying to inject them. 
The embryos then were injected with the injection solutions using a nitrogen gas injector. This 
gas injector is a relatively simple system using the pressure from compressed nitrogen in a gas 
bottle to press (shoot) the injection solution, which was filled into an injection needle using 
microloader tips, into the embryo. Because I injected embryos before the 1 cell stage the injection 
solutions were injected at random positions, cortically, just under the plasma membrane. Material 
injected that way efficiently localised to the cytoplasm of the first cell. If the material is injected 
deeper into the embryo, it might be trapped there and not be transported into the first cell. The 
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phenol red in the injection solution serves to control the amount of solution injected. The 
diameter of the injected drop of injection solution was around one tenth of the diameter of the 
embryo. The amount injected with the gas injector system can be controlled using a valve, which 
opening is controlled by a pedal. The opening time when pressing the pedal can be controlled be 
a dial. The injections were done by free hand with an injection needle attached to a holder which 
is connected to the valve via a silicone tube. The injection needles were made from borosilicate 
capillaries using a needle puller. 
2.2.3.4 Vipar knock down and rescue experiments 
The experiments aiming for the characterisation of the zebrafish vipar-morphant were performed 
in collaboration with Andrew R. Cullinane and the Gissen group. A detailed description of the 
performed experiments can be found in Andrew R. Cullinane’s PhD thesis: “Characterisation of 
the Role of VPS33B in Vesicular Trafficking in Polarised Epithelial Cells (University of 
Birmingham, 2009)”. 
MOs against the start codon (vipar ATG MO) and the intron2-exon3 splice junction (vipar Exon3 
MO) injected into early embryos prior to the formation of the first blastomere. The concentration 
in the injection solutions was 10 μM for the ATG MO and 100 μM for the Exon3 MO. As a 
control MO served a MO with five mismatches in its sequence compared to the Exon3 MO. The 
concentration of the control MO was 100 μM in the injection solutions. The MO injection 
solutions contained 10 ng/μl CFP-mRNA (cyan fluorescent protein) as a injection control. 
For rescue experiments half of the MO injected embryos were injected a second time with 100 
ng/μl vipar-mRNA. This injection solution contained RFP-mRNA as a injection control. To 
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control the specificity of the rescue with vipar-mRNA, control rescue experiments with 120 ng/μl 
RFP-mRNA were performed. Using the CFP and RFP fluorescence the embryos were sorted into 
MO injected and double injected (MO + RNA) embryos at 1 dpf (Figure 2.2). 
 
Figure 2.2 – Fluorescence sorting of embryos from rescue experiments 
The injection solutions used for the rescue experiments of the vipar-morphants contained 
mRNAs encoding for fluorescent proteins. The MO injection solutions contained CFP-mRNA 
and the vipar-mRNA injection solutions contained also RFP-mRNA. The fluorescence then was 
used to distinguish MO only injected embryos (CFP positive) from embryos which were injected 
with both, the MO and the rescuing mRNA (CFP and RFP positive). 
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2.2.4 Imaging of embryos and larvae 
All the imaging for this thesis was performed using the Stereomicroscope SMZ800 with the 
digital camera DXM1200 controlled by ACT-1 Version 2.70 software. 
2.3 MO-screen 
In the MO-screen we targeted 18 Taf proteins implicated in Pol II transcription, plus additional 
13 non Taf targets. The experiments for the non Taf targets are not discussed in this thesis. 
Because of the scale of the experiment, 31 targets, we didn’t carry out the full set of controls for a 
MO-mediated kd experiment. As specificity controls served mismatch MOs (5 mismatches) for 
the targeting MOs. But no rescue experiments were performed. All MOs used for the screen were 
translation blocking MOs, targeting the AUG or the 5’-UTR (untranslated region) sequence. The 
reason for not including splice interfering MOs is, that all Taf transcripts are already present in 
the unfertilised egg (unpublished CAGE data). Because the maternal Taf transcripts are already 
spliced, they cannot be targeted with splice MOs. 
2.3.1 MO-screen protocol 
Day 1: Injections 
The MOs were injected through the chorion, into early (<1 cell stage) embryos, like it was 
described in (chapter 2.2.3.3). The injections usually were performed in the morning between 
9.30 am and 12.30 pm. The injected embryos were obtained from crossings of the AB line. 
Because we were aiming at 100 embryos for phenotype analysis, between 100-200 embryos per 
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injection solution were injected. Twelve rounds of injections were performed to cover all 
injection solutions and the repeats of experiments. 
After injections the embryos were kept at 28°C (incubator) in large Petri dishes containing 
Hank’s medium supplemented with gentamicin (50 µg/ml). In the afternoon of the day of 
injection the Petri dishes were cleaned using plastic Pasteur pipettes. That means that everything 
what is not a developing embryo was removed: Non-fertilised eggs, fish scales, dead embryos, 
pieces of food and faeces. After cleaning, the Hank’s medium (+ gentamicin) was replaced. 
 
Day2: Fluorescence sorting and 1 dpf phenotype analysis 
In the morning, the Petri dishes were cleaned again by removing dead embryos. This in nearly all 
cases only were very few (<10 embryos) and is very unlikely to be caused by the MOs, but rather 
by damaging during injections or by maternal/paternal defects.  
Under the fluorescence microscope, non-injected, or embryos with a non-homogenous, poor 
distribution of the rhodamin tracer (red fluorescence), were sorted out. In each Petri dish 5 non-
injected embryos were left, to serve as wildtype reference embryos for the phenotype analysis. 
After the fluorescence sorting of embryos using rhodamin as an injection control, the embryos 
were enzymatically dechorionated like it is described in (2.2.3.2). The dechorionation was done 
after the fluorescence sorting because it is easier to sort embryos which are still in the chorion. 
After dechorionation the embryos were transferred into new Petri dishes and the medium used 
was changed to Hank’s medium without gentamicin. 
If a significant number of embryos at 1 dpf showed a phenotype, this phenotype was analysed. 
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Day3: 2 dpf phenotype analysis 
In some experiments the embryos not were dechorionated at 1 dpf but in the morning of the 
second day post fertilisation, either enzymatically or manually. Two dpf was the main stage for 
the analysis and documentation of the MO-induced phenotypes. 
For the phenotype analysis the embryos were transferred into a large agarose-plate. Then the 
embryos were anesthetised by adding drops of MESAB (4 mg/ml tricaine in Hank’s) to the 
medium in the agarose-plate and shaking the plate to distribute the MESAB in the medium. This 
procedure was repeated till the embryos stopped moving, but still had a relatively normal heart 
beat and blood circulation. In that condition the embryos can be left for hours to analyse their 
phenotype, without any adverse effects on their development, upon replacing medium afterwards. 
The embryos of each Petri dish (MO-injection) were separated into groups sharing same features 
of the phenotype, into categories of phenotypes. The numbers of embryos in each group (also the 
wildtype group) were documented and the phenotypes were described using the (non-injected) 
wildtype embryos as a reference. The 5 non-injected wildtype embryos were not taken into 
account when counting the embryos in each category of phenotypes. The imaging of the embryos 
and larvae was performed in agarose-plates. To obtain proper side view images, with the 
embryo/larvae in focus throughout, the yolk ball of the embryos/larvae was placed into a hole, 
which was cut out from the agarose gel using a small needle. 
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2.4 Histology Methods 
2.4.1 Staining of cartilage with alcian blue 
The larvae were fixed for 2 h in 4% PFA fixative, at RT. Afterwards they were washed once with 
0.1% Tween 20 in dH2O for 5 min. 
The larvae were stained in alcian blue staining solution (0.1 g/ml alcian blue, 0.1 N HCl, 0.1% 
Tween 20 in dH2O) for two days at 4°C. 
The larvae were bleached for two hours in bleach solution (0.3% H2O2, 1% KOH, 0.1% Tween 
20 in dH2O). Afterwards they were rinsed two times in 0.1% Tween 20 (in dH2O). 
The larvae were pre-incubated for 10 min in saturated sodium borate buffer (30% saturated 
Sodium Borate, 70% dH2O, 0.1% Tween 20). Then the soft tissue was digested O/N at 4°C by 
the trypsin in the digestion solution (0.05 mg/ml Trypsin, 30% saturated Sodium Borate, 0.1% 
Tween 20 in dH2O). 
The stained larvae were stepwise (25%, 50%, 75%) transferred into 86% Glycerol. The stained 
larvae were imaged on a depression slide under the Stereomicroscope SMZ800, with the digital 
camera DXM1200 controlled by the ACT-1 Version 2.70 software. 
2.4.2 Staining of lipids with Oil Red O 
The Oil Red O stainings were performed by Nan Li. The drug treatments and the initial analysis 
of the stainings, pictures and defining staining categories, were performed by the candidate. Nan 
Li scored the phenotypes according to the staining categories. 
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Larvae were fixed O/N in 3.7% formaldehyde (in PBS) at 4°C. The formaldehyde was removed 
by washing the samples for 5 min in PBS (2.67 mM KCl, 1.47 mM KH2PO4, 137.93 mM NaCl, 
8.06 mM Na2HPO4-7H2O). Then the larvae were incubated for two hour at RT in Oil Red O 
staining solution (0.3% ORO in 70% 2-propanol). 
2.4.2.1 GW9662-treatments (PPARγ inhibitor) 
For treatments with PPARγ inhibitor the embryos were incubated for 72 hours in E3-medium (5 
mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2 and 0.33 mM MgSO4) which was either 0.5 or 5 μM 
for the PPARγ inhibitor GW9662. There were no statistically significant differences in the lipid 
staining behaviour between larvae treated with 0.5 or 5 μM GW9662. Because of that, the three 
experiments for 0.5 μM and the three experiments for 5 μM were analysed together as GW9662-
treated larvae. Control groups were incubated in E3-medium which contained the same amount 
of DMSO which was added to the 5 μM GW9662 treated larvae as a solvent for GW9662. 
2.4.3 Whole-mount in situ hybridisation with zebrafish ovaries 
1. Fixation 
Dissected zebrafish ovaries were fixed in BT-Fix (77 mM Na2HPO4, 23 mM NaH2PO4, 120 μM 
CaCl2, 220 mM sucrose and 4% paraformaldhyde) O/N at 4°C. The next day the BT-Fix was 
replaced by 100% MeOH and the samples were kept O/N at -20°C. 
2. Rehydration and hybridisation with digoxigenin-labelled antisense YFP-probe 
The YFP-probe was generated by in vitro transcription of the reverse strand of the EYFP coding 
sequence inserted into pUT+ vector. 
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The ovaries stepwise were rehydrated via passing through a dilution series of MeOH in PTW 
(PBS with 901 μM CaCl2, 493 μM MgCl2-6H2O and 0.1% Tween 20) at RT. They were 
incubated for 5 min in each dilution (75%, 50%, 25% MeOH) to allow for equilibration. Then 
they were washed 3 times for 5 min in PTW. 
Afterwards the ovaries were preblocked in 500 µl Hyb-Buffer (50% formamide, 5xSSC, 1 mg/ml 
yeast total RNA, 50 μg/ml Heparin, 9 mM Citric Acid and 0.1% Tween 20) for 4 h at 67°C 
(water bath). Then 1 µl of digoxigenin-labelled antisense YFP-probe was added to the Hyb-
Buffer. The ovaries were incubated O/N at 67°C with that 1:500 dilution of YFP-probe. 
3. Immunodetection of hybridised probe 
Non-hybridised probe was washed out by the following washing steps in 20xSSC (3 M NaCl, 0.3 
M trisodium citrate) dilutions at 67°C: 
- 2x 30 min with Washing Buffer I (1xSSC, 50% formamide and 0,1% Tween 20) 
- 1x 15 min with Washing Buffer II (2xSSC and 0,1% Tween 20) 
- 2x 30 min with Washing Buffer III (0.2x SSC and 0,1% Tween 20) 
Afterwards the ovaries were rinsed in Blocking Buffer (1% DMSO, 0.2% BSA and 0.1% Tween 
20 in PBS). Then the ovaries were blocked in Blocking Buffer for 4 h at RT. In parallel a 1:400 
dilution of antiDIG-antibody (Fab-fragment conjugated with AP) was preblocked in Blocking 
Buffer with fish powder. After removing the fish powder by spinning it down, the preblocked 
antibody was further diluted (1:4000) in Blocking Buffer. The ovaries were incubated O/N with 
that 1:4000 dilution of antibody at 4°C. 
4. Alkaline phosphatase (AP) staining of the ovaries with BCIP/NBT chromogenic substrate 
Unbound antibody was washed out by the following washing steps: 
- 1x rinsing in PTW 
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- 6x washing in PTW for 20 min 
Then the ovaries were equilibrated in the alkaline Staining Buffer (100 mM TrisHCl pH 9.5, 100 
mM NaCl, 50 mM MgCl2 and 0.1% Tween 20) for 5 min. Finally the ovaries were incubated in 
Staining Solution (306 μM NBT and 500 μM BCIP dissolved in Staining buffer) until a purple 
staining was visible (ca 1 h). The Staining was stopped by rinsing the ovaries with PTW followed 
by postfixing them with BT-Fix. 
2.5 Preparation of cDNA (complementary DNA) from 
total RNA for qPCR and RT-PCR experiments 
2.5.1 Total RNA preparation using the TRIzol method 
Total RNA was prepared using the TRIzol Reagent (Invitrogen, Paisley, UK). This method can 
be used to simultaneously prepare RNA, DNA and protein from the same sample. For the work 
described in this thesis, it solely was used for RNA preparations. The preparations were done 
following the manufacturer’s instructions for RNA-preparations from tissue-samples. For the 
comparative gene expression experiments at 2 dpf the amount of larvae from which total RNA 
was prepared ranged from 3-5 larvae per sample. For all 3 dpf experiments 12 larvae per sample 
were used. In the following the RNA-preparation protocol for the 3 dpf experiments is described. 
For the 2 dpf experiments all volumes were scaled down to half and 0.5 ml reaction tubes were 
used. 
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Homogenisation 
The samples were put on ice and 500 μl of TRIzol-Reagent were added. Then the sample was 
homogenised crushing the larvae in the TRIzol-Reagent with a pistil. Following this initial 
homogenisation, additional 500 μl of TRIzol-Reagent were added to the samples. The samples, 
now in 1 ml TRIzol, were further homogenised by sucking them up and down three times through 
a narrow hypodermic needle. After the homogenisation the tube was left at RT for at least 5 min 
to allow complete dissociation of nucleoprotein complexes. 
Phase Separation 
200 μl Chloroform were added to the homogenate and the tube was vigorously shaken (vortexed). 
After vortexing the tubes were left at RT for 3 min. Then the tubes were spun with 12 000 g at 
4°C for at 15 min. After the centrifugation the solution had separated into three phases, with the 
upper aqueous phase containing the RNA. 
Precipitation 
For precipitation of the RNA, the aqueous phase (≈600 μl, 60% of volume of TRIzol reagent 
used) needs to be transferred into a fresh tube. To prevent carry-over of material from the other 
phases, only two thirds (400 μl) of the aqueous phase were pipetted into a fresh 1.5 ml reaction 
tube. The RNA was then precipitated by mixing the aqueous solution with 500 μl of added 
isopropanol, followed by inverting the tube several times. The tubes were spun shortly, to collect 
the solution from the wall of the tube and left at RT for around 10 min. The solution was then 
centrifuged with 12 000 g at 4°C for 10 min. 
Washing of pellet 
The RNA was now visible as a pellet on the side wall of the bottom of the tube. The supernatant 
was removed completely and 1 ml of 75% ethanol in autoclaved dH2O was added. Then the tube 
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was vortexed to break the pellet and expose it to the washing solution. Afterwards the solution 
was spun with 7500 g at 4° for 5 min. This washing step was repeated once 
Air-drying of pellet and redissolving of RNA pellet 
The washing solution was removed completely and the tube was left with an open lid in a rack 
for air-drying of the pellet. When ethanol solution had evaporated completely (≤10 min), the 
RNA was redissolved in 20 μl NFW. 
2.5.2 cDNA synthesis 
The quality of the total RNA was checked on an agarose gel and the quantity of the total RNA 
was measured using a NanoDrop spectrophotometer. 
The total RNA was reverse transcribed into cDNA using a reverse transcriptase (RT). These are 
retroviral enzymes, RNA-dependent DNA-polymerases, which use a single stranded RNA-
template (retroviral genome) to synthesise the complementary DNA strand (cDNA). Reverse 
transcriptases are used in molecular biology to produce cDNA from RNA templates. 
For reverse transcription of the total RNA from the samples the RT M-MLV (RNase H Minus, 
Point Mutant; Promega, Southampton, UK) was used. Like DNA polymerases, reverse 
transcriptases need a primer, an oligonucleotide which hybridises to the complementary sequence 
of a single stranded RNA/DNA molecule. This primer, when hybridised to its target, generates a 
double stranded starting point for the polymerase, with a 3’-end for the addition of the next 
complementary nucleotide. For reverse transcriptase reactions, one can choose from three types 
of primers: 
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1. Specific primers: Specific primers have a sequence which is complementary to a specific 
RNA template. In a RT reaction using specific primers only one type of RNA molecules 
will efficiently be reverse transcribed into cDNA, e.g. one specific mRNA. 
2. oligo dT primers: These primers are used to reverse transcribe all mRNAs in a RNA 
preparation into cDNA. Oligo dT primers hybridise to the polyA tail of mRNA, providing 
a starting point for the RT at the 3’-end of the transcript. Because the reverse transcriptase 
only efficiently synthesises around 2 kb of the complementary sequence, only the 3’-ends 
of transcripts will be quantitatively represented in a cDNA preparation using oligo dT 
primers. 
3. Random hexamers: Random hexamers are used to try to reverse transcribe all of the 
single stranded RNA molecules present in a RNA preparation into cDNA. As the name 
suggests, random hexamers are a mixture of hexamers of different, random sequence. By 
chance these random hexamers should target all RNA molecules and all regions of the 
RNA molecules in a RNA preparation. Thus, cDNA prepared using random hexamers 
should reflect the RNA used for the RT reaction. 
The principle of the protocol for cDNA synthesis using M-MLV is shown Figure 2.3. A master 
mix for the RT reaction was prepared on ice in 1.5 ml tubes. In a PCR tube, the RNA template 
(total RNA) was mixed with primers for an annealing reaction. To prepare cDNA for qPCR 
(quantitative PCR) and RT-PCR oligo(dT)15 primers were used. After the annealing reaction the 
RT Master Mix was added to the Annealing Reaction Mix and the two solutions were mixed by 
pipetting up and down several times. The resulting RT Reaction Mix then was incubated at 40°C 
for the initial 10 min and then at 50°C for 50 min in a Tetrad Thermocycler. 
85 
 
 
Figure 2.3 – Preparation of RT Reaction Mix 
The Annealing Reaction Mix, in which the primers are annealed to the RNA template, was mixed 
with a RT Master Mix. That resulted in the RT Reaction Mix, in which the RNA template was 
reverse transcribed into cDNA. 
 
 
RT Reaction Mix 
Component, Concentration Volume in µl Final Concentration 
M-MLV RT 5x Reaction Buffer 5  1x 
dNTPs (10 mM each) 1.25 400 nM 
M-MLV (H-) point mutant (200 U/µl) 0.5 4 U/µl 
RNasin (40 U/µl) 0.2 0.32 U/µl 
Annealing Reaction Mix 
- 1 µg total RNA 
- 500 μg/ml OligodT15 primer 
- NFW 
14 
<5 
1 
fill up to 14  
 
40 ng/µl 
20 ng/µl 
NFW 4.05  
Total volume 25  
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2.5.3 Agarose gel electrophoresis 
DNA and RNA fragments can be separated by size by agarose gel electrophoresis. Because of the 
phosphodiester group in the backbone of nucleic acids, which has a very low pKa, nucleic acids 
are negatively charged at a wide range of pHs. When placed into the electric field between a 
cathode and an anode, the negatively charged nucleic acid molecule will be accelerated towards 
the positively charged anode. Because of the highly similar charge/mass ratio of nucleic acid 
fragments of different length, they would move with the same velocity, if there wouldn’t be 
differential resistance acting on their movement. This differential resistance is generated by the 
matrix of an agarose gel, which lets fragments of a smaller size travel faster than fragments of a 
larger size. Parameters which influence the velocity with which the nucleic acid fragment will 
travel in the gel are: The percentage of the gel, the electric field applied (potential), the 
temperature, and besides the length of the nucleic acid fragment, also its geometry. 
Agarose gel electrophoresis protocol 
A suspension of agarose powder in TBE-Buffer, the running buffer for agarose gel 
electrophoresis, was prepared in a flask. The percentage of agarose was depending on the size of 
fragments to be separated on the gel. In most cases 1% gels were prepared. The suspension then 
was heated in a microwave till the solution was completely clear. The gel then was left on the 
bench to cool down (hand warm, ≤60°C), before 2 μl ethidiumbromide (500 μg/ml) per 50 ml gel 
were added. The ethidiumbromide was distributed homogenously by carefully shaking the flask. 
The gel then was pureed into a tray for solidification. Combs can be positioned over the tray that 
way, that their teeth generate little wells in the gel, after solidification. 
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The agarose gel then was placed in chamber between a cathode and an anode. The chamber was 
filled with TBE-Buffer till the gel just was covered with solution. Then the comb was removed. 
This generates little wells in the gel, which can be loaded with samples. After loading the 
samples, an electric field was applied by a power source. The voltage applied was depending on 
the length of the gel. The rule of thumb for the voltage is: 5-10 V per cm of distance between the 
electrodes. Usually samples are mixed with a (gel) loading buffer before loading. The loading 
buffer contains visible dyes, which running behaviour on the gel is comparable of DNA/RNA-
fragments of a certain size. Usually a loading buffer contains one small, fast running and one 
large, slow running dye. Thus the dyes are demarcating the range where the DNA/RNA-
fragments are running on the gel. 
The ethidiumbromide is used to visualise the double stranded DNA/RNA molecules. It 
intercalates in between the stacks of base pairs in the double helix, which intensifies the 
fluorescence of ethidiumbromide about 20 fold. When placed in the dark on a certain UV tables, 
the UV light excites the fluorescence of the ethidiumbromide. Because the ethidiumbromide will 
be concentrated and stronger at accumulations of DNA fragments, DNA fragments of the same 
length will appear as fluorescent bands on the gel. The size of the fragments in those bands can 
be estimated by comparing their height on the gel to the bands of a marker (DNA/RNA ladder), 
which ran alongside the sample. Because the composition of the marker is known, the size of the 
fragment corresponding to each band of the marker is known. Comparing the height of a band to 
bands of the markers running at a similar height can give a good estimation of the size of a 
fragment. 
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2.6 Comparative gene expression analysis 
2.6.1 Genotyping PCRs 
The genotyping PCRs for the 2 dpf qPCR experiments were performed with a piece of tail, 
analogue to a colony-PCR. A small piece of tail was cut from the 2 dpf embryos using small 
hypodermic needles. The rest of the embryo was immediately homogenised in TRI-Reagent for 
total RNA preparation. The embryos were terminally anesthetised with MESAB just prior to the 
procedure to prevent RNA degradation in dead embryos. The small piece of tail was directly 
thrown into a genotyping PCR reaction mix.  
The reaction mix contained three primers for the potential amplification of both alleles in the 
PCR, the wildtype and the mutant allele. The size of the PCR-products for the wildtype and the 
mutant allele were sufficiently different to be resolved on an agarose gel. The genotyping PCRs 
enabled us to prepare cDNAs from mutants and their wildtype siblings at a developmental stage, 
at which wildtypes and mutants are indistinguishable from each other. 
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PCR reaction mix for the taf8 genotyping PCRs 
Component, Concentration Volume in µl Final concentration 
5x Taq Buffer (+ MgCl2) 4 1x 
dNTPs (10 mM each) 0.4 200 µM 
gDNA Taf8 fw primer, 10 μM 1.2 600 nM 
gDNA Taf8 rev primer, 10 μM 0.8 400 nM 
Insert rev primer, 10 μM 0.6 300 nM 
Taq DNA Polymerase (5 U/µl) 0.2 0.05 U/µl 
Template, piece of tail   
NFW 12.8  
Total volume 20  
 
PCR reaction mix for the taf6 genotyping PCRs 
Component, Concentration Volume in µl Final concentration 
5x Taq Buffer (+ MgCl2) 4 1x 
dNTPs (10 mM each) 0.4 200 µM 
gDNA Taf8 fw primer, 10 μM 1.2 600 nM 
gDNA Taf8 rev primer, 10 μM 0.6 300 nM 
Insert rev primer, 10 μM 0.6 300 nM 
Taq DNA Polymerase (5 U/µl) 0.2 0.05 U/µl 
Template, piece of tail   
NFW 13  
Total volume 20  
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Thermocycler program for genotyping PCRs 
Step Temperature in °C Time 
Preheating 95 5 min 
Template Melting 95 30 s 
36x Annealing 55 30 s 
Extension 72 30 s 
Final Extension 72 10 min 
End 4 for ever 
2.6.2 RT-PCR 
RT-PCR is the combination of cDNA preparation in a RT-reaction and the subsequent 
amplification of a specific sequence from the cDNA. The sequence is amplified from the cDNA 
using a primer pair framing the sequence on the cDNA target in a conventional PCR. In this 
thesis RT-PCR was used to check total RNAs for substantial gDNA (genomic DNA) 
contamination. The reactions were performed analogous to the actual qPCR-reactions, with same 
primer concentrations, template concentration, annealing temperature and cycle number. The 
differences were that no SYBRGreen master mix was used and that the extension time was 
increased to allow amplification of gDNA. 
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PCR reaction mix for RT-PCRs 
Component, Concentration Volume in µl Final concentration 
5x Taq Buffer (+ MgCl2) 4 1x 
dNTPs (10 mM each) 0.4 200 µM 
Foward primer, 10 μM 0.2 or 04 100 or 200 nM 
Reverse primer, 10 μM 0.2 or 0.4 100 or 200 nM 
Taq DNA Polymerase (5 U/µl) 0.2 0.05 U/µl 
NFW 15 or 14.6  
Total volume 20  
 
Thermocycler program for RT-PCRs 
Step Temperature in °C Time 
Preheating 95 3 min 
Template Melting 95 30 s 
40x Annealing 60 30 s 
Extension 72 2 min 
Final Extension 72 10 min 
End 4 for ever 
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2.6.3 qPCR 
The advantage of qPCR in comparison to conventional RT-PCR is that qPCR measures the 
amount of PCR-product during each cycle of the PCR-reaction. This ensures comparisons 
between samples during the quantitative, exponential phase of the PCR-reaction. Not the amount 
of DNA is measured by the thermocycler (Real Time machine) during each cycle, but a 
fluorescence signal which is proportional to the amount of DNA. There are several variants of 
qPCR. What was performed in this thesis is qPCR following the SYBR Green method. Like 
ethidiumbromide, SYBR Green is a fluorochrome which intercalates into double stranded DNA 
(nucleic acids). Therefore SYBR Green fluorescence can be used to measure the amount of PCR-
product after each cycle. The disadvantage of the SYBR Green method is that there is no 
sequence specificity of the fluorescence signal. SYBR Green intercalates into any double 
stranded nucleic acid, regardless of the sequence. 
2.6.3.1 Specificity controls for qPCR experiments 
Because of this limitation of the SYBR Green method, the specificity of the qPCR-reaction needs 
to be thoroughly controlled. SYBR Green would intercalate into qPCR-products which are 
amplified from genomic DNA. In this work all primers were designed that way, that they target 
exons framing large introns (≥1 kb). The amplification of the large PCR-product from gDNA is 
suppressed during the qPCR run. All primers used for the qPCRs in this thesis have a PCR-
product larger than 1 kb from genomic DNA, except for Bactin1 II and Ef1a. The Ef1a primers 
cross exon-exon boundaries and do not anneal to genomic DNA. 
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Even if the amplification of gDNA is suppressed by primers framing large exons, differential 
contamination of samples with gDNA would have an impact on the quantification of transcript 
levels by qPCR, by differentially influencing the efficiency of the qPCR reaction. Therefore, 
additionally to the appropriate primer-design, also the DNA-contamination of the total RNA used 
for cDNA preparations needs to be minimised. All total RNAs used for this work, except for the 
2 dpf experiments I and III, were subject to a DNA digest by DNase. The DNA digests was 
carried out using the Turbo DNA-Free Kit (Applied Biosystems, Warrington, UK) following the 
manufactures instructions. 
The specificity of the qPCR reaction was controlled in three ways: 
1. A dissociation curve was recorded after each qPCR run. 
2. In some cases cDNA from –RT reactions were tested by conventional RT-PCR. 
3. The correct product size of the qPCR-products was validated by agarose gel 
electrophoresis. 
Dissociation curve (melting curve): 
The melting curve is recorded after the amplification cycle during a qPCR run. The fluorescence 
is recorded by the Real Time Cycler while the temperature in the tubes increases from 55°C to 
95°C. The that way recorded melting curve depicts RFUs (relative fluorescence units) over 
temperature. The RFUs decrease steadily over the increasing temperature because the amount of 
double stranded DNA with intercalated SYBR Green decreases. Around the melting point of the 
PCR-product the drop of fluorescence is dramatic (high negative slope). The melting point of the 
PCR-product is the turning point of that curve. The negative first deviation of the curve 
transforms this turning point into a peak. The results of melting curves are usually depicted as the 
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negative first deviation. A successful qPCR run shows only one peak, reflecting only one PCR-
product.  
In Figure 2.4 representative melting curves of the PCR-product for all primers used for qPCR in 
this thesis are shown. The melting curves contain only one peak, with five exceptions: Bactin1, 
Bactin1 II, Fabp11a, Pparγ and Taf6. The melting curves for Bactin1 and Pparγ contain small 
peaks indicative of a second PCR-product. It could be primer dimers, but the relatively high 
melting points of around 78.5°C (Bactin1) and 80°C (Pparγ) for the small peaks argue against it. 
The peaks are not recognised by the iQ5 software. Corresponding bands for these peaks are not 
observed, when PCR-product from PCRs using those primers is analysed by agarose gel 
electrophoresis (Figure 2.5). The size of those additional peaks is always very small, but 
proportional to the specific product. I therefore concluded that this not very substantial presence 
of a second PCR-product is unlikely to cause any asymmetrical miss-measurement of CT-values 
by qPCR. The broad single peak for Bactin1 II also contains a second peak, which is not always 
resolved by the melting curve. Also for the PCR-product derived from PCRs using Bactin1 II 
primers, no band corresponding to the second peak is observed on agarose gels (see Figure 2.5). 
 The melting curve for Fabp11a contains a clearly visible shoulder, which is indicative of a 
second PCR-product, besides the specific product. The Tm of around 78°C argues against primer 
dimers. When cDNA derived from a –RT reaction is analysed by qPCR, the peak corresponding 
to the shoulder and the specific product disappears from the melting curve, and a peak with a Tm 
indicative of primer dimers appears. This finding suggests that the second PCR-product is 
amplified from cDNA. All primers used for qPCR and RT-PCR were checked for specificity by 
running an in silico PCR against the zebrafish genome (Zv9), using the respective tool in the 
UCSC browser. The Fabp11a primer pair is the only primer pair for which the tool found two 
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PCR-products. The hits correspond to two different copies of the Fabp11a (fabp11a) gene in 
close vicinity on chromosome 19. The transcripts from the two different loci are nearly identical. 
The Fabp11a primer pair amplifies the same PCR-product from them. A second band is not 
visible when PCR-product from PCR-reactions using Fabp11a primers is analysed on an agarose 
gel and the size of the small shoulder is always proportional to the size of the specific product. 
The peak of the melting curve for Taf6 is suspiciously broad. The broad peak contains additional 
PCR-products, which are not resolved by the melting curve, but which are visible as additional 
bands on an agarose gel. However, these bands are very faint in comparison to the specific PCR-
product (Figure 4.2). 
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Figure 2.4 – Representative melting curves 
Representative melting curves are depicted for each of the primer pairs used for qPCRs and/or 
RT-PCR in this thesis. The melting curves were recorded after qPCR runs in triplicates. 
 
2. –RT-reaction 
A –RT-reaction is performed like a RT-reaction for cDNA preparation, but the Reverse 
Transcriptase is replaced by NFW. Any template which is amplified from –RT cDNA is not 
derived from the reverse transcription of RNA and must therefore be DNA contamination. This 
fact can be utilised to assess the extent of DNA contamination in a total RNA preparation, when 
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cDNA from RT and –RT are compared by conventional PCR. Substantial DNA contamination 
would result in bands from the PCR-product of the PCR-reaction using the –RT cDNA. The size 
of the PCR-product is of the same size, or larger than the PCR-product using RT cDNA, 
depending on whether or not, the primers target the same, or different exons on the cDNA. 
The DNA contamination of total RNA preparations prepared following the protocol described in 
(chapter 2.5) is usually not substantial. This has been tested by Heather Woodhouse in her 
masters project “Study of PPARγ-dependent transcription in Zebrafish embryos”. 
In Figure 2.5, RT and –RT cDNAs from the first 3 dpf experiment were compared by PCR 
amplifying Bactin1 II and Fabp11a. The Bactin1 II primers target sequences on the same exon of 
the bactin1 cDNA. Therefore substantial gDNA contamination would result in amplification of a 
PCR-product of the same size like the one which is amplified from RT cDNA. No band (PCR-
product) can be seen in the lanes with samples from the –RT-PCR in contrast to the RT-PCR 
where a band of the correct size (102 bp) can be seen. In this experiment also Fabp11a primers 
were used. They anneal to different exons. Consequently the expected product size from cDNA is 
203 bp and from gDNA is 1781/1772 bp. No band indicative of a substantial contamination of the 
total RNA with gDNA can be seen. However, in the samples from the –RT there are bands 
running on the height of primer dimers, which are also seen in the non template control (NTC) 
for Fabp11a. 
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Figure 2.5 – Specificity controls of qPCR reactions 
Analysed on this agarose gel were 10 μl of PCR-product from qPCR-reactions using following primer 
pairs: Pparγ, Ef1a, Fabp2, Fabp11b, Lpl, Slc27a1a, Cd36 and Bactin1. The expected product size is given 
in brackets. The lanes in the middle are loaded with 10 μl of PCR-product from RT-PCR reactions (lanes 
5-12 upper part) using cDNA from the first 3 dpf qPCR experiment (taf8-mutants, taf8-wildtype siblings, 
taf6-mutants, taf6-wildtype siblings). Lanes 5-12 in the lower part of the gel were loaded with 10 µl PCR-
product from corresponding -RT-PCR. 
 
2.6.3.2 qPCR reaction 
The primer concentration for each primer pair used for qPCR needs to be optimised to yield 
optimal efficiency while maintaining specificity. In this thesis two concentrations for primer pairs 
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were used for qPCR 100 and 200 nM. The table below specifies which concentration was used 
for which primer pair. 
Name of primer pair Final concentration of 
each primer in the qPCR 
reaction mix 
Name of primer pair Final concentration of 
each primer in the qPCR 
reaction mix 
Taf8 200 nM Taf6 100 nM 
Slc27a1a 200 nM Pparγ 100 nM 
Lpl 200 nM Bactin1 100 nM 
Fabp2 100 nM Bactin1 II 100 nM 
Fabp11a 100 nM Cd36 100 nM 
Fabp11b 100 nM Ef1a 100 nM 
 
qPCR Reaction 
Component, Concentration Volume in µl Final concentration 
Power SYBR Green Master Mix, 2x 12.5 1x 
Template (1:20 dilution of cDNA from RT) 5 1:100 
Forward primer, 10 µM 0.25 or 0.5 100 nM or 200 nM 
Reverse primer, 10 µM 0.25 or 0.5 100 nM or 200 nM 
NFW 7 or 6.5  
Total volume 25  
 
First a qPCR Master Mix was prepared, containing all components except the template. Then an (optical) 
96-well plate was loaded with 5 µl Template. Finally 20 µl qPCR Master Mix were added to the template. 
After the plate was sealed with optical film (Applied Biosystems, Warrington, UK), the plates were spun 
down for one minute to collect the qPCR reaction mix at the bottom of the wells. 
The 96-well plates were than placed into a iQ5 Multicolor Real-Time PCR Detection System (BIORAD, 
Hemel Hempstead, UK) for the qPCR run. The cycler program can be specified in the iQ5 software which 
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is controlling the Real Time machine. The cycler program is shown in Figure 2.6. The template used for 
the plates was instructing the machine to measure SYBR Green fluorescence in all 96 wells. 
 
Figure 2.6 – Cycler Program for Real Time PCRs 
Depicted is the cycler program used for all qPCRs. After an initial preheating step at 50°C for 2 
min the polymerase is activated by heating up to 95 °C for 10 min. Next is the amplification 
cycle. It consists of cycles of template melting at 95°C for 15 s followed by a combined 
annealing elongation step at 60°C for 1 min. After the amplification cycle the dissociation curve 
is recorded. The respective cycle records the changes in fluorescence during the stepwise increase 
of the temperature from 55 to 95 °C in 0.5°C increments. 
 
2.6.3.3 Analysis of qPCR experiments 
Relative quantifications of transcript levels by qPCR assume that the PCR-product doubles with 
each cycle. The fluorescence signal, which is proportional to the PCR-product, doubles as well. If 
there was double as much template at the beginning of the reaction in one sample compared to a 
reference, then, at each cycle of the qPCR run, the fluorescence signal for the sample is double as 
high as the one for the reference. The reference would reach the same fluorescence signal one 
cycle later. This principle is the basis for calculating differences in transcript levels using CT-
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values (cycle threshold). If a threshold of the fluorescence signal is set, the cycle when different 
samples reach that threshold can be used to infer differences in the amount of template in the 
samples. Double as much template in one sample results in a difference of one cycle (ΔCT = 1) 
when the samples reach the threshold for the fluorescence. To correct for differences in the total 
amount of cDNA used for the qPCR reaction, the CT-values for the assayed gene is normalised to 
the CT of an internal standard. A good internal standard just reflects differences in the overall 
amount of template and is unaffected by the different conditions, which are compared by the 
qPCR (wildtype/mutant, treated/untreated). The internal standard used in this thesis was bactin1, 
which was described as a good internal standard for qPCR in zebrafish (McCurley and Callard, 
2008). 
The difference in the transcript level for one gene normalised to the internal standard can then be 
calculated using the ΔΔCT-method using following equation: 
ΔΔCT= ΔCTsample-ΔCTreference = (CTtarget - CTinternal standard)sample - (CTtarget - CTinternal standard)reference 
The fold change of the gene between sample and reference is then 2-ΔΔCT. 
This method contains the flaw that it assumes 100% efficiency of the reactions, meaning a 
doubling of the PCR-product with each cycle. If the efficiency of the qPCR reaction is not 100% 
it can cause miss-interpretation of qPCR results. This is especially the case if the efficiencies of 
the reactions for the assayed genes (target) and the internal standard differ greatly. To be able to 
correct for differences in the efficiency of the PCR reactions I determined the efficiency of the 
PCR reactions for each primer pair. The efficiency was inferred from the slope of a standard 
curve generated from qPCR with a dilution series of a mix of cDNAs used for qPCR in this 
thesis. The dilution series of cDNA diluted 1:10, 1:20, 1:40, and 1:80 should cover the range 
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where CTs where determined in qPCRs for this thesis. For all qPCR experiments 1:20 dilutions 
of cDNA were used as a template. The efficiencies of the qPCR reactions for each primer pair a 
shown in table below. 
Table 2.1 – Efficiencies of primer pairs used for qPCR 
Gene Efficiency 
Ef1a 1.47 
Bactin1 II 1.81 
Bactin1 1.69 
Fabp11a 1.76 
Fabp11b 1.77 
Fabp2 1.78 
Cd36 1.71 
Lpl 1.76 
Taf8 1.81 
Taf6 1.93 
Slc27a1a 1.83 
Pparγ 1.70 
 
Because the efficiencies between the target and the internal standard differed, fold changes were 
calculated using the Pfaffl-method (Pfaffl, 2001). The Pfaffl-method implements and therefore 
corrects for differences in the efficiencies of the PCR-reactions between the target and the 
internal standard. The formula used is the following: 
Fold change = ((Efficiency target)ΔCT target) / ((Efficiency internal standard)ΔCT internal standard) 
The optimal fluorescence threshold for the determination of CT-values was set relative to each 
gene. But for one gene the same threshold was used throughout all experiments. This ensures the 
comparability of different experiments performed on different plates. Two experiments were 
performed to test the comparability of experiments on different plates. An experiment using the 
Fabp11b primer pair and 8 samples from the 3 dpf experiments was repeated on another plate. 
The Pearson correlation coefficient for the CT-values derived from the repeats was 0.95. For a 
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similar experiment using 4 samples from the 2 dpf experiments and the Bactin1 primer pair, the 
Pearson correlation coefficient was 0.98. This good correlation between experiments on different 
plates justifies the comparison of data from different experiments on different plates. 
For each sample qPCRs were performed in triplicates. The mean CT-value of this three technical 
repeats was used to calculate fold changes following the Pfaffl-method. If evaporation occurred 
in one well the corresponding data was discarded. Experiments with a standard deviation of the 
triplicate CT-values greater than 0.5, were discarded. 
2.6.4 Microarray analysis 
2.6.4.1 Preparation of total RNA for microarrays 
Production of 4 dpf fish-larvae 
Pairs of heterozygous taf8-mutants were crossed. Seven clutches of eggs were collected. The 
larvae were kept in large Petri dishes at 28.5°C. The medium used was Hank’s without additions 
(antibiotics). The medium was changed at least once a day. At 2 dpf the embryos were 
dechorionated manually with fine forceps. At 3 dpf the larvae were separated into mutants and 
wildtypes (large Petri dishes). 
Preparation of samples 
Three different pools of 50 wildtype-larvae (taf8-mutant siblings) in small Petri dishes were 
generated mixing larvae from all of the seven large wildtypet Petri dishes. Three different pools 
of taf8-mutants were generated in a similar way. Now there were 3x50 wildtype and 3x50 taf8-
mutant larvae in small Petri dishes. The larvae were transferred from the small Petri dishes into 2 
ml reaction tubes (-> 6 samples). They were washed one time in Hanks. The samples were fixed 
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by snap-freezing them in liquid nitrogen (no MESAB used). They were kept at -80°C till they 
were further processed later the same day. 
Homogenisation of samples 
The samples were homogenised in 1 ml Trizol-Reagent (Invitrogen) using an IKA T 25 basic 
ULTRA-TURRAX mixer (setting 6, 24 000 rpm). The tubes with the samples were kept on dry 
ice till homogenisation. After homogenisation they stayed at RT. Always experimental pairs were 
homogenised one after the other (wildtype/mutant I, wildtype/mutant II, wildtype/mutant III). 
The homogenisation-procedure included the following steps: 
1. Homogenisation of sample in 1 ml Trizol for 1 min. 
2. Washing of mixer with 10 ml autoclaved dH2O in a 15 ml Falcon for 30 s. 
3. Discarding dH2O. 
4. Washing mixer in 10 ml mixer wash solution (4 M guanidine thiocyanate) in a 15 ml tube for 1 
min. 
5. Washing of mixer with 10 ml 70% ethanol in a 15 ml tube for 30 s. 
6. Discarding ethanol after each experimental pair (for example wildtype/mutant I). 
7. Washing of mixer with 10 ml autoclaved dH2O in a 15 ml tube for 30 s. 
Before usage the mixer was washed with steps 2-7. Also different mixer wash solutions were 
used after each sample. 
Then total RNA was prepared as it is described in 2.5.1. 
Analysis of quantity and quality of the RNA 
The concentration of the total RNA in ng/µl and the 260/280 ratio were determined using a 
NanoDrop photometer, to assess the amount and the purity of the total RNA. The values are as 
follows: 
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Measurement of concentration and purity of prepared total RNA 
Sample Concentration in ng/µl 260/280 ratio 
wildtype I 1170.4 2.09 
wildtype II 1024.3 2.09 
wildtype III 1108.4 2.08 
taf8-mutant I 871.0 2.09 
taf8-mutant II 966.6 2.09 
taf8-mutant III 757.9 2.08 
2.6.4.2 Hybridisation of microarrays with labelled cRNA 
This experiment was carried out by Lixin Yang. 
Cy3/Cy5-labelled cRNA was synthesized using “Agilent Low RNA Input Linear Amplification 
Kit Plus (two color, Cat# 5188-5340)”. The procedure was performed following the protocol for 
using a waterbath, not a thermocycler, in the respective manual (version 4.0). 
 
Annealing of a T7 Promoter Primer and cDNA synthesis by RT 
This step was performed exactly following Agilent’s protocol. A 11.5 µl Annealing-Mix was 
pipetted together containing 2 µg of total RNA, 1.2 µl T7-Primer and the appropriate amount of 
either SpikeA or SpikeB-Mix. The Annealing-Mixes were heated to 65 °C for 10 min in a water 
bath. Afterwards they were cooled down for 5 min on ice. Now 8.5 µl cDNA Master Mix were 
added, resulting in a 20 µl cDNA Synthesis Mix. For the RT-reaction these cDNA Synthesis 
Mixes were incubated at 40 °C for 2h in a circulating water bath. Afterwards the M-MLV-RT 
was inactivated by heating the mixes to 65°C for 15 min in a water bath. Then the samples were 
cooled down for five minutes on ice. 
106 
 
Amplification by in vitro transcription incorporating Cyanin 3- or Cyanin 5-CTP 
This step was not performed exactly following Agilent’s protocol, because it was performed with 
10µl cDNA instead of 20 µl. 30 µl of a cRNA Master Mix was added to 10 µl of the cDNA from 
the previous step resulting in 40 µl in vitro Transcription Reactions. The cRNA Master Mixes 
contained either Cyanin 3 or Cyanin 5-CTP. The in vitro Transcription Reactions were incubated 
for 2 h at 40°C in a water bath. The cDNA (and indirectly the underlying mRNA) is thereby 
amplified through in vitro Transcription into Cy3/Cy5-labelled cRNA. 
 
Purification of the amplified cRNA 
For the cRNA-purification Quiagen’s RNeasy Mini Kit was used. The protocol used was the 
protocol for this Kit modified by Agilent. Again the procedure was performed with half the 
volume used in the Agilent-protocol. 10 µl of nuclease-free water were added to the 40 µl in vitro 
Transcription Reactions. For precipitation of the cRNA 175 µl RLT and then 125 µl ethanol were 
added. Then 350 µl of this mix were loaded on a RNeasy column. By centrifugation with 13 000 
rpm for 30 s at 4 °C with a cooled centrifuge the precipitated cRNA was loaded onto the RNeasy 
mini column. It followed two washing steps with 250 µl RPE. The cRNA was eluted from the 
column pipetting 60 µl nuclease-free water directly on the membrane, followed by centrifugation 
with 13 000 rpm for 30 s at 4°C. 
 
Quantification and QC of the synthesized cRNA 
A ND-1000 spectrophotometer (NanoDrop Technologies, Rockland, DE) was used to determine 
the concentration of synthesized cRNA in ng/µl. 
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The samples then were hybridised to G2519F microarrays (see chapter 2.1.3) according to the 
manufacturer’s instructions. The slides then were scanned with a GenePix4000B microarray 
scanner resulting in TIFF-files of the scans. The analysis of those TIFF-files (scans) with the 
GenePix software generated the raw data of the microarray experiments. 
2.6.4.3 Analysis of microarrays 
Analysis of the raw data 
The analysis of the scanned microarray slides was carried out by Remo Sanges (Stazione 
Zoologica Anton Dohrn, Napoli) using the LIMMA library from the BioConductor collection of 
packages for the R statistical environment. The operations performed in the R statistical 
environment were: 
1. Background subtraction. 
2. Loess normalisation within arrays. 
3. Quantile normalisation between arrays. 
4. Differential expression significance analysis using linear models. 
The analysis from Remo provided lists (Excel tables) for each microarray experiment containing 
information about differential expression of genes and the significance of the result. 
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Figure 2.7 – Example for tables derived from microarray analysis 
Column B provides the Agilent ID for the probe on the array and column C links the identifier of 
a zebrafish transcript to the probe. The identifiers were a mix of Esembl, RefSeq, GeneBank, 
TIGR and UniGene identifiers. In column D the logarithmic fold change to the base 2 of the 
signal for the probe between mutants and wildtypes in is given. Columns E and F provide the p-
values from the statistical analysis. F gives the adjusted p-value using the Benjamini and 
Hochberg method. In G a gene name is linked to the probe. Because each probe (feature) is 
present on two positions on the array, each probe appears twice on the lists. 
 
 
Analysis of microarray data 
The analysis of the microarray data was performed by the candidate using the tables derived from 
Remo’s analysis of the raw data. A cut-off for significantly different expressed genes was 
defined. The cut-off applied was a logarithmic fold change of >1 (up-regulated) or <-1 (down-
regulated) with an adjusted p-value ≤0.05. Each probe is present twice on the arrays and only 
genes for which both probes passed the cut-off were kept for further analysis. The above 
mentioned criteria were used to generate lists of significantly up-regulated genes, called Taf8up 
and Taf6up. The respective lists for significantly down-regulated genes were called Taf8down 
and Taf6down. 
For further analysis of the microarray data Ensembl gene IDs were generated for each entry in the 
lists of significantly different expressed genes. BioMart and the DAVID ID conversion tool were 
used for the ID conversions. A few probe IDs could not be converted into Ensembl IDs using 
other identifiers but had a chromosomic position associated with it. Yavor Hadzhiev wrote a 
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script to retrieve Ensembl gene IDs for them, when this position overlapped with a transcript for 
an Ensembl gene. The same ID conversions into a unified identifier, Ensembl gene ID, were also 
applied to the list with the annotations for all probes on the array. That resulted in a list of all 
genes on the array with an Ensembl gene ID. 
I used BioVenn, a web-based bioinformatics tool (Hulsen et al., 2008), for comparison of the 
gene lists in area-proportional Venn diagrams. The same application was also used to determine 
the overlap of genes between the different gene lists. 
The DAVID Functional Annotation Tool provides enrichment analysis within data sets covering 
over 40 annotation categories. I used this tool for enrichment analysis within the gene sets from 
the microarray experiments. As background for the analysis the gene list of all Ensembl genes on 
the array was used. Genes with Ensembl IDs which are not annotated in the DAVID system are 
excluded from the analysis using DAVID tool. Thus some genes from the lists are lost during the 
conversion of Ensembl IDs into DAVID IDs. The percentages of lost genes during the ID 
conversions were: Taf8down 2.6%, Taf6down 4.7%, Taf8up 15.2%, Taf6up 22.2% and genes on 
array (background) 9.4%. 
2.7 Statistical methods 
Excel 2007 and SigmaStat 3.5 software were used for statistical analysis of the data. 
The arithmetic means of data sets were calculated using the AVERAGE function in Excel. 
The standard deviation of data sets was determined using the Excel STDEV function. 
Standard errors of the mean (SEM) were calculated by following formula in Excel: 
𝑺𝑬𝑴 = 𝑺𝑻𝑫𝑬𝑽 (𝒅𝒂𝒕𝒂)
√𝒏
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Linear correlation between datasets was estimated using the Excel PEARSON function. 
T-Tests 
In this thesis two-tailed t-tests were performed to test for statistically significant difference in the 
mean between two data sets. Because the test is sensible to normal distribution of the data, the 
data was always checked for normal distribution using the respective tool in the Sigma Stat 
software. Only data which passed the test for normal distribution was further analysed by two-
tailed t-tests. The hypothesis that the means of two samples are significantly different was 
rejected, if the p-value returned from t-tests was higher than 0.05.  
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3 Differential requirement of Tafs during zebrafish 
development suggested by systematic knock down 
3.1 Introduction and Overview 
In the classical model of transcriptional regulation the core promoter plays a passive role. In this 
model a set of GTFs assembles into a single type of PIC. This is sufficient for the initiation of a 
low, basal level of transcription. For a robust, high level of transcription additional regulatory 
input from other sites like enhancers is required. According to this model, transcriptional 
regulation is mainly driven by sequence-specific activators and repressors binding away from the 
core promoter. 
In the last decades it became clear that multiple layers of transcriptional regulation exist, for 
example on the level of chromatin (chromatin modifications and remodelling), on the level of the 
transcription elongation step and also on the level of transcription initiation at the core promoter. 
The diversity of core promoter structures and of the complexes forming on them suggests a 
participation of the core promoter in tissue-specific gene expression and development. Several 
lines of evidence support this hypothesis: 
Transcription in early embryos seems to largely follow the classical model for transcription 
initiation and is mediated by canonical TFIID. There is some evidence suggesting that with the 
advent of lineage-restricted transcription, this strict requirement for full TFIID gradually 
diminishes. Partial TFIID complexes and roles for non-prototypical promoter recognition factors 
have been described. A decrease or complete depletion of TFIID subunits has been observed in 
several differentiation processes: i) during the all-trans retinoic acid induced differentiation of F9 
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embryonal carcinoma cells into primitive endodermal cell-types (Perletti et al., 2001), ii) the 
differentiation of 3T3-L1 preadipocytes into adipocytes (Guermah et al., 2003), iii) the 
differentiation of myoblasts into myotubes (Deato and Tjian, 2007) and iv) the differentiation of 
hepatoblasts into hepatocytes (D'Alessio et al., 2011). Moreover, it has been demonstrated that 
certain lineage-restricted and differentiated cell-types do not contain or require prototype full 
TFIID: Hepatocytes (D'Alessio et al., 2011, Tatarakis et al., 2008), mouse trophoblast cells (Voss 
et al., 2000), mouse taf4-/- cells (Mengus et al., 2005) and more. In that context it is worth 
mentioning that also yeast cells growing at high density show reduced levels of several Tafs and 
Tbp (S. S. Walker et al., 1997). 
In the case of myogenesis a complete replacement of TFIID by a TBP2/TAF3 complex has been 
proposed. An alternative transcription machinery also seems to be acting in the context of meiosis 
in vertebrates. The two vertebrate TBP-paralogs TBP2 and TLF seem in that respect to play 
opposing roles in the two sexes, with TBP2 acting in oogenesis and TLF in spermatogenesis 
(Gazdag et al., 2009, Martianov et al., 2001). 
These findings feed into a model where TFIID is required for transcription in the pluripotent state 
(early embryos) and in mitotically dividing cells, to integrate all possible regulatory input. In 
differentiated cells not all TFIID subunits are required anymore so that partial TFIID and 
alternative PRFs are observed in those cell-types. The specialisation of the cells is paralleled by a 
specialisation of the basal transcription machinery. The transcript levels of zebrafish tafs decrease 
during early development, which might reflect the decreasing deployment of full TFIID in certain 
lineages (Figure 1.6). 
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3.2 Aims 
The natural environment of a metazoan cell is not a Petri dish. In metazoans the cells are 
embedded in an organism with extensive crosstalk between the cells in the different tissues and 
organs. Findings made in vitro are not always valid in vivo, in the context of a whole organism. 
Therefore the significance of a finding made in vitro always needs to be tested in an in vivo 
model. 
As described in the introduction, TAFs are expected to have specific functions in the complexity 
of a metazoan organism. The role of TAFs during early vertebrate development to date not has 
been comprehensively studied. Zebrafish is an excellent in vivo model to study the function of 
genes during early development, due to the large number of mutants and to the powerful MO-
mediated kd technology available in that model. Therefore, I chose zebrafish to study the role of 
Tafs during development. Besides the relative contribution of distinct TFIID-subunits to early 
zebrafish development, the study might reveal some interesting specific phenotypes for certain 
Tafs, similar to the implication of Taf3 in hematopoiesis (Hart et al., 2009). Furthermore it will 
be interesting to analyse the Taf-morphants in the light of what is already known about their 
function. This analysis will address questions like: 
1. Does systematic knock down of TFIID complex subunits reveal general and specific roles 
of Tafs in embryo development? 
2. Can Taf kd phenotypes reveal core and peripheral functions for TFIID Taf subunits? 
3. Do kd phenotypes of TFIID-specific Taf subunits suggest diverged function from Tafs 
specific for SAGA? 
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3.3 Results 
We generated and analysed MO-mediated LOF-phenotypes for the Pol II Tafs annotated in the 
zebrafish genome (assembly Zv9). The phenotypes were analysed at three developmental stages 
(1, 2 dpf embryos and 5 dpf larvae) to cover most of early zebrafish development. 
In most cases not one very distinct morphant phenotype was observed, but rather a range of very 
similar phenotypes, varying in the degree of severity. The pictures in Table 3.3, Table 3.5 and 
Table 3.7 depict representatives of the observed morphant phenotypes. If several distinct groups 
of phenotypes were observed in one kd experiment, they were analysed separately. When more 
than 30% of the injected embryos or larvae showed a phenotype, the phenotype was considered 
as a significant Taf-morphant phenotype. Additionally, when the percentage of abnormal 
embryos in the larvae injected with the mismatch control MO for the targeting MO remained 
below the 30% threshold, the phenotype induced by the targeting MO was regarded as a specific 
phenotype. 
3.4 1 dpf (Prim-6 stage) phenotypes 
Only a small subset of Taf-morphants showed a specific phenotype at 1 dpf in our MO-screen: 
Taf2/5l/6/6l/9/10/11/12 and 13 (see  
Table 3.2 and Table 3.3). This subset contained the orthologs of the SAGA-specific TAF5L and 
TAF6L. Phenotypes for the core TAFs were observed (Taf6/9/10/11/12 and 13), but this subset 
was incomplete, as phenotypes for Taf4/5/8 were lacking. Interestingly, there seemed to be a 
strong requirement for orthologs of the DNA-binding TAFs, TAF2 (Inr) and the TAF6/9 
heterodimer (DPE element), for zebrafish development before 1 dpf. 
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The phenotypes observed at 1 dpf after MO-injection are shown in Table 3.3. At this stage; after 
gastrulation, neurulation and segmentation; the major body plan of the vertebrate embryo has 
been established. However, only a limited number of organs can be easily studied under the light 
microscope. Main phenotypes observed at 1 dpf were cell death, the patterns of cell death and a 
varying degree of underdevelopment, suggesting general cellular defects. 
Table 3.1 – Categories of phenotypes in 1 dpf Taf-morphants 
Morphants Observed phenotype 
Taf2, Taf6 Underdeveloped and cell death. Body plan not established. 
Taf5l, Taf6l, Taf11 Body plan established. Extensive cell death in many parts. 
Taf9, Taf12, Taf13 Body plan established. Cell death restricted to anterior part. 
 
Table 3.2 – Analysis of Taf-morphant phenotypes at 1 dpf 
N/A = not analysed. 
Gene MO Experiments Embryos Morphants % Morphants 
taf1 
taf1ATG 1 108 13 12 
taf1ATGmm 2 244 0 0 
taf1UTR 1 96 1 1 
btaf1 btaf1ATG 
3 353 0 0 
btaf1mm 3 227 0 0 
taf2 
taf2ATG 2 122 115 94 
taf2ATGmm 2 211 0 0 
taf2UTR 2 173 13 8 
taf3 
taf3ATG 2 157 10 6 
taf3ATGmm 1 122 0 0 
taf3UTR 2 190 9 5 
taf4l taf4lATG 
2 147 0 0 
taf4lmm 2 123 0 0 
taf5 taf5ATG 
1 122 29 24 
taf5ATGmm 2 157 0 0 
taf5l 
taf5lATG 1 100 5 5 
taf5lUTRmm 2 187 0 0 
taf5lUTR 1 62 54 87 
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Gene MO Experiments Embryos Morphants % Morphants 
taf6 
taf6ATG 4 306 289 94 
taf6ATGmm 2 177 0 0 
taf6UTR 1 91 14 15 
taf6l taf6lATG 
2 211 189 90 
taf6lATGmm 3 342 0 0 
taf7 
taf7ATG 2 146 0 0 
taf7ATGmm NA NA NA NA 
taf7UTR 2 148 0 0 
taf8 taf8ATG 
1 125 0 0 
taf8ATGmm NA NA NA NA 
taf9 
taf9ATG 1 105 80 76 
taf9ATGmm 2 210 0 0 
taf9UTR 1 70 20 29 
taf10 
taf10ATG 1 81 25 31 
taf10ATGmm 4 369 41 11 
taf10UTR 1 82 0 0 
taf11 
taf11ATG 4 383 355 93 
taf11ATGmm 2 178 8 4 
taf11UTR 2 157 60 38 
taf12 
taf12ATG 2 201 102 51 
taf12ATGmm 2 228 0 0 
taf12UTR 2 217 18 8 
taf13 
taf13ATG 3 272 224 82 
taf13ATGmm 2 265 0 0 
taf13UTR 2 219 22 10 
taf15 
taf15ATG 3 217 25 12 
taf15ATGmm 2 212 0 0 
taf15UTR 1 160 0 0 
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Table 3.3 – Taf-morphant phenotypes at 1 dpf 
 Representative experiment1 
MO Picture Phenotypes (Categories A,B ...) 
non-
injected 
wildtype 
 
reference embryo 
taf2ATG 
 
92% (70/76) 
- severely underdeveloped 
- dark and grainy appearance of body 
taf5lUTR  
87% (54/62) 
- dark and grainy appearance of body 
taf6ATG 
A) 
 
B) 
 
A) 62% (36/58) 
- severely underdeveloped 
- dark and grainy appearance of body 
B) 36% (21/58) 
- Embryonic arrest during gastrulation 
 
taf6lATG 
A) 
 
 
 
 
 
 
 
A) 67% (63/94) 
- lots of dark tissue (necrosis) especially in the head 
- Certain pattern of dark tissue (ring around eye) 
- Somites misshapen and reduced, slower twitching 
 
 
 
 
 
 
 
 
 
                                                          
1 Pictures of dechorionated embryos have been taken at a different magnification. 
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B) 
 
 
B) 16% (15/94) 
- like A but milder with nearly normal twitching 
- whole body gives a darker grainy appearance  
- Somites U-shaped 
taf9ATG  
72% (76/105) 
- dark and grainy appearance of body 
taf11ATG  
91%  
- bodies appear dark and grainy 
- the dark tissue has a more ubiquitous pattern than in the Taf6l-
morphant 
- somites U-shaped 
taf12ATG  
96% (71/74) 
- dark and grainy appearance of body 
taf13ATG  
72% (72/100) 
- dark and grainy appearance of body 
(picture flipped horizontally) 
 
3.5 2 dpf phenotypes 
Most Taf-morphant phenotypes were observed at the 2 dpf stage, which suggests contributions of 
maternal Tafs to development. Eleven of the 17 Tafs targeted in the MO-screen showed a specific 
phenotype at this stage: Taf1/2/5l/6/6l/8/9/10/11/12 and 15 (see Table 3.4 and Table 3.5). All the 
Tafs which displayed a significant phenotype at 1 dpf (Taf2/5L/6/6L/9/11/12 and 13), also 
displayed a significant phenotype at 2 dpf. The knock down of Taf5 and Taf13 induced a 
significant phenotype at 2 dpf, but their control MOs induced a significant phenotype as well. 
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However, in the case of Taf5, the proportion of abnormal embryos was much higher in the 
targeting MO injected embryos than in the control injected ones. 
Table 3.4 – Analysis of Taf-morphant phenotypes at 2 dpf 
% Morphants:  Percentage of phenotype showing embryos 
% Survival:  Percentage of embryos surviving from 1 to 2 dpf. The number in brackets is the  
number of experiments from which the survival rate was calculated. 
N/A = not analysed. 
Gene MO Experiments Embryos Morphants % 
Morphants 
% 
Survival 
taf1 
taf1ATG 3 245 57 23 82 (2) 
taf1ATGmm 2 242 10 4 98 (1) 
taf1UTR 3 210 109 52 82 (2) 
btaf1 btaf1ATG 3 373 72 19 97 (3) btaf1mm 3 195 53 27 85 (3) 
taf2 
taf2ATG 3 163 159 98 98 (2) 
taf2ATGmm 2 194 54 28 87 (1) 
taf2UTR 3 217 17 8 82 (2) 
taf3 
taf3ATG 3 270 14 5 90 (2) 
taf3ATGmm 1 122 7 6 NA 
taf3UTR 3 301 34 11 91 (2) 
taf4l taf4lATG 2 127 17 13 88 (2) taf4lmm 2 94 14 15 78 (2) 
taf5 taf5ATG 3 261 243 93 90 (3) taf5ATGmm 2 131 44 34 85 (2) 
taf5l 
taf5lATG 2 157 24 15 77 (1) 
taf5lUTRmm 2 185 14 8 97 (1) 
taf5lUTR 2 174 165 95 100 (1) 
taf6 
taf6ATG 1 106 86 81 100 (1) 
taf6ATGmm 2 148 13 9 78 (2) 
taf6UTR 2 121 4 3 86 (2) 
taf6l taf6lATG 3 233 192 82 80 (3) taf6lATGmm 3 316 44 14 79 (3) 
taf7 
taf7ATG 2 117 12 10 77 (2) 
taf7ATGmm N/A N/A N/A N/A N/A 
taf7UTR 2 135 17 13 91 (2) 
taf8 
taf8ATG 1 125 58 46 NA 
 
taf8ATGmm 
 
N/A 
 
N/A 
 
N/A 
 
N/A 
 
N/A 
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Gene MO Experiments Embryos Morphants % 
Morphants 
% 
Survival 
taf9 
taf9ATG 2 139 124 89 73 (2) 
taf9ATGmm 2 180 48 27 80 (2) 
taf9UTR 2 153 35 23 81 (2) 
taf10 
taf10ATG 4 268 106 40 88 (4) 
taf10ATGmm 4 313 56 18 82 (4) 
taf10UTR 2 146 13 9 88 (2) 
taf11 
taf11ATG 5 447 405 91 88 (5) 
taf11ATGmm 3 254 59 23 87 (3) 
taf11UTR 3 239 76 32 89 (3) 
taf12 
taf12ATG 4 350 260 74 89 (4) 
taf12ATGmm 2 178 10 6 80 (2) 
taf12UTR 3 262 28 11 87 (3) 
taf13 
taf13ATG 5 594 182 31 96 (5) 
taf13ATGmm 2 257 155 60 93 (2) 
taf13UTR 4 322 49 15 94 (4) 
taf15 
taf15ATG 5 348 92 26 70 (4) 
taf15ATGmm 2 198 36 18 89 (1) 
taf15UTR 2 228 92 40 87 (2) 
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Table 3.5 – Taf-morphant phenotypes at 2 dpf 
The percentages in the table are the percentages of embryos showing the described phenotype in that particular experiment. If 
several categories of phenotypes were observed in one experiment, the percentages and descriptions of phenotypes for the 
different categories are given. Only the phenotype categories with percentages >10% are listed. N/A = not available. 
 Representative experiment Repeat of experiment 
MO Picture Phenotype              
(Categories: A,B…) 
Picture 
 
Phenotype             
(Categories: A,B…) 
non-injected 
 
Reference embryo 
taf1ATG 
 
No significant phenotype observed 
taf1ATGmm 
 
No significant phenotype observed 
taf1UTR 
 
55% (50/91) 
- blood accumulation in 
front of pericardium 
(maybe more blood) 
- yolk sac edema 
- most likely also heart 
defect 
- circulation is visible 
 
52% (29/56) 
- heart defect 
- circulation range normal   
-> absent 
- blood clot in front of the 
heart or in the ductus 
cuvieri 
- otherwise normal 
btaf1ATG 
 
No significant phenotype observed 
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btaf1mm 
 
No significant phenotype observed 
taf2ATG 
A) 
 
B) 
 
 
A) 90% (28/31) 
- pleiotropic and degenerating 
B) 89% (78/88) 
- circulation absent 
- axis problem 
- blood accumulation in a clot in front of the pericardium -> no blood reaches the heart 
- yolk sac edema (region of blood clot) 
- head, eyes and yolk extension normal 
 
taf2ATGmm 
 
No significant phenotype observed 
taf2UTR 
 
No significant phenotype observed 
taf3ATG 
 
No significant phenotype observed 
taf3ATGmm 
 
No significant phenotype observed 
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taf3UTR 
 
No significant phenotype observed 
taf4lATG 
 
No significant phenotype observed 
taf4lmm 
 
No significant phenotype observed 
taf5ATG 
 
85% (63/74) 
General phenotype  
- smaller head/eyes 
- less pigmentation 
(brownish) 
- thinner body and yolk 
extension 
 
93% (75/81) 
- circulation problem  
- haemorrhage in head 
- thin yolk extension 
- funny shaped yolk 
 
taf5ATGmm N/A 34% of injected embryos exhibit an abnormal phenotype 
taf5lATG 
 
No significant phenotype observed 
taf5lUTRmm  
No significant phenotype observed 
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taf5lUTR 
A) 
 
B) 
 
67% (70/105) 
- smaller head/eyes but pigmented 
- thin trunk with very thin or no yolk extension 
- big roundish yolk sac 
- Circulatory problem ranging from normal over reduced to no blood flow (less red blood cells?) 
- pronounced hydrocephalus 
B) 30% (31/105) 
- like A but with curved body axis 
- shorter body and no or hardly visible blood flow 
 
taf6ATG 
A) 
 
B) 
 
C) 
 
A) 42% (45/106) 
- 30% (32/106) S-shaped  
- 24% (25/106) yolk sac edema  
- 37% (39/106) less pigmentation and axis problem  
- heart tubular and reduced or absent circulation 
B) 19% (20/106) 
- yolk sac edema and accumulation of blood in front of heart 
- heart defect (underdeveloped) and axis defect (mix) 
C) 14% (15/106) 
- pleiotropic  
 
 
 
taf6ATGmm 
 
No significant phenotype observed 
125 
 
taf6UTR 
 
No significant phenotype observed 
taf6lATG 
A) 
 
B) 
 
C) 
 
D) 
 
A) 76% (71/94) 
- heart is underdeveloped 
- circulation is absent 
- eye phenotype (ventral gap and reduced pigment in RPE, retinal pigment epithelium) 
- yolk sac edema 
- axis problem 
- somites sausage-shaped 
B) 37% (30/82) 
- dead and necrotic 
C) 23% (19/82) 
- necrotic, pleiotropic, no pigment, no circulation 
- yolk sac edema 
D) 17% (14/82) 
- hydrocephalus and yolk sac edema 
taf6lATGmm 
 
No significant phenotype observed 
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taf7ATG 
 
No significant phenotype observed 
taf7UTR 
 
No significant phenotype observed 
taf8ATG 
 
46% (58/125) 
- slightly retarded 
- embryo on picture was PTU-treated (0.003% PTU in E3-medium) 
taf9ATG 
 
A) 69% (60/87) 
- slightly underdeveloped (smaller eyes) and slightly weaker pigment 
- circulation is reduced 
B) 26% (23/87) 
- like A but with a blood clot in the tail 
taf9ATGmm 
 
No significant phenotype observed 
taf9UTR 
 
No significant phenotype observed 
taf10ATG 
 
30% 
- barrel-shaped yolk sac  
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taf10ATGmm 
 
No significant phenotype observed 
taf10UTR 
 
No significant phenotype observed 
taf11ATG 
A) 
 
B) 
 
C) 
 
D) 
N/A 
A) 68% (40/59) 
- axis problem but notochord is present  (mix but mostly curled upwards) 
- smaller head/eyes 
- big yolk sac with edema and no or small extension 
- heart beat present but no circulation in trunk and tail 
- eye (RPE) phenotype 
B) 57% (111/195) 
- axis problem and hydrocephalus 
- varying degree of yolk sac edema 
- big round yolk sac and very thin extension 
- circulation range normal -> absent 
- no pigment in RPE sometimes concentrated on ventral half 
C) 37% (72/195) 
- like B but: 
- straight axis 
- eyes and head slightly bigger 
- circulation reduced or absent 
D) 25% (15/59) 
- 15% (9/59) hydrocephalus  
- reduced or no circulation 
- yolk sac edema and axis problem (slightly curved down) 
taf11ATGmm 
 
No significant phenotype observed 
taf11UTR N/A 32% of injected embryos exhibit an abnormal phenotype 
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taf12ATG 
A) 
 
B) 
 
A) 56% (54/97) 
- slightly less pigmented 
- mild general phenotype with smaller head and eyes and a thin yolk extension 
- big roundish yolk sac and reduced or absent circulation 
- 6% (6/97) hemorrhage  
- 13% (13/97) hydrocephalus  
- quite a variation in the phenotype but all have circulation defect 
B) 52% (33/63) 
- weak general phenotype 
 - slightly smaller head/eyes 
- pigmented 
- thin bodies and yolk extensions 
taf12ATGmm 
 
No significant phenotype observed 
taf12UTR 
 
No significant phenotype observed 
taf13ATG 
A) 
 
B) 
 
 
 
 
 
A) 33% (22/67) 
- yolk and extension are nearly normal 
- shorter, blood clot in tail and big yolk sac 
- 12% (8/67) no circulation or reduced circuitry 
- 16% (11/67) enlarged 4th ventricle 
B) 15% (10/67) 
- yolk sac edema and axis problem (bend downwards) 
- no or reduced circulation 
- yolk and extension are nearly normal 
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C) 
 
C) 12% (8/67) 
- funny shaped yolk sac 
- blood accumulation in front of heart 
 
taf13ATGmm 
 
60% of injected embryos exhibit an abnormal phenotype 
taf13UTR 
 
No significant phenotype observed 
taf15ATG 
 
No significant phenotype observed 
taf15ATGmm 
 
No significant phenotype observed 
taf15UTR N/A 40% of injected embryos exhibit an abnormal phenotype 
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3.6 5 dpf phenotypes 
At 5 dpf most of embryos which displayed a strong phenotype already at 1 dpf, morphants for 
Taf2/5l/6/6l/11, were dead. Some of the morphants which showed a weak significant phenotype 
at 2 dpf appeared to recover by 5 dpf. This was observed for the morphant phenotypes induced by 
MOs targeting Taf8/10/13 and for Taf15. Also the significant morphant phenotype induced by 
injection of the control morpholino for Taf5 recovered by 5 dpf. Taf1/5/912 and the control MO 
for Taf13, which already displayed a significant phenotype at 2 dpf, also displayed a phenotype at 
5 dpf. 
Table 3.6 – Analysis of Taf-morphant phenotypes at 5 dpf 
In this table dead embryos were included into the calculation of the percentage of phenotype 
showing embryos, because death between 2 dpf and 5 dpf is very likely due to the phenotype 
induced by the MO. N/A = not analysed. 
Gene MO Experiments Embryos Morphants Dead % Phenotype 
(% Morphants, % Dead) 
taf1 
taf1ATG 3 245 110 3 46 (45, 1) 
taf1ATGmm 2 242 11 0 5 (5, 0) 
taf1UTR 3 210 117 10 60 (56, 4) 
btaf1 
btaf1ATG 3 373 0 0 0 (0, 0) 
btaf1mm 3 195 16 8 12 (8, 4) 
taf2 
taf2ATG 2 119 0 119 100 (0, 100) 
taf2ATGmm 2 194 27 18 23 (14, 9) 
taf2UTR 1 73 0 0 0 (0, 0) 
taf3 
taf3ATG 1 133 0 0 0 (0, 0) 
taf3ATGmm 1 122 0 0 0 (0, 0) 
taf3UTR 1 125 0 0 0 (0, 0) 
taf4l 
taf4lATG 2 127 0 0 0 (0, 0) 
taf4lmm 2 94 0 0 0 (0, 0) 
taf5 
taf5ATG 3 261 210 32 93 (81, 12) 
taf5ATGmm 2 131 18 10 21 (14, 7) 
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Gene MO Experiments Embryos Morphants Dead % Phenotype 
(% Morphants, % Dead) 
taf5l 
taf5lATG 1 80 0 0 0 (0, 0) 
taf5lUTRmm 2 185 0 0 0 (0, 0) 
taf5lUTR 2 174 39 125 94 (22, 72) 
taf6 
taf6ATG 1 106 0 106 100 (0, 100) 
taf6ATGmm 2 148 0 0 0 (0, 0) 
taf6UTR 1 54 0 0 0 (0, 0) 
taf6l 
taf6lATG 3 233 40 179 94 (17, 77) 
taf6lATGmm 3 316 22 2 8 (7, 1) 
taf7 
taf7ATG 1 81 0 0 0 (0, 0) 
taf7ATGmm N/A N/A N/A N/A N/A 
taf7UTR 2 135 0 0 0 (0, 0) 
taf8 
taf8ATG 1 125 0 0 0 (0, 0) 
taf8ATGmm N/A N/A N/A N/A N/A 
taf9 
taf9ATG 1 87 83 0 95 (95, 0) 
taf9ATGmm 1 127 0 0 0 (0, 0) 
taf9UTR 1 107 0 0 0 (0, 0) 
taf10 
taf10ATG 3 192 20 2 11 (10, 1) 
taf10ATGmm 3 201 16 5 10 (8, 2) 
taf10UTR 1 84 0 0 0 (0, 0) 
taf11 
taf11ATG 3 332 114 162 83 (34, 49) 
taf11ATGmm 3 254 42 11 21 (17, 4) 
taf11UTR 2 145 0 0 0 (0, 0) 
taf12 
taf12ATG 2 160 54 44 61 (34, 27) 
taf12ATGmm 2 178 0 0 0 (0, 0) 
taf12UTR 1 73 0 0 0 (0, 0) 
taf13 
taf13ATG 2 333 67 0 20 (20, 0) 
taf13ATGmm 2 257 257 0 100 (100, 0) 
taf13UTR 2 124 0 0 0 (0, 0) 
taf15 
taf15ATG 2 156 0 0 0 (0, 0) 
taf15ATGmm 2 198 0 0 0 (0, 0) 
taf15UTR 1 107 0 0 0 (0, 0) 
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Table 3.7 – Taf-morphant phenotypes at 5 dpf 
The percentages in the table are the percentages of embryos showing the described phenotype in that particular experiment. If 
several categories of phenotypes were observed in one experiment, the percentages and descriptions of phenotypes for the 
different categories are given. Only the phenotype categories with high percentages ≥10% are listed. N/A = not available. 
 Representative experiment Repeat of experiment 
MO Picture Phenotype              
(Categories: A,B…) 
Picture 
 
Phenotype             
(Categories: A,B…) 
non-injected 
 
 
taf1ATG 
 
64% (65/102) 
- non-inflated swim bladder 
taf1ATGmm 
 
No significant phenotype observed 
taf1UTR 
A) 
 
B) 
N/A 
A) 47% (43/91) 
- whole body edema 
- generally 
underdeveloped 
B) 21% (19/91) 
- non inflated swim-
bladder 
- underdeveloped liver/gut 
- slight pericardial edema 
A) 
 
B) 
 
A) 32% (18/56) 
- non-inflated swim-
bladder  
- appear slightly 
underdeveloped 
- 5 % (5/56) 
pericardial edema and 
strongly reduced 
circulation 
B) 30% (17/56) 
- total body edema 
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btaf1ATG N/A No significant phenotype observed 
btaf1mm 
 
No significant phenotype observed 
taf2ATG N/A All dead 
taf2ATGmm 
 
No significant phenotype observed 
taf2UTR N/A No significant phenotype observed 
taf3ATG N/A No significant phenotype observed 
taf3ATGmm N/A No significant phenotype observed 
taf3UTR N/A No significant phenotype observed 
taf4lATG N/A No significant phenotype observed 
taf4lmm N/A No significant phenotype observed 
taf5ATG 
A) 
 
B) 
 
 
 
 
 
 
A) 32% (24/74) with pigmentation gap 
- pericardial edema 
- smaller head/eyes and underdeveloped liver /gut 
- pointed jaw 
- sometimes yolk looks like rotting 
- 15% (11/74) hemorrhage in head 
- pigmentation gap in tail is lacking 
B) 46% (34/74) no pigmentation gap 
- like A1 but without pigmentation gap 
- 15% (11/74) shorter body axis 
- 24% (18/74) hemorrhage 
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C) 
 
D) 
 
E) 
 
F) 
 
C) 31% (25/81) 
- mild to severe whole body edema 
- circulation is absent 
- blood clot in tail 
- severely underdeveloped 
D) 26% (21/81) 
- no circulation 
- 12% (10/81) blood clot in tail 
- dark yolk 
- pericardial and beginning total edema 
- severely underdeveloped 
- trunk appears rough and dark 
E) 14% (11/81) 
- slightly underdeveloped 
- nearly normal circulation 
-shiny bodies 
F) 11% (9/81) 
- reduced circulation 
 
taf5ATGmm 
 
No significant phenotype observed 
taf5lATG N/A No significant phenotype observed 
taf5lUTRmm N/A No significant phenotype observed 
taf5lUTR N/A Dead 
taf6ATG N/A Dead 
taf6ATGmm N/A No significant phenotype observed 
taf6UTR N/A No significant phenotype observed 
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taf6lATG N/A Dead 
taf6lATGmm N/A No significant phenotype observed 
taf7ATG N/A No significant phenotype observed 
taf7UTR N/A No significant phenotype observed 
taf8ATG N/A No significant phenotype observed 
taf8ATGmm NA NA 
taf9ATG 
A) 
 
B) 
 
 
A) 46% (40/87) 
- mild to severe whole body edema 
- 5% (4/87) hemorrhage in head 
- pericardial edema 
- pointed jaw 
- 18% (16/87) small or no gap in pigmentation 
B) 25% (22/87) 
- 15% (13/87) no gap in pigmentation 
- 1% (1/87) hemorrhage 
- pericardial edema 
- no or very mild whole body edema 
- mild phenotype underdeveloped liver/gut but head looks quite normal except of pointed jaw 
 
taf9ATGmm N/A No significant phenotype observed 
taf9UTR N/A No significant phenotype observed 
taf10ATG 
 
No significant phenotype observed 
taf10ATGmm 
 
No significant phenotype observed 
taf10UTR N/A No significant phenotype observed 
taf11ATG N/A Dead 
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taf11ATGmm 
 
No significant phenotype observed 
taf11UTR N/A No significant phenotype observed 
taf12ATG 
A) 
 
B) 
 
 
A) 22% (14/63) 
- non inflated swim 
bladder 
- some with 
underdeveloped liver and 
gut 
- 10% (6/63) some with 
dark yolk 
B) 22% (14/63) 
- dark yolk 
A) 
 
 
A) 20% (19/97) 
- dark yolk 
- liver and gut are 
underdeveloped 
 
taf12ATGmm N/A No significant phenotype observed 
taf12UTR N/A No significant phenotype observed 
taf13ATG N/A No significant phenotype observed 
taf13ATGmm N/A 100% of injected larvae exhibit an abnormal phenotype 
taf13UTR N/A No significant phenotype observed 
taf15ATG N/A No significant phenotype observed 
taf15ATGmm N/A No significant phenotype observed 
taf15UTR N/A No significant phenotype observed 
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3.7 Summary MO-screen 
 
 
Figure 3.1 – Summary of Taf-morphant phenotypes at 2 dpf 
A) Taf kd phenotypes observed at 2 dpf. The different Tafs are arranged according to the complexes they 
are found in (TFIID, SAGA and both). The percentage given with the name of the Taf in brackets is the 
percentage of kd phenotype showing embryos at 2 dpf. B) The chart compares the efficiencies of the three 
types of MOs used in the screen, to induce a phenotype at 2 dpf. Brackets with an asterisk indicate groups 
with a significantly different efficiency in inducing a kd phenotype at 2 dpf, by two-tailed t-test (p-value 
≤0.05). C) The charts display the percentages of kd phenotype showing embryos for each Taf at 1, 2 and 5 
dpf. If more than 30% of injected embryos were abnormal, the phenotype was considered a significant 
phenotype. 
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Most of the Taf-morphant phenotypes manifested at a developmental stage ≤2 dpf, whereas the 
phenotypes of zygotic mutants of Tafs appear after 2 dpf. 
The consistent phenotypes observed for Taf5, Taf6, Taf9 and Taf12 support the presence of a 5 
TAF core complex within TFIID. However, the knock down of the TAF4 homolog, Taf4l, did not 
result in a significant phenotype. The very weak and rather inconsistent phenotypes observed for 
Taf8/10 argues against a strong participation of that heterodimer in the core complex. The results 
for the Taf11/13 heterodimer were inconclusive. Taf11 gave a strong specific phenotype, while 
Taf13 gave a weaker phenotype, which might be unspecific (control shows phenotype). 
All the orthologs of TAFs which have been shown to bind to specific core promoter motifs: Taf1, 
Taf2 and Taf6/9, showed a consistent, specific phenotype. 
The phenotypes observed for the orthologs of histone mark binding TAFs, Taf1 and Taf3, are not 
arguing for a big importance of that function within TFIID during zebrafish development. 
The two orthologs of SAGA-specific TAFs tested in our screen, Taf5l and Taf6l, showed a 
strong, very similar phenotype. Although Taf10 and Taf12 can be found in both complexes, 
TFIID and SAGA, the phenotypes for their zebrafish orthologs were not stronger than the ones 
observed for the orthologs of SAGA-specific subunits. 
3.8 Discussion 
In conjunction with a MO-screen targeting 17 different zebrafish Tafs we performed at least 59 
kd experiments and I analysed the phenotypes of around 10 000 injected embryos (Table 3.4). 
The suitability of MOs for medium scale kd screens in zebrafish model was confirmed by the 
results of our MO-screen. Overall the targeting MOs were more efficient in inducing a phenotype 
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than the control MOs (Figure 3.1). Interestingly, only the ATG-targeting MOs were significantly 
more efficient in inducing a phenotype than the control MOs. The slightly higher efficiency of 
UTR-targeting MOs was not statistically significant. 
3.8.1 Characteristics of Taf kd phenotypes 
Due to the pleiotropy of most of the phenotypes in the MO-screen, it was not practical and the 
scope of this study, to perform a very detailed characterisation of the morphants. A basic 
description of the morphants is given in Table 3.3, Table 3.5 and Table 3.7. Reoccurring 
phenotypes at 2 dpf, the definitive stage of phenotype analysis in the screen, were, amongst 
others, circulation and heart defects. A functional circulation is required for proper development 
and organ growth beginning with early larval stages (Korzh et al., 2008). Therefore, some of the 
defects observed at 5 dpf might be secondary to circulation defects. 
This study is the first comprehensive study on the role of TAFs during vertebrate development. 
There are four zebrafish Taf-mutant phenotypes annotated in the ZFIN database (Taf2, Taf6, 
Taf7 and Taf8). None of the morphant phenotypes generated in the MO-screen exactly 
phenocopies their mutant counterparts. Regarding Taf2 and Taf6, the morphant phenotypes are 
stronger than their mutant counterpart. That can be explained by an additive effect resulting from 
blocking translation of the zygotic and the maternally derived transcripts by the MO. This 
additional blocking of the maternally derived transcripts also explains the earlier appearance of 
the morphant phenotypes for Taf2 and Taf6 than their mutant phenotypes. There is however 
discrepancy between the morphant phenotypes of Taf7 and Taf8 compared to their mutants. 
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The Taf8-morphant showed a weak phenotype around 2 dpf (weak retardation), but recovered by 
5 dpf. The earlier appearance of the phenotype easily can be explained (see above) but not the 
lack of a 5 dpf phenotype. It has been shown that the efficiency of early injected MOs to block 
translation of their targets drops during stages beyond 3 dpf. This has been attributed to dilution 
of the MO. However, it is not clear why the Taf8 MO would be more diluted than other MOs, 
which induce a phenotype at 5 dpf. An explanation for this would be that the later phenotypes are 
a consequence of the efficient block of translation by MOs at earlier stages. If Taf7 is dispensable 
for embryonic development, it might not be possible to efficiently knock it down by early 
injection of MOs. 
Many injected targeting MOs in the screen did not induce any phenotype. This was observed also 
for MOs where another MO, targeting the same transcript, induced a phenotype. There are two 
possible explanations for this: Either the phenotype observed with one of the MOs is caused by 
off-target effects or the non-phenotype inducing MO is not efficiently targeting the target mRNA. 
Performing rescue experiment would help to resolve that issue. 
3.8.2 Limitations of MO antisense technology 
Due to limitations of the technology, kd experiments using MOs need to be well controlled for 
off-target effects. A fully controlled experiment comprises two MOs inducing the same 
phenotype, no phenotype with the mismatch control MO and a rescue of the phenotype with 
mRNA of the targeted gene (also see chapter 2.3). Induction of p53-mediated cell death is a 
common off-target effect of MOs (Robu et al., 2007). It has been suggested by Robu et al. to co-
inject a MO against p53 to suppress this off-target effect. The problem with that approach in turn 
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is that all true phenotypes involving p53-activation are masked. To include all above mentioned 
controls is quite time consuming and not practical for higher throughput experiments. In a trade 
off between throughput and controlling specificity, I decided not to perform rescue experiments 
and to rely on the use of mismatch control MOs for the targeted genes. For similar reasons the 
concentration of the injected MOs were not optimised. Only one concentration (100 µM) was 
injected. Another limitation of the MO kd technology is non-efficient targeting of the target 
sequence by the MO. Non efficient targeting of the mRNA can be caused by: 
1. Inaccessibility of the targeted sequence for the MO due to occupation by RNA-binding 
proteins, or due to the secondary structure of the targeted mRNA. 
2. Polymorphisms in the targeted sequence. 
3. Poor MO design due to insufficient knowledge about transcripts of the targeted gene. 
In respect of point 3 I made an interesting observation in this screen. We know that the majority 
of the genome is transcribed and that for a given gene there are usually numerous alternative 
transcripts (Aanes et al., 2011, Birney et al., 2007). It needs to be considered for MO-design, that 
the MO is efficiently targeting all alternative transcripts of the gene. Our knowledge about the 
zebrafish transcriptome is incomplete, what can have a significant impact on the success of MO-
mediated kd experiments (see Figure 3.2). 
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Figure 3.2 – Implications of CAGE data for MO design 
The figure shows in a histogram the 5’-ends (last base) of capped RNAs mapped to the zebrafish genome. 
The data is derived from CAGE (capped analysis of gene expression) experiments using RNA from 48 hpf 
embryos (Christian Previti, Yavor Hadzhiev, Chirag Patel, Nan Li, Vanja Haberle, Hazuki Takahashi, 
Santosh Amand, Jochen Gehrig, Altuna Akalin, Jan Christian Bryne, Ying Sheng1, Wilfred van IJcken, 
Olivier Armant, Sepand Rastegar, Uwe Strähle, Elia Stupka, Piero Carninci, Boris Lenhard and Ferenc 
Müller, unpublished data). This example illustrates how MO design will benefit from improving our 
knowledge about the zebrafish transcriptome. Because the reference sequence used for MO design is not 
the predominant transcript, the taf9UTR MO does not efficiently target taf9. Consequently only the 
taf9ATG MO induces a phenotype and no significant phenotype is observed after injection of the taf9UTR 
MO (Table 3.4). 
 
The mRNAs for all of the Tafs targeted in the MO-screen are maternally provided (unpublished 
CAGE data, see Figure 3.2). The already spliced maternal RNA only can be targeted with MOs 
against the ATG and the 5’-UTR. It can be assumed, that there is also a maternal supply of the 
Taf proteins, which are not affected by MOs. A differential contribution of maternal Taf proteins 
to early zebrafish development would mean a major flaw for the conclusions drawn from MO-
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induced kd experiments. The differences in the strength of the observed phenotypes might not 
only reflect differential requirement of the Tafs for early development, they might also reflect 
differential contribution of the maternal proteins. 
Because of the limitations in using MOs to study the role of Taf proteins during early zebrafish 
development, the data and conclusions from the MO-screen have to be taken with caution. The 
data is rather meant to provide a baseline characterisation of Taf-morphant phenotypes, for 
further in depth analysis by alternative LOF techniques. 
3.8.3 Alignment of MO-screen results to the structure of TFIID 
and SAGA 
The results of the MO-screen do not clearly favour one of the three models (chapter 1.1.2.2) 
suggested for the TFIID core complex. The 7 TAF core complex (TAF4/5/6/8/9/10/12) is, due to 
the weak phenotypes for Taf8 and Taf10, not well supported by the data. The significant 
phenotype for the Taf11/13 heterodimer is in line with a participation of this heterodimer in a 
core complex. However, the control MO for Taf13 also induced a phenotype, so that this result is 
inconclusive. The data is in line with the existence of a 5 TAF core complex (TAF4/5/6/9/12) in 
vivo. The lack of a significant kd phenotype for Taf4l is disappointing, considering the 
importance of TAF4 for the integrity of TFIID and viability in other model organism. However, 
mouse embryonic fibroblasts lacking TAF4 are viable and contain intact TFIID complexes, in 
which TAF4 is replaced by TAF4b (Mengus et al., 2005). Similarly Taf4b might replace Taf4 in 
zebrafish TFIID during early development. Knock down experiments targeting taf4b could help 
to clarify that issue. 
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Knock down of the orthologs of the SAGA subunits TAF5L and TAF6L results in a similar 
phenotype. This offers the possibility to use their kd as a tool to study specialised roles of SAGA 
subunits during early zebrafish development. 
3.8.4 Strong kd phenotypes for orthologs of DNA-binding TAFs 
The majority of zebrafish promoters lack a detectable TATA-box. The nucleation of PIC 
assembly by binding of a PRF to the core promoter is consequently in the majority of the cases 
not by TBP-binding to the TATA-box. Alternative mechanisms, which have been demonstrated, 
are the binding of certain TAFs to core promoter motifs and/or chromatin. The data from our MO 
screen is potentially consistent with a model that the DNA-binding (Taf1, Taf2 and Taf6/9) of 
Tafs within TFIID is more important during early zebrafish development than chromatin binding 
(Taf1 and Taf3). A requirement of TAF2 for Inr-dependent transcription has been demonstrated, 
alone or in a complex with TAF1 (Papai et al., 2009, Verrijzer et al., 1994). Given that the Inr is 
the most abundant promoter element it is feasible, that loss of TAF2 would cause a lack of 
recruitment of TFIID to many promoters. In that light the strong phenotype observed for Taf2 is 
not surprising. The kd of the Taf6/9-heterodimer also induces a strong phenotype. TAF6 has been 
shown to bind to the DPE in complex with its heterodimer partner TAF9 (Burke and Kadonaga, 
1997). These findings suggest that orthologs of the DNA binding TAFs are more rate limiting 
than non DNA-binding TAFs. 
The phenotype for the ortholog of TAF1 suggests a weaker contribution of that Taf to promoter 
recognition via binding to the Inr or to acetylated histone tails (chromatin). Same is the case for 
the ortholog of the H3K4me3 binding TAF3. 
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3.9 Conclusions 
1. In a MO-screen targeting the majority of the Tafs found in the zebrafish genome, we observed 
a range of different phenotypes for the different Tafs. This finding suggests differential functions 
of Tafs during zebrafish development. The results are in line with variant complexes acting 
during development, but our study did not include biochemical analysis of Taf-containing 
complexes. 
2. The relatively strong phenotypes observed for orthologs of TAFs, which are part of a proposed 
five TAF core complex (TAF4, 5, 6, 9 and 12), in comparison to the overall weaker kd 
phenotypes for orthologs of peripheral TAFs (TAF1, 2, 3, 7 and 15), supports the existence of 
this core complex in vivo. However, a significant phenotype for Taf4l, a zebrafish homolog of 
TAF4, was not observed. This might be explained with substitution of Taf4l by Taf4b during 
zebrafish development. This question should be addressed in future experiments. 
3. The kd of the zebrafish orthologs of the SAGA-specific TAF5L and TAF6L resulted in very 
similar phenotypes, suggesting specific, non-redundant functions of SAGA-specific Tafs during 
zebrafish development. 
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4 Mutant phenotype analysis of zebrafish taf8 
compared to taf6 with focus on a potential 
coactivator function of Taf8 for Pparγ 
4.1 Introduction and objectives 
The observation that TBP only in conjunction with the higher molecular weight TFIID complex, 
and not by itself, can mediate activated transcription, let to the establishment of TAFs as 
coactivators. Many coactivator functions for TAFs have been described in the literature:  
An interaction of TAF3 with Antennapedia was found in Drosophila (Prince et al., 2008). In 
mouse an interaction of TAF3 with MyoD has been proposed to drive myogenin transcription 
(Deato et al., 2008). TAF4 is a mediator of Wnt signalling in Drosophila (Wright and Tjian, 
2009). Human TAF4 interacts with several activators like SP1 and CREB, via a well conserved 
domain (TAFH), which binds to a short hydrophobic motif often present in transcriptional 
regulators (X. Wang et al., 2007). 
Several activators apparently target multiple TAFs within TFIID. TAF1 and TAF4 are 
coactivators for SP1 (Hilton et al., 2005, Rojo-Niersbach et al., 1999). TAF1 and the TAF6/9-
heterodimer mediate p53-dependent transactivation (Thut et al., 1995). TAF1 and TAF7 seem to 
be coactivators for c-Jun (Lively et al., 2004, Munz et al., 2003). Liu et al determined the position 
of p53, SP1 and c-Jun bound to holo-TFIID by negative stain EM (Liu et al., 2009). In 
combination with photoactivatable protein cross-linking label transfer assays they were able to 
also determine the TFIID-subunits in close proximity (within 21 Ǻ) to the bound activator. Their 
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data validated and extended the multiple TAF-activator contacts found for p53, SP1 and cJun in 
other studies (Figure 4.1). 
 
Figure 4.1 – Structure of complex of TFIID bound to activators 
By a combination of EM and biochemical mapping analysis the position and potential interaction 
partners of p53, SP1 and c-Jun in complex with holo-TFIID have been determined. SP1 contacts 
TAF1, TAF4 and TAF6, while p53 contacts TAF1, TAF5, TAF6 and weakly TBP. For c-Jun 
contacts with TAF1 and TAF6 have been observed. Taken from (Liu et al., 2009). 
 
The nuclear receptor PPARγ is a master regulator of adipocyte biology. PPARγ is essential for 
the process of adipogenesis and sufficient to drive conversion of fibroblastic precursors into fat 
cells (Choi et al., 2010). Two major isoforms exist of PPARγ: The broadly expressed PPARγ1 
and PPARγ2, which expression is restricted to adipocytes. Pparγ-/- mice die before stage E9.5, 
due to defects in the extraembryonic trophoblast tissue causing cardiomyopathies in the embryo. 
Pparγ ko mutant pups can be obtained by rescue of the trophoblast phenotype via generation of 
tetraploid aggregate chimeras. They display lipodystrophy, fatty liver and multiple haemorrhages, 
e.g. in the intestine and in the brain (Barak et al., 1999). 
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A plethora of co-regulators have been shown to interact with PPARγ: Steroid receptor 
coactivators (SRC-1, SRC-2), peroxisome proliferator receptor γ coactivator 1 (PGC-1), nuclear 
receptor corepressor (N-CoR), activating signal cointegrator-2 (ASC-2), silencing mediator of 
retinoid and thyroid receptors (SMRT), receptor-interacting protein 140 (RIP140) and adenovirus 
E1A-associated 300 kDa protein (p300)(McKenna and O'Malley, 2010). Furthermore PPARγ 
connects to the basal transcription machinery via interactions with Mediator subunits 1 and 14 
(Ge et al., 2002, Grontved et al., 2010). 
Recent findings suggest that the specialisation of cell-types (differentiation) is in part 
accomplished by a specialisation of the basal transcription machinery. TAFs, as specific 
mediators of regulatory input from transcriptional activators during ontogeny might play a crucial 
role in that process. There are several mechanisms proposed for specific roles of TAFs during 
ontogeny. One mechanism would be a dominant role of specific TAFs in certain lineages, 
established by retention of those TAFs in the context of depletion of other TFIID components. 
This for example has been observed for TAF8 in adipocytes and for TAF3 in myotubes. Another 
mechanism is the cell-type specific expression of non-prototypic TAFs, which replace their 
prototypic counterparts. An example for this is the gonad-specific expression of certain TAF 
paralogs. It is therefore important to study the role of TAFs in vivo, to potentially discover 
lineage-specific roles, also as coactivators. 
4.2 Aims 
I chose the zebrafish model to study the role of Taf8 in the complexity of the organism and with 
special focus on vertebrate development. There is one distinct advantage of using zebrafish as in 
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vivo model to investigate specific functions of (general) factors, like Taf8. In zebrafish, due to 
attenuation of the zygotic mutant phenotype by maternal contribution, late evolving subfunctions 
of such, otherwise generally required factors may be revealed in specific cell-types and organs. In 
contrast mouse mutants of these general transcription factors are mostly early embryonic lethal, 
providing little insight into specific developmental functions. 
I compare taf6-mutants to taf8-mutants to identify general TFIID-dependent functions of tafs and 
to reveal potential taf-specific phenotypes that may indicate specialised roles of Taf8 and Taf6. 
The taf8- and taf6-mutants (in the following just taf-mutants) have been generated by a similar 
insertional mutagenesis approach and TAF6 is also a subunit of TFIID (and the core complex), 
like TAF8. 
One of the objectives of my PhD is to use zebrafish model to address in an animal model if TAF8 
may be a specific coactivator of PPARγ, which was demonstrated in vitro with the human TAF8 
protein (chapter 1.3). My hypothesis was that if Taf8 is required to mediate Pparγ-activated 
transcription, then Pparγ-related defects should be observed in zebrafish taf8-mutants. 
The characterisation of the taf8-mutant compared to the taf6-mutant addressed the following 
questions: 
1. What are the roles of Taf8 and Taf6 during zebrafish development? 
2. Does Taf8 have distinct, specific roles from other TFIID components such as Taf6? 
3. Is there a specific requirement of taf8 for Pparγ-activated transcription? 
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4.3 Results 
4.3.1 Validation of mutant phenotypes on the level of taf8 and taf6 
gene expression 
The taf8- and taf6-mutants used in the experiments were generated by insertional mutagenesis. In 
both mutants the foreign sequence used for mutagenesis has inserted into the first intron of the 
respective gene. It is not obvious how this would be mutagenic, causing LOF-phenotypes for the 
respective genes. It has previously been demonstrated that insertions into the first intron of the 
gene s often cause a significant reduction of the transcript levels of the affected gene.(Amsterdam 
et al., 2004). I performed qPCR and RT-PCR experiments to investigate whether the analysed 
taf8- and taf6-mutant phenotypes are associated with loss of taf expression. The experiments 
were performed with cDNAs prepared from 12 mutant larvae and 12 of their wildtype siblings. 
The bactin1 levels served as an internal standard for the normalisation of the taf transcript levels 
in the qPCR and RT-PCR experiments. Mutants were identified by their morphological 
phenotype. A substantial reduction in the transcript-levels for taf8 and taf6 in their mutants was 
observed by qPCR and RT-PCR, while the transcript levels of the respective other taf were 
largely unaffected. For taf8 this was validated by WISH (whole-mount in situ hybridisation, data 
not shown). That finding confirmed the hypothesis, that the insertion of the transgene into the 
first intron of taf8 and that of taf6 causes depletion of their transcript levels. 
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Figure 4.2 – Validation of LOF of taf8- and taf6 in the respective mutants 
A) UCSC browser view of the taf8 and taf6 loci in zebrafish genome assembly Zv9. The black 
arrow heads point to the insertion sites of the foreign sequences in the mutant alleles. Note that 
there is a presumptive mis-assembly of fragments for the 5’-sequence of the taf6 locus. Due to 
that mis-assembly, exon1 and intron1 of the reference sequence for taf6 are missing. For this 
figure the correct fragment from another locus was added. The dashed line indicates where the 
added sequence begins. The results from comparative gene expression analysis experiments using 
cDNAs from 3 dpf taf-mutants and their wildtype siblings are shown. The chart in B) summarises 
the results for five qPCR experiments and C) shows the results of a RT-PCR using cDNAs from 
one of the qPCR experiments. PCR and gel in C) were done by Irene Miguel. 
4.3.2 Comparison of Taf8, Taf6 and Pparγ LOF-phenotypes 
In this subchapter results for the morphological and anatomical characterisation of the taf8- and 
taf6-mutant phenotypes are presented. As it was also an objective of the PhD-project to address 
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the putative role of Taf8 in Pparγ signalling, the focus of the mutant characterisation has been on 
general morphology followed by analysis of PPARγ-related processes and defects. 
4.3.2.1 Distinct craniofacial defects in taf8- and taf6-mutants suggest 
differential functions 
The taf8- and taf6-mutants are recessive mutants and their phenotype manifests in the 25% of 
embryos from crossing of heterozygous parents which are homozygous for the mutant allele. 
Those homozygous embryos are not viable and cannot be grown to adulthood. There is no 
obvious heterozygous phenotype. Also, there is no additive effect of heterozygosity for the tafs. 
All larvae from 7 crosses of heterozygous taf8-mutants with heterozygous taf6-mutants show 
normal wildtype phenotype (data not shown). 
The morphological phenotypes of zebrafish taf8 and taf6 are very similar. Like the phenotypes 
for many other essential genes they resemble the category of the “general phenotype” described 
in chapter 1.2.1. The morphological phenotype manifests at 3 dpf in a general underdevelopment 
of most of the organs and structures (Figure 4.3). This general underdevelopment seems to be 
somewhat more pronounced in the anterior part of the embryo. Most anterior organs and 
structures in the mutants are smaller than their wildtype counterparts: The head, the eyes, the 
jaws, the liver and the intestinal bulb (Figure 4.3). What also can be observed is a swelling of the 
pericardium (pericardial edema) in the mutants appearing at 4 dpf (Figure 4.3). Also the 
endodermal organs liver, intestine and pancreas are severely underdeveloped. The drunk and tail 
have an almost normal appearance. Also the somites appear normal and the taf-mutant larvae 
have no obvious defects in motility. At 5 dpf the diameter of the trunk of taf8- and taf6-mutants is 
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significantly larger then the one of their respective wildtype siblings (Marko Saric, unpublished 
data).  
Besides the similarities of the two taf-mutant phenotypes there are also differences in the detail 
and degree of the defects observed. Both mutants have a circulation defect and develop 
pericardial edema. But this defect is more severe in taf6-mutants, were in approximately 50% of 
the larvae it develops into whole body edema around 5 dpf (data not shown). The head-
morphology of the mutants differs throughout the examined stages, partly due to differential 
defects in the cartilaginous head skeleton. Overall, the pharyngeal skeleton of taf8-mutants 
appears larger than the one of taf6-mutants in side views (Figure 4.6). The cartilaginous head 
skeleton appears somewhat compressed along the anterior-posterior axis in taf8-mutants 
compared to taf6-mutants and wildtype siblings (Figure 4.4). There is a kink in the neurocranium 
of 5 dpf taf8-mutant larvae, at the level where the trabeculae join the parachordals (polar cartilage 
region) (Figure 4.5). The region of the abc cartilage (anterior basicranial comissure) appears 
larger in side views pictures of 5 dpf taf8-mutants compared to taf6-mutants and wildtype 
siblings (Figure 4.5). The ceratohyal cartilage in ventral views of taf8-mutants has a larger 
diameter than the ceratohyal of taf6-mutants (Figure 4.5). 
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Figure 4.3 – Morphological differences between the taf8- and taf6-mutant phenotypes 
Representative taf8-mutant larvae compared to taf6-mutants and wildtypes at different 
developmental stages. Shown are side view (left side) pictures of the anterior halves of the larvae, 
with anterior to the left and dorsal to the top. Markers in the figure point to eyes (red arrow 
heads), ears (red arrows), jaws (black arrow), pericardium (blue arrow heads), liver (green 
arrows) and intestine (green arrow heads). 
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Figure 4.4 – Differences in cartilaginous head skeleton between taf8- and taf6-mutants 
A) and B) show whole-mounted larvae at different stages. Their cartilage is stained blue by alcian blue staining. A) Side view 
pictures with anterior to the left and dorsal to the top. B) Ventral view pictures with anterior to the top. 
Black arrows point to the anterior basicranial comissure cartilage in A) and to the ceratohyal cartilage in B). The purple arrow in 
A) points to a kink in the neurocranium. C) Camera lucida drawing of the cartilage elements from the 4 dpf wildtype in side view 
and ventral view. Distinct cartilage elements are depicted in different colours and their names are given. 
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Figure 4.5 – Defects in the cartilaginous head skeleton of 5 dpf taf8-mutants 
Shown in this figure is the quantification of defects in the cartilaginous head skeleton of 5 dpf taf-
mutants. Features of craniofacial cartilages are compared between taf-mutants and their wildtype 
siblings. The pictures of alcian blue stained lavae on the right side of each bar chart illustrate 
what feature was quantified Brackets with asterisks indicate groups which are significantly 
different for the analysed feature by two-tailed t-test (p-value ≤0.5). The error bars in the charts 
are SEMs. The numbers of analysed larvae in each group were: 21 for chart A), 30 for chart B) 
and 22 for chart C). ImageJ straight line selection tool was used to measure the diameter of 
ceratohyal cartilages in ventral views (mean of six measurements as depicted in A) for each 
larva). The ImageJ angle tool was used to measure angles for chart B) and the freehand selection 
tool was used to measure the area of the abc cartilage in chart C). 
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Figure 4.6 – Larger pharyngeal skeleton of taf8-mutants compared to taf6-mutants 
The area of the pharyngeal skeleton in side view pictures of 3 dpf, 4 dpf and 5dpf taf-mutants and their 
wildtype siblings was measured using the ImageJ freehand selection tool. The principle of the 
measurements is shown in A) for 3 dpf larvae, where the measured pharyngeal skeleton area is outlined in 
red. Below examples for the appearance of the pharyngeal skeleton of taf-mutants and their wildtype 
siblings in side view pictures at the examined stages are shown. The results of the measurements are 
summarised in chart B). Brackets with asterisks indicate groups with a statistically different size of the 
pharyngeal skeleton by two-tailed t-test (n = 30, p-value ≤0.05). The 5 dpf experiment was carried out 
with transgenic mutants (fli1a:EGFP gata1:dsRed). 
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4.3.2.2 Specific defect in Pparγ-dependent lipogenesis in taf8-mutants 
PPARγ regulates the process of intracellular neutral lipid accumulation (lipogenesis) not only in 
adipocytes, but also in many other tissues (liver, muscle). Many of the orthologs of mammalian 
PPARγ target genes involved in lipogenesis are expressed during embryogenesis in zebrafish. At 
early larval (4-5 dpf) stages an obvious overlap between the expression patterns of these 
orthologs of PPARγ target genes with the expression patterns of pparγ itself emerges (see ZFIN 
database for expression patterns, http://zfin.org/cgi-bin/webdriver?MIval=aa-xpatselect.apg). 
This overlap is obvious for the expression of lpl, pparγ, cd36, fabp11b and fabp2 in liver and 
intestine. This raises the questions, if Pparγ is involved in lipogenesis in those organs during early 
larval stages and if this Pparγ function requires Taf8, as suggested by Mate Demeny’s data 
(chapter 1.3). To address those questions, I together with Nan Li (Müller group) performed lipid 
stainings of fixed 5 dpf larvae with Oil Red O, which is commonly used to visualise intracellular 
neutral lipid accumulations (lipid droplets). 
First we determined the lipid staining patterns in taf8-mutants compared to taf6-mutants and their 
respective wildtype siblings at 5 dpf. At that stage, wildtype larvae display ORO staining of the 
swim bladder, the yolk, the heart, the liver, the vasculature and head structures (Imrie and Sadler, 
2010, N. Li et al., 2010, Schlegel and Stainier, 2006). In our experiments we observed much 
fewer lipid droplets in the liver and intestine of taf8-mutants compared to their wildtype siblings 
and taf6-mutants (Figure 4.7, Figure 4.8). Note that the strongly stained, lipid rich yolk sac is 
much bigger in mutant larvae, while liver and intestine are much smaller. This suggests a specific 
defect in lipogenesis in liver and intestine of 5 dpf taf8-mutants. Liver and intestine are organs 
which strongly express pparγ at 5 dpf (Figure 4.7, panels B and C). Interestingly, there was also a 
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clear difference in the staining behaviour of the wildtype phenotype showing larvae, between the 
two mutant lines. The wildtype siblings of taf8-mutants display much more lipid droplets in the 
liver and intestine than the wildtype siblings of taf6-mutants (Figure 4.8). 
The strong expression of pparγ in liver and intestine of 5 dpf larvae suggests a possible 
involvement of Pparγ in lipogenesis in those tissues, at that stage. We hypothesised that, if the 
observed lipid droplets are formed by Pparγ-dependent lipogenesis, then they should be removed 
by treatment with a PPARγ inhibitor. To test the hypothesis, we performed drug treatments of 
taf6-mutants and their wildtype siblings with the selective and irreversible PPARγ antagonist 
GW9662 (Leesnitzer et al., 2002). We did not include taf8-mutants into those experiments, 
because they already display a very low amount of lipid droplets in their livers and intestine. 
Larvae derived from crosses of heterozygous taf6-mutants were incubated in E3-medium 
containing either 500 nM or 5 µM GW9662 for approximately 75 h, from 2 dpf till 5 dpf. As 
controls served larvae treated with the same amount of DMSO, which has been introduced with 
the GW9662 treatments. 
Treatment with the PPARγ inhibitor GW9662 efficiently reduces the number of lipid droplets 
observed in liver and intestine of taf6-mutants (Figure 4.7, Figure 4.8). The DMSO treated larvae 
stained similar to non-treated taf6-mutant larvae. Also the wildtype siblings showed reduction of 
the lipid droplets observed in intestine and liver. Taken together the data suggests a requirement 
of Pparγ for the lipogenic process leading to lipid droplet accumulation in liver and intestine at 5 
dpf. 
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Figure 4.7 – Specific defect in Pparγ-dependent lipogenesis in taf8-mutants 
Shown are side view pictures (left side) of the region containing the liver and intestine (intestinal 
bulb) in 5 dpf larvae. Anterior is to the left and dorsal is to the top. A) depicts whole-mounted 
larvae stained for lipids with Oil Red O. B) shows a bright field image of a wildtype larva and C) 
a wildtype larva from a whole-mount in situ staining against pparγ-mRNA (purple staining). The 
blue dashed lines outline the liver and the green dashed lines outline the intestine in A), B) and 
C). Accordingly, the blue and the green arrows in A) point to the respective organs in the mutant 
larvae. Black arrows point to lipid droplets in liver and intestine in A). Oil Red O staining of 
fixed embryos was performed by Nan Li. 
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Figure 4.8 – Lipogenesis in liver and intestinal bulb of taf6-mutants is Pparγ-dependent and 
taf6-independent 
Shown are side view pictures (left side) of the region containing the liver and intestine (intestinal 
bulb) in 5 dpf larvae. Anterior is to the left and dorsal is to the top. B) defines three categories for 
lipid staining with ORO in mutant livers and intestine. The measure for the strength of the 
staining is not the overall strength of the red staining, but the number of stained lipid droplets 
(Figure 4.7) that can be seen in the intestine and liver area in side views. The bar chart in A) 
shows the proportion of larvae from different treatment groups falling into the different lipid 
staining categories. Brackets with an asterisk indicate treatment groups, which are significantly 
different for lipid staining within the respective category, by two-tailed t-test. Oil Red O staining 
of fixed embryos and scoring of the stained embryos were performed by Nan Li. 
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Figure 4.9 – Lower level of lipogenesis in wildtype siblings of taf6-mutants compared to 
wildtype siblings of taf8-mutants 
Shown are side view pictures (left side) of the region containing the liver and intestine (intestinal 
bulb) in 5 dpf larvae. Anterior is to the left and dorsal is to the top. B) defines three categories for 
lipid staining with ORO in wildtype (sibling) livers and intestine. The measure for the strength of 
the staining is not the overall strength of the red staining, but the number of stained lipid droplets 
(Figure 4.7), that can be seen in the intestine and liver area in side views. The bar chart in A) 
shows the proportion of larvae from different treatment groups falling into the different lipid 
stainig categories. Brackets with an asterisk indicate treatment groups, which are significantly 
different for lipid staining within the respective category, by two-tailed t-test. Oil Red O staining 
of fixed embryos and scoring of the stained embryos were performed by Nan Li. 
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4.3.3 Similarities and differences of gene expression in taf-
mutants revealed by comparative gene expression analysis 
We investigated the consequences of loss of Taf8 and Taf6 on transcription in their respective 
mutants by comparative gene expression analysis between the respective mutants and their 
wildtype siblings. We addressed this question globally by performing microarray analysis using 
cDNAs from 4 dpf larvae. In qPCR experiments with cDNAs fom 2 and 3 dpf larvae we focused 
on the expression of a set of orthologs of bona fide PPARγ target genes, to address a possible 
requirement of Taf8 for Pparγ-activated transcription, as suggested by Mate Demeny’s data. 
 
Figure 4.10 – Stages and methods of comparative gene expression analysis 
This figure depicts the developmental stages together with the respective method used for comparative 
gene expression experiments with taf-mutants. For the 2 dpf experiment the larvae needed to be genotyped 
prior to cDNA preparation for qPCR. In the 2 and 3 dpf experiments the transcript levels of a selected set 
of orthologs of mammalian PPARγ target genes in taf-mutants were analysed. In the 4 dpf experiment the 
set of genes analysed was expanded to more than 10 000 by the use of microarray technology. 
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4.3.3.1 Transcriptome analysis indicates common and distinct roles of Taf8 
and Taf6 in regulating gene expression during larval development 
At 4 dpf, the taf8- and taf6-mutant larvae are well distinguishable from their wildtype siblings, 
but are not displaying the severe circulation defect, which appears at later stages. Many orthologs 
of mammalian PPARγ target genes and pparγ are co-expressed at this stage (ZFIN database). I 
therefore selected the 4 dpf stage for comparing the transcriptomes of taf8- and taf6-mutants to 
the ones of their wildtype siblings, and to each other. 
I prepared total RNA from 4 dpf taf8-mutants, taf6-mutants and their wildtype siblings. This total 
RNA was used to prepare fluorescent labelled cRNA (complementary RNA), which then was 
hybridised to G2519F microarrays (Agilent, Waldbronn, Germany). Three experiments for the 
microarray analysis of the transcriptome of taf8-mutants compared to their wildtype siblings were 
performed. Because the three experiments included a dye swap, six microarrays were hybridised. 
For the comparison of the transcriptome of taf6-mutants to the transcriptome of their wildtype 
siblings only one experiment was performed (two microarrays hybridised). 
Remo Sanges (Stazione Zoologica Anton Dohrn, Napoli) carried out a bioinformatic analysis of 
the microarray raw data, which provided lists of genes, which are significantly different 
expressed between mutants and wildtypes. In the case of taf8 this list is derived from combined 
statistical analysis of all three experiments performed for taf8. For taf6 only one experiment was 
performed and analysed. That means that the analysis of the microarrays comprised 12 spots for 
each probe in the case of taf8, and 4 spots for each probe in the case of taf6 (chapter 2.6.4.3). 
As expected from RT-PCR and qPCR data, taf8 appears in the set of down-regulated genes from 
the taf8-microarray experiment and is not affected in taf6-mutants. This validates the reliability 
165 
 
of the microarray data. Unfortunately taf6 is not represented on the array. Only a small 
percentage of the 11 972 Ensembl genes represented on the microarray, approximately 2 %, are 
significantly different expressed in the taf-mutants. There is a substantial overlap of the sets of 
down-regulated genes in both mutants. About two thirds of the set of down-regulated genes in 
taf8-mutants overlaps with the corresponding set of taf6-mutants. In contrast the overlap between 
the respective sets of up-regulated genes is much smaller (Figure 4.11). 
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Figure 4.11 – Overlap of the sets of regulated genes from microarray experiments 
In A) gene lists from the 4 dpf microarray experiments are compared to each other for overlap in 
Venn diagrams. The table in B) gives information about the number of genes in the different gene 
lists and about the extent of overlap between the gene lists. The numbers in the table are the 
numbers of genes in the respective gene lists, which have an Ensembl accession number. The 
associated percentage is the respective percentage of all genes with Ensembl accession number 
on the array. Less than 2% of the genes queried by the taf8 and taf6 microarray experiments are 
significantly different expressed in the respective mutant. The overlap between the significantly 
different expressed genes is substantial. More than one third of the differentially expressed genes 
in both mutants overlap. This overlap is due to an extensive similarity of the down-regulated 
genes in the two mutants. The up-regulated genes differ between the two mutants. The overlap of 
down- and up-regulated genes does not add up to the number of the total overlap because one 
gene is part of Taf8up and Taf6down. 
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I used the Functional Annotation Tool of the DAVID Bioinformatics Database to analyse the 
gene sets from the microarray experiments for enrichment of ZFIN anatomical terms, KEGG 
pathways and GO-terms (data not shown). The results from this analysis are in line with Figure 
4.11. There is a substantial overlap of enriched anatomical terms in the set of down-regulated 
genes from both mutants and hardly any overlap in respect of the up-regulated genes. Only three 
of the enriched anatomical terms in Taf8down are not also enriched in Taf6down: Fat cell, lens, 
lens vesicle (Table 4.2). The appearance of the anatomical term “fat cell” only in Taf8down is a 
specific link of Taf8 to Pparγ-function. PPARy has been shown to regulate transcription of many 
genes in fat cells (Nielsen et al., 2008). Taf8down is enriched for genes which are part of the 
PPAR pathway. Because also Taf6down is enriched for genes belonging to the PPAR pathway, 
this finding does not provide a specific link of Taf8 to Pparγ function (Table 7.6). Furthermore, 
only two of the genes belonging to the PPAR pathway in Taf8down, are orthologs of bona fide 
PPARγ target genes (Table 4.6). 
The anatomical term “pharyngeal arch” is enriched in Taf8down (Table 4.1). This finding is in 
line with the differential craniofacial defects described in chapter 4.3.2.1. The appearance of 
anatomical terms linked to muscle in Taf8up and Taf6up might reflect the larger diameter of the 
trunk observed in side views of taf-mutants. The KEGG pathways enriched in Taf8up strongly 
suggest an up-regulation of p53-dependent apoptosis in taf8-mutants (Table 4.5). 
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Table 4.1 – Enriched ZFIN anatomical terms in the sets of up-regulated genes 
The table depicts the results of the enrichment analysis of the microarray data for ZFIN 
anatomical terms using the DAVID functional annotation tool. The columns in the table contain 
following information: Term is a specific ZFIN anatomical term. Count contains the number of 
genes in the analysed gene list linked to that anatomical term. The percentage (%) is the 
percentage of genes from the analysed list falling into the respective category (anatomical term). 
The p-value is a measure to assess the significance of the enrichment of genes in the analysed 
gene list falling into the respective category. The DAVID functional annotation tool uses a 
modified Fisher Exact test (EASE Score) for calculation of p-values. The default cut-off in 
DAVID for categories being listed is at least two genes falling into respective category and a p-
value <0.1. 
Taf8 microarray Taf6 microarray 
Term Count % P-value Term Count % P-value 
musculature 
system 
6 17.1 7.86E-04 mesoderm 5 45.5 2.35E-05 
pharynx 5 14.3 0.002885 presumptive blood 3 27.3 1.00E-04 
sternohyoid 2 5.7 0.016241 sternohyoid 2 18.2 0.003766 
gut 6 17.1 0.019195 
intermediate cell 
mass of mesoderm 
3 27.3 0.005534 
epidermal 
superficial 
stratum 
2 5.7 0.028255 blood 3 27.3 0.006424 
liver 7 20.0 0.042052 nucleate erythrocyte 
2 18.2 0.008456 
pharyngeal 
arch 
5 14.3 0.044214 fast muscle cell 2 18.2 0.021491 
proliferative 
region 
3 8.6 0.04557 blood island 2 18.2 0.027034 
somite 7 20.0 0.087047 axial chorda mesoderm 
2 18.2 0.061533 
fast muscle cell 2 5.7 0.089983 hypaxial myotome region 
2 18.2 0.069553 
epidermis 4 11.4 0.096562     
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Table 4.2 – Enriched ZFIN anatomical terms in the sets of down-regulated genes 
The columns in this table are organised like in Table 4.1 
Taf8 microarray Taf6 microarray 
Term Count % P-value Term Count % P-value 
intestinal bulb 16 15.1 2.80E-10 intestinal bulb 37 19.8 4.35E-26 
pancreas 12 11.3 4.47E-08 liver 44 23.5 1.13E-11 
exocrine 
pancreas 
6 5.7 1.77E-06 
retinal 
photoreceptor 
layer 
14 7.5 1.83E-08 
liver 22 20.8 2.42E-06 retinal cone cell 7 3.7 1.07E-06 
pronephric 
proximal 
straight 
tubule 
3 2.8 0.004926 gut 25 13.4 4.00E-06 
pronephric 
proximal 
convoluted 
tubule 
3 2.8 0.005979 pancreas 13 7.0 1.09E-05 
gut 10 9.4 0.024315 retinal outer nuclear layer 
6 3.2 5.89E-05 
lens 8 7.5 0.04881 eye 25 13.4 7.69E-04 
retinal 
photoreceptor 
layer 
4 3.8 0.057136 exocrine pancreas 5 2.7 8.48E-04 
lens vesicle 7 6.6 0.060716 
pronephric 
proximal straight 
tubule 
4 2.1 0.001139 
fat cell 2 1.9 0.06332 
pronephric 
proximal 
convoluted tubule 
4 2.1 0.001541 
    YSL 19 10.2 0.002831 
    epiphysis 16 8.6 0.003625 
    retina 30 16.0 0.017006 
    intestine 8 4.3 0.029788 
    gill 8 4.3 0.059054 
    
stratum fibrosum 
et griseum 
superficiale 
2 1.1 0.064996 
170 
 
Table 4.3 – KEGG pathways enriched in Taf8down 
The columns in this table are organised like in Table 4.1 
Term Count % P-value 
dre03320:PPAR signaling pathway 4 3.8 0.006083 
 
Table 4.4 – KEGG pathways enriched in Taf6down 
The columns in this table are organised like in Table 4.1 
Term Count % P-value 
dre03320:PPAR signaling pathway 6 3.2 9.86E-04 
dre00982:Drug metabolism 4 2.1 0.003867 
dre00980:Metabolism of xenobiotics by cytochrome P450 4 2.1 0.004686 
dre00591:Linoleic acid metabolism 3 1.6 0.023287 
dre00520:Amino sugar and nucleotide sugar metabolism 4 2.1 0.040761 
dre00260:Glycine, serine and threonine metabolism 3 1.6 0.070900 
dre00140:Steroid hormone biosynthesis 3 1.6 0.077280 
dre00250:Alanine, aspartate and glutamate metabolism 3 1.6 0.083835 
 
Table 4.5 – KEGG pathways enriched in Taf8up 
The columns in this table are organised like in Table 4.1 
Term Count % P-value 
dre04115:p53 signaling pathway 3 8.6 0.006307 
dre04110:Cell cycle 3 8.6 0.024537 
dre04010:MAPK signaling pathway 3 8.6 0.067443 
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Table 4.6 – Genes belonging to the PPAR pathway down-regulated in taf-mutants 
Shown in the first two columns are the genes belonging to the KEGG PPAR pathway and the 
mutants, in which they are down-regulated. The third column gives the full gene names. The third 
column gives information about which PPAR isotype has been shown to regulate the respective 
gene. This information is derived from the nuclear receptor resource database. 
Genes belonging to PPAR pathway 
taf6-mutants taf8-mutants Gene Name PPARγ target? 
(nrresource.org) 
cd36 cd36 CD36 antigen PPARα, β and γ 
fabp6 fabp6 fatty acid-binding protein 6, ileal PPARα and β 
scp2a scp2a sterol carrier protein 2 PPARα 
- fads2 fatty acid desaturase 2  PPARα and γ 
cyp8b1 cytochrome P450, family 8, subfamily B, polypeptide 1 PPARα 
acsl5 acyl-CoA synthetase long-chain family member 5 PPARγ 
pck2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) PPARα and γ 
 
4.3.3.2 Gene expression in 2 dpf and 3 dpf mutants 
The 4 dpf microarray analysis did not convincingly demonstrate a requirement of Taf8 for Pparγ-
dependent transcription. However, some findings are suggestive for a link between both factors, 
for example the enrichment of the anatomical term “fat cell” in Taf8down. To exclude the 
possibility, that a requirement of Taf8 for Pparγ-dependent transcription was missed due to the 
limitations of microarrays, I decided to analyse the expression of a small set of zebrafish othologs 
of well established PPARγ target genes by qPCR. This method has higher specificity, sensitivity 
and covers a wider dynamic range for the quantification than microarray analysis. 
Transcription regulation has direct and indirect consequences due to epistatic relationships of 
genes. It is therefore important to aim for the earliest possible detection of changes, when looking 
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for direct regulatory roles of a factor. I decided to analyse the expression of orthologs of PPARγ 
target genes at two stages, 2 dpf and 3 dpf. At 2 dpf, taf8-mutants and taf6-mutants are 
indistinguishable from each other. However, transcriptional mis-regulation, causative for the later 
appearing morphological phenotype, might already occur at this stage. Three dpf is the 
developmental stage when the taf-mutant phenotypes manifest morphologically. Because the 
morphological differences between mutants and wildtypes are rather subtle at that stage, it can be 
assumed, that differences in the quantification of tanscript levels, due to differences in the 
morphology between wildtypes and mutants, will be minimal. The transcript levels of following 
othologs of PPARγ target genes were analysed by qPCR: 
LPL (lipoprotein lipase):  
LPL is an enzyme which is hydrolysing the TGs in chylomicrons and in VLDL. The TG 
depletion turns VLDL into IDL (LDL) and chylomicrons into chylomicron remnants (Eckel, 
1989, Goldberg and Merkel, 2001). The TGs are hydrolysed into two FFA (free fatty acid) 
molecules and into one monoacylglycerol molecule. LPL is a secreted protein, which is produced 
in the parenchymal cells of heart, skeletal muscle and adipose tissue. The secreted enzyme 
transverses the endothelial layer and gets anchored to the luminal surface of vascular endothelial 
cells via interactions with proteoglycans and GPIHBP1 (glycosylphosphatidylinositol-anchored 
high-density lipoprotein-binding protein 1) (H. Wang and Eckel, 2009). 
CD36 molecule (thrombospondin receptor):  
CD36 is a surface protein present on many mammalian cell-types including platelets, 
macrophages, hepatocytes, adipocytes and enterocytes (Febbraio et al., 2001). It is the fourth 
major glycoprotein on the platelet surface (Clemetson et al., 1977). CD36 seems to play a role in 
cell adhesion, because it is a receptor for thrombospondins, proteins involved in cell adhesion 
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(Asch et al., 1987, Silverstein et al., 1992) . Furthermore, CD36 also functions as a scavenger 
receptor, which is recognising molecular patterns on potential pathogens, which are then cleared 
by phagocytosis. CD36 was shown to be a negative regulator of angiogenesis (Dawson et al., 
1997). Another important function of CD36 is promoting fatty acid uptake in adipocytes, muscle, 
liver and intestine (Abumrad et al., 1993, Coburn et al., 2000, Nassir et al., 2007, Zhou et al., 
2008). 
FABP2 and FABP4 (fatty acid-binding proteins):  
FABPs are intracellular fatty acid-binding proteins. They are thought to associate with lipids to 
guide them to their destination in the cell (e.g. lipid droplets, endoplasmatic reticulum and 
nucleus). Therefore they are also regarded as lipid chaperones. The FABP-family contains at least 
nine members: FABP1 (Liver FABP, L-FABP), FABP2 (Intestinal FABP, I-FABP), FABP3 
(Heart FABP, H-FABP), FABP4 (Adipocyte FABP, A-FABP), FABP5 (Epidermal FABP, E-
FABP), FABP6 (Ileal FABP, Il-FABP), FABP7 (Brain FABP, B-FABP), FABP8 (Myelin FABP, 
M-FABP), FABP9 (Testis FABP, T-FABP). This nomenclature is misleading because the FABPs 
are not exclusively expressed in the name giving tissue. Liver FABP is for example also 
expressed in pancreas and kidney. 
FABP2 (I-FABP) is expressed throughout the intestine and in the liver. Its Mouse knock out 
suggest that FABP2 is not essential for dietary fat absorption, which is likely due to 
compensation by the other two FABPs expressed in the intestine, FABP1 (L-FABP) and FABP6 
(Il-FABP). 
FABP4 is used as a molecular marker for differentiated adipocytes, where its expression is 
regulated by PPARγ (Hunt et al., 1986, Nielsen et al., 2008). It is also expressed at lower levels 
in macrophages (Makowski et al., 2001), dendritic cells (Rolph et al., 2006) and in bronchial 
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epithelial cells (Shum et al., 2006). Because FABP4 deficiency in mouse models and humans 
seems to have a protective effect against disorders associated with the metabolic syndrome, 
insulin resistance (diabetes 2) and atherosclerosis, it was suggested as a drug target against those 
disorders (Furuhashi and Hotamisligil, 2008, Tuncman et al., 2006, Uysal et al., 2000). 
The fish-specific whole genome duplication event in the actinopterygian lineage (Meyer and Van 
de Peer, 2005) has resulted in two copies of the ortholog of the mammalian FABP4 gene, 
fabp11a and fabp11b, in zebrafish. The co-expression of fabp11a with pparγ in neutral lipid 
accumulating cells, presumptive adipocytes, suggests that this gene is the functional as well as 
the evolutionary ortholog of FABP4 (Flynn et al., 2009). However, also fabp11b is co-expressed 
with pparγ, in the liver and intestine, and its expression can be stimulated by administration of a 
PPARγ agonist (Jones et al., 2008). 
SLC27A1 (solute carrier family 27 (fatty acid transporter), member 1; FATP1): 
FATPs are integral membrane proteins, which facilitate the uptake of long-chain fatty acids. 
Because they possess acyl-CoA synthetase activity, they are thought to combine the uptake with 
CoA-esterification of the fatty acids (Wiczer and Bernlohr, 2009). The FATP-family comprises 
six members in mammals, which show tissue-specific expression patterns (Hirsch et al., 1998). 
FATP1 was initially identified as a fatty acid transporter in adipocytes (Schaffer and Lodish, 
1994). FATP1 is expressed in tissues with high fatty acid uptake like adipose, skeletal muscle and 
heart (Kim et al., 2004). The majority of FATP1 seems to be associated with intracellular 
structures and it tanslocates to the plasmamembrane in response to insulin (Stahl et al., 2002). 
Due to the aforementioned genome dublication event, zebrafish contains two genes encoding for 
mammalian FATP-1 orthologs, slc27a1a and slc27a1b. The gene analysed in the comparative 
gene expression experiments at 2 and 3 dpf was slc27a1a. Its duplicate, slc27a1b, was not 
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differentially expressed between taf8-mutants and their wildtype siblings in the 4 dpf microarray 
experiments. 
The results of the 2 dpf analysis of transcription are shown in Figure 4.12. The transcript levels of 
Taf8 and Taf6 are severely reduced in their mutants, while they are unaffected in the respective 
other mutant. There are no significant changes in the transcript levels of the other genes. 
The study of transcription in 3 dpf taf-mutants revealed a tendency of orthologs of PPARγ target 
genes to be down-regulated in taf8-mutants at that stage (see Figure 4.12). However, after 
statistical analysis of the data, the 3 dpf experiments fail to demonstrate a convincing defect in 
Pparγ-activated transcription in taf8-mutants compared to their wildtype siblings and taf6-
mutants. There is only one statistically significant down-regulated gene besides the respective taf 
gene in both taf-mutants. That gene is cd36. It is not significant different regulated between the 
two mutants by two-tailed t-test. Lpl levels are significantly different between the mutants, but it 
is not significantly down-regulated in taf8-mutants. 
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Figure 4.12 – Expression of orthologs of PPARγ target genes in taf8- and taf6-mutants 
Shown are bar charts depicting relative transcript levels of Taf8, Taf6, Pparγ and orthologs of PPARγ 
target genes at 2 dpf A) and 3 dpf B), comparing mutants to wildtypes. The transcript levels were 
normalised to Bactin1 levels. Brackets with an asterisk indicate genes which are significantly different 
regulated between taf8- and taf6-mutants by two-tailed t-test. Asterisks below the x-axis label genes which 
are significantly different regulated between mutant and wildtype siblings by two-tailed t-test. The Fabp2 
qPCRs were performed by Irene Miguel. 
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4.4 Discussion 
4.4.1 Similarities and differences in the mutant phenotypes for 
taf8 and taf6 
The taf8- and taf6-mutants display very similar morphological defects (see Figure 4.3). Their 
mutant phenotype manifests beginning with early larval stages (around 3 dpf) and from then 
onwards subsequent developmental processes are generally impaired in zygotic mutants due to 
the lack of essential gene function. Most of the anterior organs and structures are smaller 
comparing mutants to wildtypes. They share this phenotype with many other zebrafish mutants 
for essential genes (Amsterdam et al., 2004). An explanation for this phenomenon would be the 
following: 
There is a substantial maternal supply of the gene products for housekeeping genes (essential 
genes) which is sufficient for most of zebrafish embryonic development up into early larval 
stages. The maternal supply runs out during early larval stages and beginning from then on 
developmental processes (proliferation, cell and organ growth, differentiation) are generally 
impaired, because of the lack of a cell-essential gene. That would lead to the phenotype observed 
for many essential genes because the developmental changes in size and shape of the organs are 
more dramatic at the anterior part than in trunk and tail. The general phenotype is actually the 
manifestation of a general cellular defect, delayed by maternal supply of the gene product. 
That the principle described above, to a certain extend applies to the taf-mutants, cannot be 
excluded. Full TFIID might be required for mitotically dividing cells. Partial TFIID complexes 
178 
 
and/or alternative complexes might be required to restrict transcriptional programmes to specific 
cell-types, during differentiation and meiosis (Deato and Tjian, 2007, Gazdag et al., 2009). 
Most likely the phenotypes for taf8 and taf6 are mixtures of both, a general phenotype and a taf-
specific phenotype. The general cellular defect is mostly affecting mitotically dividing cells (cell 
cycle defect) and the resulting general phenotype is similar for both mutants. Cell cycle defects 
have been demonstrated for yeast Taf-mutants (Green, 2000). Additionally to the similarities 
there are subtle differences due to a specific function of the particular Taf in certain cell lineages. 
Both mutants develop a circulation defect and pericardial edema around 4 dpf. As a prerequisite 
to address the question whether this circulation defect is caused by a heart defect of by a mis-
development of the vasculature I crossed the taf-mutants to the fli1a:EGFP gata1:dsRed 
transgenic line. In this transgenic line the fli1a:EGFP transgene labels the vasculature and the 
gata1:dsRed transgene labels red blood cells. The mutant transgenic lines to date not were fully 
analysed for defects in the vasculature. The overall pattern of the vasculature looks similar 
between both, mutant transgenics and their wildtype siblings (data not shown). However, a 
relatively high incidence of haemorrhages, predominantly in the brain, was observed in the taf8-
mutant line (72 mutants and 38 wildtype siblings out of 2982 examined larvae). This hemorrhage 
phenotype is literally absent in the taf6-mutant line. Considering the expression of some zebrafish 
orthologs of PPARγ target genes in the head vasculature and the hemorrhage phenotype of pparγ 
ko mice, this would be interesting to follow up. Adipogenesis is coordinated with angiogenesis 
and a vascular niche has been suggested for preadipocytes (Billon et al., 2010, Hausman and 
Richardson, 2004). The taf8-mutant transgenic line might prove in the future useful in 
establishing a link between Taf8 and Pparγ. 
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The circulation defect might be the primary cause of death of the taf-mutants starting at stages 
beyond 5 dpf. At 5 dpf the edema restricted to the pericardium at 4 dpf has developed into whole-
body edema in a certain proportion of the mutants. The mutants displaying whole body edema 
also display a strong circulation defect. The lack of circulation is causing a lack of supply of 
peripheral tissues with nutrients and oxygen. Consequently the peripheral tissue is dying and 
shows opaque appearance by light microscopy. At stages beyond 5 dpf, dead mutant embryos, 
completely lacking a visible heart beat are observed. There is a difference in the proportion of 
whole body edema displaying embryos at 5 dpf between taf6 and taf8-mutants. 
In this thesis I describe a statistically different phenotype between taf8- and taf6-mutants 
regarding the pharyngeal skeleton. The pharyngeal skeleton of taf8-mutants appears larger 
throughout early larval stages (3-5 dpf) in side views (Figure 4.6). I also found a corresponding 
difference in the mutant phenotypes regarding craniofacial cartilages at 5 dpf. Some of the 
cartilaginous elements appear larger in side views of taf8-mutants than in side views taf6-mutants 
(Figure 4.4, Figure 4.5). This is unlikely to be explained simply by differences in position and 
orientation of the respective elements, because differences are also observed in ventral views and 
side views. 
Most of the zebrafish head skeleton develops from CNC. The CNC migrates to specific positions 
in the head, where the postmigratory CNC then develops into specific cartilaginous elements 
(Kimmel et al., 2001). The patterning of the skeletal derivatives of the postmigratory CNC is 
achieved via a combination of intrinsic signals, depending on the origin of the premigratory CNC 
in the brain, and extrinsic signals from adjacent tissues (Knight and Schilling, 2006). 
The craniofacial defects observed in the taf-mutants do not clearly suggest a defect in the 
patterning of the craniofacial cartilages. There is no clear difference in the degree of defects 
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along the anterior-posterior axis, or along the dorsal ventral axis. Also the shape of the 
neurocranium in the mutants does not suggest a defect in the midline. However, the kink in the 
neurocranium of taf8-mutants might be caused by a lack or overgrowth of the overlying brain 
tissues. There is also no obvious fusion of head cartilages, but their presence was not thoroughly 
investigated by flat mouting of dissected alcian blue stained head skeletons on slides. Whether 
there is a defect in CNC was not addressed in this study, where the mutant phenotype analysis 
focused on early larval stages, after the migration of CNC (Yelick and Schilling, 2002). 
4.4.2  Link of Taf8 to Pparγ function 
A functional interaction of TAF8 with PPARγ has been demonstrated in vitro for the human 
proteins by Mate Demeny (Tora lab, Strasburg). One objective of this thesis was to establish a 
link of Taf8 to Pparγ function in vivo using zebrafish model. Both factors have been implicated in 
adipogenesis (see chapter 1.3). Because of this biological link of TAF8 and PPARγ via 
adipogenesis, the focus of the phenotype characterisation exploring a potential role of Taf8 for 
Pparγ was on aspects of PPARγ linked to fat cells and their function (lipogenesis, adipocyte 
PPARγ target genes). 
4.4.2.1 Craniofacial defect might be linked to Pparγ 
To date, only a few studies on adipogenesis during early zebrafish development have been carried 
out. There is conflicting data about the first appearance of adipocytes during early zebrafish 
development. One study observed the first preadipocytes at 6 dpf in the pancreas. These cells 
begin to accumulate neutral lipids at 8 dpf. They also found that feeding is required for the 
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formation of the visceral preadipocytes (Flynn et al., 2009). Another study described the 
appearance of lipid accumulating cephalic adipocytes at an earlier stage, at 120 hpf. These 
adipocytes reside in the region of the developing hyomandibular skeleton which expresses the 
adipocyte marker cebpa beginning with 48 hpf. One of those regions is the second pharyngeal 
arch (N. Li et al., 2010). The 4 dpf microarray data is in line with the differential pharyngeal 
skeleton phenotypes of the taf-mutants (see chapter 4.3.3.1). 
This provides a possible link of the taf8-mutant phenotype to Pparγ. There is a differential 
phenotype of the pharyngeal skeleton between the two taf-mutants. The pharyngeal skeleton of 
taf8-mutants is significantly larger. It has been previously demonstrated that cephalic adipocytes 
and osteoblasts share a common ancestor, mesenchymal stem cells (MSC) derived from cephalic 
neural crest. There is a reciprocal relationship between the differentiation of those MSC into 
adipocytes or osteoblasts. One goes on the expense of the other ((N. Li et al., 2010). To address 
the question, if there is increased osteogenesis in taf8-mutants compared to taf6-mutants and their 
wildtype siblings, Nan Li (Mueller group, University of Birmingham) performed alizarin red 
stainings of calcified bones with 5 dpf larvae. The results were negative. There is a comparably 
defect in osteogenesis in both mutants (data not shown). However, MSC can also differentiate 
into chondrocytes. If adipogenic differentiation is blocked due to impaired function of Pparγ in 
taf8-mutants, this might cause an increase of chondrogenesis and a relative enlargement of the 
pharyngeal skeleton in taf8-mutants compared to taf6-mutants. 
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4.4.2.2  Specific defect in Pparγ-dependent lipogenesis in taf8-mutants 
The strongest link between Taf8 and Pparγ function found in this thesis is the specific defect in 
lipogenesis in taf8-mutants relative to their wildtype siblings and taf6-mutants (see chapter 
4.3.2.2). The taf8-mutants display a defect in the accumulation of Oil Red O stainable lipid 
droplets in liver and intestinal bulb. This lipogenic process in liver and intestinal bulb can be 
blocked in taf6-mutants with a PPARγ inhibitor. Taken together the data suggests that the 
observed lipogenic process is taf8-and Pparγ-dependent, but taf6-independent. 
The PPARγ inhibitor used for those experiments was GW9662, which binds irreversibly to the 
LBD of all three PPAR subtypes by forming a covalent bond (arylation) with a conserved 
cysteine residue (Leesnitzer et al., 2002). This cysteine residue is not present in zebrafish Pparγ, 
although there is another cysteine residue present in close vicinity in the primary structure of 
zebrafish Pparγ. It has been demonstrated by reporter gene assays with full length PPARs that 
GW9662 is functionally a subtype selective PPARγ antagonist, with a nanomolar IC50 (half 
maximal inhibitory concentration) (Leesnitzer et al., 2002). 
Another finding was a clear difference in the staining behaviour of the wildtype siblings of the 
taf-mutants compared to the wildtype siblings of taf8-mutants. The data suggests reduced 
lipogenesis in liver and intestine in the taf6-mutant line. 
Interestingly, in a study on a gene important for fat storage, a similar lipogenesis phenotype was 
observed. In this study fit2 (fat induced transcript 2) morphants showed severely reduced ORO 
staining in intestine and liver compared to control larvae, after feeding of 6 dpf larvae with a high 
fat diet (Kadereit et al., 2008). 
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4.4.2.3 Similarities and differences in Taf8- and Taf6-dependent 
transcription of genes expressed in larval zebrafish 
The results from the comparative gene expression experiments with taf-mutants give some 
support to the hypothesis that Taf8 is required for Pparγ function. But the data is not entirely 
convincing. The Taf8down gene set from the 4 dpf microarray experiments is enriched for genes 
belonging to the PPAR pathway. But the same is the case for Taf6down. Taf8down is also 
enriched for genes linked to the anatomical term “fat cell”, a cell-type in which PPARγ plays a 
crucial role for the transcription of many genes (Nielsen et al., 2008). Taken together, the link of 
Taf8down to Pparγ is there, but it is not very convincing. 
The Taf8up and Taf6up gene sets are dissimilar and so are the enriched anatomical terms and 
KEGG pathways within them. The exception is that genes linked to muscle are enriched in both 
sets, what might reflect the larger diameter of the trunk observed in side views of taf-mutants 
compared to their respective wildtype siblings. The enriched p53 pathway in Taf8up strongly 
suggests substantial apoptosis in taf8-mutants. Interestingly, this up-regulation of genes 
indicating p53-mediated apoptosis is not observed in 4 dpf taf6-mutants. This finding is in line 
with the proposed coactivator function of TAF6 for p53. 
The comparative gene expression experiments performed with 2 dpf and 3 dpf larvae failed to 
reveal a convincing specific down-regulation of orthologs of PPARγ target genes in taf8-mutants. 
At 2 dpf, most of the examined genes are not significantly different expressed between wildtypes 
and mutants. This suggests that parallel to the phenotypes, there is also hardly any difference in 
gene expression between mutants and wildtypes. The picture changes at 3 dpf. Now more mis-
regulation of transcription appears. The ortholog of the PPARγ target gene LPL is significantly 
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different regulated between taf8-mutants and taf6-mutants. However, Lpl is not significantly 
down-regulated between taf8-mutants and their wildtype siblings. 
In conclusion the 2 dpf and 3 dpf experiments did not reveal a specific requirement of Taf8 for 
Pparγ-dependent transcription. However, there is a tendency of orthologs of PPARγ target genes 
in taf8-mutants to be lower expressed relative to their wildtype siblings and to taf6-mutants at 3 
dpf. The addition of more biological repeats might turn these tendencies into statistically 
significant differences. 
4.5 Conclusions 
1. Zebrafish taf8 and taf6 are both essential genes for development. Their zygotic mutant 
phenotypes morhologically manifest around 3 dpf. The fact that the first defects appear after 
embryogenesis, during early larval stages, suggests contribution of maternally supplied Taf8 and 
Taf6 protein to development. The taf8 and taf6 transcript levels are already severely reduced at 2 
dpf, as a consequence of the insertional mutation. The mutants display a general 
underdevelopment of most structures and organs, which is more pronounced in the anterior part 
of the larvae. In both mutants the diameter of the trunk is significantly larger than the one of their 
wildtype siblings, what might reflect the up-regulation of genes linked to muscle at 4 dpf. 
2. There is clearly a high degree of similarity on the global morphologies between the taf8- and 
taf6-mutants. This similarity might be explained by a general cellular defect, which is attenuated 
and delayed by a substantial maternal supply of the respective gene products. However, a more 
detailed characterisation of the phenotypes revealed subtle differences in the phenotypes. Those 
differences are not simply differences in the degree of the observed defects, resulting from a 
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different degree of LOF for a TFIID core subunit. If this was the case, then all defects would be 
stronger in one of the mutants. However, some of the observed defects are more severe in taf8-
mutants (lipogenesis defect, kink in neurocranium) and others are more severe in taf6-mutants 
(edema, diameter of ceratohyal). That argues against the possibility that both mutants merely 
reflect different degrees of the same phenotype, caused be destabilisation of TFIID. It more likely 
reflects differential functions of those two Tafs during zebrafish development. 
3. This study did not convincingly demonstrate a requirement of Taf8 for Pparγ function. Future 
work must link the lipogenesis defect observed in liver and intestine of 5 dpf taf8-mutants to 
down-regulation of Pparγ target genes in those tissues. It also might be worth to explore the 
significance of the increased incidence of hemorrhages observed in the brain of taf8-mutants, 
given the expression of some orthologs of PPARγ target genes in the head vasculature. 
The transcriptome analysis indicates that some aspects of Taf8 regulated gene expression are 
distinct from that of Taf6 and include a specific requirement for fat cell differentiation. This 
observation suggests that at least some aspects of Pparγ regulated gene expression are likely 
specifically Taf8-dependent. However, other aspects of Pparγ-dependent gene expression require 
both Taf8 and 6 (genes in KEGG PPAR pathway). 
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5 Generation of a zebrafish model for ARC-
syndrome 
5.1 Introduction and Overview 
Zebrafish is becoming increasingly used as a model for lipid-metabolism and the development 
and pathologies of associated organs, such as the liver. Liver development in zebrafish is rapid 
and at 5 dpf the liver is nearly fully functional, displaying bile production, serum protein 
secretion, glycogen storage, lipogenesis and xenobiotic metabolism (Chu and Sadler, 2009). The 
transcriptional networks controlling hepatogenesis appear to be very similar between zebrafish 
and mammals. The same is true for liver function, cellular composition and many pathologies 
like hepatocarcinogenesis (Lam et al., 2006). But there are also differences, which are not 
necessarily disadvantages for using zebrafish as a model for liver biology. 
The teleost liver has a different architecture from the mammalian liver. The arrangement of 
vasculature, the biliary network and other liver cell-types into an organ differs, but the function of 
the organ is conserved. An exception is embryonic hematopoiesis, which takes place in the liver 
of mammals but not in the liver of zebrafish. Therefore defects in liver development in zebrafish 
will not lead to early lethality associated with hematopoietic dysfunction. Also, early liver 
development in zebrafish is independent from vasculogenesis and therefore not affected by a 
defective vasculogenesis. Because of the substantial maternal contribution to early development, 
zebrafish mutant phenotypes are often milder than their mammalian counterparts. This enables 
one to study the role of genes, which are early embryonic lethal when mutated in mouse, at later 
stages of development, e.g. during organogenesis, in zebrafish model. For instance, the 
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requirement of Hdac1 in liver and pancreas formation could only be revealed in the context of the 
milder zebrafish hdac1 mutant phenotype and not in the more severe mouse mutant phenotype 
(Noel et al., 2008). 
In the last decade zebrafish became increasingly used as a model for hepatobiliary development 
and diseases. Matthews et al. showed that zebrafish members of the onecut family of 
transcription factors, onecut1 (Hnf6 ortholog) and onecut3 play a role in intrahepatic biliary 
development (Matthews et al., 2008, Matthews et al., 2004). Analysis of the kd phenotypes of 
zebrafish jagged and notch genes established a role of Jagged-mediated Notch signalling in 
biliary development. The defects observed in the jagged and notch morphants were also in line 
with a phenocopy of the multisystem disorder Allagille syndrome, which is in the majority of the 
cases caused by haploinsufficiency for Jagged 1 (Lorent et al., 2004). Sadler et al. screened, in 
conjunction with a large scale mutagenesis screen, for mutants displaying hepatomegaly, which is 
a hallmark of many liver diseases (Sadler et al., 2005). They identified three mutants displaying 
signs of hepatic pathology. The mutant for the tumor suppressor nf2 (neurofibromatosis2) 
displays type I and type II choledochal cysts. The fgr-mutant (foie gras) showed defects 
resembling non-alcoholic steatohepatitis (NASH, hepatocyte enlargement, steatosis and death), 
but displayed no signs of hepatic inflammation. Pigmentation defects, hepatomegaly and biliary 
paucity were observed in the third mutant, the mutant for vps18. The pigmentation defects and 
the hepatomegaly might be caused by the failure of targeting endosomes to pigment granules in 
melanocytes and to lysosomes in hepatocytes. 
The congenital metabolic disease ARC syndrome comprises the disorders arthrogryposis (joint 
contractures), renal dysfunction (wasting of sugars and amino acids in the urine) and cholestasis 
(reduced bile flow). Other defects observed in ARC are lipid malabsorption, diarrhea, poor 
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growth, dysmorphic facial features, reduced motor neuron density, ichthyosis and platelet defects 
(Eastham et al., 2001). Most cases of ARC-syndrome are caused by mutations in the VPS33B 
gene, an otholog of the yeast class C vacuolar protein sorting protein Vps33p. Hepatic defects 
observed in ARC-syndrome comprise hepatomegaly, severely reduced intrahepatic bile flow 
(cholestasis) associated with mislocalisation of canalicular markers, biliary paucity (hypoplastic 
peripheral biliary radicles), hepatocyte giant-cell transformation and intrahepatocyte pigment 
accumulation (Gissen et al., 2004, Gissen et al., 2006, Horslen et al., 1994). 
Matthews et al. analysed the kd phenotype of zebrafish vps33b and found that the morphants 
display a phenotype in line with a partial phenocopy of the digestive defects in ARC-syndrome 
(Matthews et al., 2005). They determined the expression patterns of vps33b by whole-mount in 
situ hybridisation. At early stages vps33b is broadly expressed. Beginning with 48 hpf the 
expression patterns becomes more restricted to the brain, retina, ear, liver and proximal intestine. 
The reticular pattern of vps33b expression in the liver suggested expression predominantly in 
biliary epithelial cells. Electron micrographs showed a disrupted ultrastructure of biliary 
epithelial cells and the accumulation of vesicles in their cytoplasm. Keratin 18 immunostaining of 
livers revealed a reduction in the terminal branches of the biliary tree, a reduction in interhepatic 
interconnecting ducts and terminal ductules in the morphants. Ultrastructural defects also have 
been observed in enterocytes, which display Golgi abnormalities and accumulation of 
cytoplasmic vesicles. Furthermore labelling experiments using a fluorescent lipid (AM1-43) used 
to track exocytosis showed evidence of altered vesicle transport in enterocytes. The defects 
observed in biliary epithelial cells and in enterocytes point to a defect in intracellular trafficking. 
PED6 is a fluorescent phospholipid, which green fluorescence is quenched until the quencher is 
cleaved off by the intestinal enzyme phospholipase A2. Processed PED6 accumulates in the 
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intestine and in the gall bladder via the hepatobiliay system. The PED6 assay can be used in 
zebrafish to visualise biliary morphology, and to test biliary secretion and intestinal lipid 
absorption. Zebrafish vps33b-morphants display reduced PED6 fluorescence in the gall bladder. 
The observed biliary and intestinal defects probably both contribute to the PED6 phenotype. 
5.2 Aims 
It was one of my personal objectives for my PhD, to receive training and gain experience in using 
zebrafish as a model to study genes linked to lipid-metabolism and metabolic disorders, like 
pparγ. A collaborative project with the group of Paul Gissen (University of Birmingham) offered 
an opportunity to generate a zebrafish model for a metabolic disease, ARC-syndrome. 
A human VPS33B interacting protein, identified by yeast two-hybrid assay, was found to be the 
causative mutation in patients with classical ARC without mutations in VPS33B. This gene was 
named VIPAR (VPS33b-interacting protein involved in polarity and apical protein restriction). In 
his PhD-project Andrew R. Cullinane (Paul Gissen-group, University of Birmingham) 
functionally characterised this new gene and placed it in a novel intracellular trafficking pathway 
together with VPS33B and Rab11a. This pathway is required for normal epithelial polarisation 
and development in liver and kidney. We chose zebrafish to test the cell culture and ARC-patient 
data based finding that VIPAR and VPS33b act in the same pathway, which is disrupted in the 
pathogenesis of ARC-syndrome, in an in vivo model. We functionally characterised the zebrafish 
vipar LOF-phenotype in comparison to the published vps33b LOF-phenotype (Matthews et al., 
2005) in collaboration with the Gissen-group. Similarities of the phenotypes would argue for both 
genes playing a role in the same pathway, in support of the findings of Andrew R. Cullinane. 
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Furthermore the work on vipar would additionally to the work on pparγ explore the suitability of 
zebrafish as a model for genes linked to lipid-metabolism and metabolic diseases. 
Major aims and questions to answer by this study were: 
1. What are the expression patterns of vipar? Are they overlapping with the expression 
patterns of vps33b? 
2. What is the effect of LOF of vipar on lipid-metabolism and biliary development? 
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5.3 Results 
First we determined the expression patterns of vipar-mRNA by whole-mount in situ 
hybridisation. The vipar message is broadly expressed at embryonic stages and later becomes 
more restricted. At 5 dpf there is substantial expression of vipar in the liver, intestine and also 
pancreas (Figure 5.1). The expression patterns of vipar and vps33b overlap during embryonic and 
early larval stages. 
We performed MO-mediated kd experiments of vipar, by injections of MOs targeting the ATG 
and the splice site for exon 3 into one cell stage embryos. At a concentration of 100 µM in the 
injection solution the vipar ATG MO caused a severe growth defect phenotype (data not shown). 
At a concentration of 10 µM (ATG MO) and 100 µM (Exon 3 MO) the targeting MOs caused a 
milder phenotype compatible with a partial phenocopy of ARC-syndrome at 5 dpf. 
Like the vps33b-morphant the vipar-morphants display defects resembling the digestive and 
hepatobiliary defects observed in ARC (Figure 5.1). The terminal part of the intrahepatic biliary 
tree is underdeveloped in vipar-morphants and they accumulate less PED6 through the 
hepatobiliary system in their gall bladders than control MO injected and non-injected larvae 
(Figure 5.1). Additionally, decreased expression of the adherens junction protein E-cadherin was 
observed by immunohistochemistry in livers of vipar-morphants, similar to what was observed in 
the livers of ARC-patients (Figure 5.1). 
The similarities between the defects observed in vipar/vps33b morphants and the hepatobiliary 
defects observed in ARC-patients are in line with the finding of Andrew R. Cullinane, that a 
(conserved) VPS33b/VIPAR-complex plays a role in the hepatopathology of ARC syndrome. 
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Figure 5.1 – Phenotype for vipar resembles hepatobiliary defects of ARC 
A) Brightfield and green fluorescence images of PED6-treated non-injected and vipar ATG MO injected 5 dpf 
larvae. Liver (white arrow), swim bladder (white arrowhead) and gallbladder (red arrowhead) are indicated. B) Bar 
chart showing that the size of the gall bladder in side views is significantly smaller in ATG and Exon3 MO injected 
larvae than in non-injected control larvae, or in control MO injected larvae. Co-injection of vipar-mRNA but not an 
unrelated RNA (RFP) rescued the phenotype (n = 90 for each treatment group (3 independent injections with 30 
larvae in each clutch); error bars, ± 1 s.d., *P<.0.001 by z-test). C) Keratin 18 immunostaining (green fluorescence) 
of livers from 5 dpf vipar ATG MO injected and control MO injected larvae. D) Lateral and ventral views of 5 dpf 
wildtype larvae after WISH against vipar-mRNA using DIG-labelled antisense and sense (control) vipar RNA 
probes. Substantial expression in liver (L, outlined) and intestine (arrow) is seen. E) Immunostaining of 5 dpf larvae 
livers for E-cadherin showing markedly reduced E-cadherin staining in morpholino-injected larvae compared with 
controls. Scale bars, 200 µm (A, D), 50 µm (C) or 10 µm (E). The immunostainings and imaging in C and E were 
performed by Anna Straatman-Iwanowska and Andrew R. Cullinane (Gissen group). 
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5.4 Discussion 
The work on the role of vipar during zebrafish development produced a zebrafish model for 
cholestasis. The morphant phenotype for vipar was in line with a partial phenocopy of ARC-
syndrome. It would be interesting to test if the more severe phenotype observed after injection of 
a higher dose of vipar MO is rescuable with vipar-mRNA. The more severe phenotype might 
display features of ARC, which are not found in the mild phenotype. Another interesting question 
is whether vipar is also regulated by hnf6 and its downstream target vhnf1, like it was shown for 
vps33b. 
The vipar-morphants display hepatobiliary defects reminiscent of the ones observed in ARC-
patients. The morphants show reduced numbers of terminal branches of intrahepatic bile ducts 
and they have smaller gall bladders in side views. This suggests that the filling state of the gall 
bladder differs between morphants and controls, presumeably due to reduced excretion of PED6 
into the gall bladder. However, it cannot be excluded that the gall bladder is underdeveloped. In 
that respect the vipar-morphants differ slightly from the vps33b-morphants, which display a 
reduced intensity of the PED6 fluorescence in the gall bladder. Overall morphology of the larvae 
and the liver size between morphants and controls used for the vipar experiments were 
comparable. 
The cause of the reduced PED6 accumulation in the gall bladders of vipar-morphants is not 
entirely clear. The PED6-assay does not distinguish between a defective lipid absorption in the 
intestine and defective excretion through the hepatobiliary system. There is some evidence for 
lipid malabsorption in vps33b-morphants. Electron micrographs revealed Golgi abnormalities and 
the accumulation of cytoplasmic vesicles in vps33b-morphant enterocytes. After ingestion of a 
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fluorescent lipid (AM1-43), more fluorescent vesicles were seen in the cytoplasm of vps33b-
morphant enterocytes than in the cytoplasm of wildtypes. These findings suggest that lipid 
malabsorption contributes to the PED6 phenotype in vps33b-morphants and likely also in vipar-
morphants. 
A number of hepatopathologies are observed in ARC. A hallmark of ARC is the mis-sorting of 
apical proteins in polarised cells of the liver. If there is mis-sorting of apical proteins in the livers 
of vipar or vps33b morphants was not investigated. Interestingly the zebrafish vps18-mutant 
displays mis-sorting of the canalicular marker MDR-1 (multi drug resistance, member 1) (Sadler 
et al., 2005). Like in the livers of ARC-patients the expression of the adherens junction protein E-
cadherin is severely reduced in the livers of vipar-morphants. The observed reduced 
immunodetection of E-cadherin in the AJC (apical junction complex) of hepatocytes cannot 
directly be attributed to a defect in intracellular trafficking, because it is due to reduced 
transcription of E-cadherin. However, vps33b-morphants display accumulation of cytoplasmic 
vesicles, which points to defective intracellular trafficking. 
Injection of the vipar ATG MO at concentration of 10 μM in the injection solution induced a 
specific hepatobiliary phenotype, while at a concentration of 100 μM in induces a severe growth 
arrest phenotype. A similar phenomenon has been observed for the MO-mediated knock down of 
vps18. Injection of the lower dose of vps18 MO induced a hepatomegaly, while a higher dose 
caused global developmental defects and albinism. The vps18-mutant displayed a compound 
phenotype, with hepatomegaly and albinism. The stronger developmental defects could be 
explained with an additionally effect by knocking down the maternal transcript. These findings 
suggest that the vps18-morphants displayed a dose-dependent degree of severity of a specific 
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phenotype. The same might be true for the vipar-morphants, but a mutant as a reference was not 
available. 
Other features of ARC are renal dysfunction and motor axon defects. Neither kidney defects nor 
motor neuron defects were obvious in vipar- and vps33b-morphants. The motoric behaviour of 
vipar-morphants did not differ from that of controls. Kidney function in the morphant larvae 
could not be addressed, because of a lack of suitable assays. It would be interesting to test the 
presence of platelet defects in the morphants. An assay to test the function of zebrafish 
thrombocytes has been developed (Jagadeeswaran et al., 2005). 
5.5 Conclusions 
1. Analysis of the expression patterns of vipar revealed a ubiquitous expression of vipar at    
Prim-5 stage (24 hpf). The 5 dpf expression patterns are more restricted, with substantial 
expression in liver and intestine. The observed expression patterns for vipar resemble the ones 
described for vps33b. 
2. The characterisation of the vipar-morphants revealed a role of vipar in biliary development. 
Knock down of vipar causes a reduction of the terminal branches of the intrahepatic biliary tree. 
We demonstrated that a lower volume of the fluorescent lipid reporter PED6 accumulates in the 
gall bladders of vipar-morphants, which suggests a defect in bile secretion in vipar-morphants. 
 
  
196 
 
6 Development of a method to culture and transplant 
stage I and stage II oocytes to allow manipulation 
of maternal gene products 
6.1 Introduction and Overview 
During my PhD I have recognised how interference with zygotic gene activity may only partially 
address the function of genes during development and the importance to study the contribution of 
maternal gene products to zebrafish embryonic development. However, to interfere with maternal 
gene function remains a technically challenging task. The difficulty in inhibiting maternal genes, 
contributes to our lack of understanding of the degree of maternal contribution to embryo 
development. 
Early zebrafish development until the MBT is almost entirely driven by maternal factors. Besides 
supporting all basic cellular functions those maternal factors are also involved in processes like 
fertilisation, egg activation, the first cell divisions and the ZGA. Maternal factors also contribute 
to the establishment of the axes in zebrafish embryos: The animal-vegetal axis (Marlow and 
Mullins, 2008), the dorsal-ventral axis (Lu et al., 2011) and anterior-posterior axis (Pelegri, 
2003). But maternal contribution to development reaches far beyond the MBT. Most of the 
maternal mutant phenotypes manifest at post MBT stages, although they might be initiated at 
earlier stages (Wagner et al., 2004). There are numerous examples for maternal zygotic (MZ) 
mutants, which display a more severe phenotype than the zygotic mutant or the maternal mutant 
alone: For example the MZ mutant oep (one-eyed pinhead), pou5f1 (POU domain, class 5, 
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transcription factor 1), gart (phosphoribosylglycinamide formyltransferase) and paics 
(phosphoribosylaminoimidazole succinocarboxamide synthetase) (Gritsman et al., 1999, Lunde et 
al., 2004, Ng et al., 2009) all show dramatically enhanced phenotypes as compared to the zygotic 
counterparts. 
There are several strategies used in zebrafish to generate maternal mutants. Maternal mutants can 
be obtained simply by inbreeding, of homozygous zygotic mutants when those are viable. This 
strategy was applied in a four-generation maternal-effect mutant screen carried out in the lab of 
Mary C. Mullins ((Dosch et al., 2004, Wagner et al., 2004). If homozygous zygotic mutants are 
not viable, the generation of maternal mutants is still possible in some cases. Maternal mutants 
for genes required for early development can be obtained by rescue of early phenotypes by 
microinjection of synthetic wildtype mRNA (Gritsman et al., 1999). If the zygotic phenotype is 
not rescuable by mRNA injection the generation of a maternal mutant is more complicated. In 
those cases a PGC (primordial germ cell) replacement method can be used to generate chimeric 
fish with a mutant germline in a wildtype background (Ciruna et al., 2002), which then generates 
functionally null mutant gametes in the mother. 
The above mentioned methods are either not applicable for all genes (rescue of zygotic mutants 
and imbreeding) or are time consuming and tedious (PGC-replacement). Therefore there is a need 
for new methods to interfere with maternal gene function, which circumvent the need of a zygotic 
mutant as a prerequisite and which are easily applicable to all genes. 
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6.2 Aims 
Antisense technologies using MOs or RNAi are universally applicable to interfere with gene 
function. Many maternal RNAs and proteins are produced during early stages of oogenesis, in 
stages I and II (Pelegri, 2003). Thus, to utilise antisense effectors to efficiently block maternal 
genes they need to be introduced into early stage oocytes. In collaboration with Zsolt Csenki we 
aimed to establish an early stage oocyte transplantation protocol as a prerequisite to interfere with 
maternal gene function in the oocytes. In those experiments we addressed the following 
questions: 
1. Can stage I-II oocytes be recovered and transplanted into the ovary of recipient mothers? 
2. Do those transplanted oocytes resume and complete oogenesis? Can viable embryos be 
obtained by oocyte transplantation? 
3. Can this transplantation protocol be used as a tool to interfere with maternal gene 
function? 
6.3 Results 
This work composed part of the PhD-project of Zsolt Csenki. A substantial part of this work was 
carried out during visits of Zsolt in the ITG (Institute of Toxicology and Genetics) at the KIT 
(Karlsruhe Institute of Technology). The below described results were the outcome of my joint 
work with Zsolt in the ITG. I isolated oocytes for transplantations and microinjections and I 
performed whole-mount in situ analysis of expression of reporter and endogenous gene products 
in ovaries. 
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First we asked whether early stage oocytes can be transplanted into recipient females. We 
transplanted YFP-positive stage I-II follicles, dissected from transgenic donor females with 
ubiquitous YFP expression (bactin:yfp), into the ovaries of YFP-negative wildtype recipient 
mothers. The YFP transgene enabled us to monitor the fate of the transplanted follicles, because 
they can be distinguished from the non-transgenic follicles of the recipient mother by YFP-
fluorescence under a fluorescence microscope and by detection of the YFP-mRNA with WISH 
(Figure 6.1). 
We assessed the retention of transplanted early stage oocytes in the recipient ovaries at several 
time points after the transplantation (dpt, days post transplantation). The number of recovered 
transplanted follicles is initially high, 47.5% (171/360) at 1 dpt, but steadily drops with further 
days post transplantation. At 14 dpt just 2.6% (9/350) of transplanted oocytes were recovered. 
We then investigated whether the transplanted oocytes fully integrate into the recipient ovaries 
and continue with oogenesis. We hypothesised that the transplanted oocytes (follicles) would 
increase in size, if they continued with oogenesis after transplantation. To test that hypothesis we 
measured the diameter of follicles before transplantation and compared it to the diameter of 
transplanted follicles, recovered at certain time points post transplantation. Follicle diameter is 
commonly used for staging of oocytes (Selman et al., 1993). Follicles matching the histological 
and the size criteria for stage III follicles were recovered at 1 week and 2 weeks after 
transplantation of stage I follicles. This suggests that transplanted follicles can integrate into 
recipient ovaries and continue with oogenesis. 
Finally, we asked whether normally developing embryos can be obtained from transplanted 
oocytes. We injected 10 recipient females with up to 100 stage I follicles and mated them weekly 
with wildtype males over a course of six weeks. Four YFP-positive embryos were obtained from 
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the 3rd and 4th week’s matings. Microsatellite marker analysis confirmed that those embryos’ 
maternal genome was derived from the donor females and not from the recipient mothers. 
We also addressed the question, if the oocytes can be microinjected prior to transplantation. 
Microinjetion is a widely used method in zebrafish, to introduce molecules interfering with gene 
function, like MOs. We injected stage I and II oocytes with mRNA encoding for DsRed, a red 
fluorescent protein. DsRed-fluorescence was observed in 10.3% (5/58) of DsRed-mRNA injected 
oocytes, after one day of in vitro incubation in agarose-plates with Ringer solution. We also 
recovered microinjected and then transplanted oocytes (YFP- and DsRed-positive) one day after 
transplantation from recipient mothers. 
 
Figure 6.1 – Recovery of transplanted follicles from recipient ovaries 
Dark field (left), YFP filter view (middle) and whole-mount in situ analysis against YFP-mRNA 
of ovaries which are specified by the labels of the rows. Transgenic, YFP-positive donor follicles 
are yellowish green in YFP filter view and purple in the whole-mount in situ hybridisation 
analysis, while no YFP-signal is detected in ovaries from wildtypes which not have be subjected 
to transplantation. 
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6.4 Discussion 
In collaboration with Zsolt Cenki we developed a transplantation protocol for early stage oocytes 
into surrogate mothers. With a very low frequency, viable embryos from those transplanted 
oocytes were obtained, which later developed into fertile adults. Furthermore we showed that it is 
possible to microinject the oocytes prior to transplantation. The combination of microinjection 
and transplantation could be further developed into an experimental tool to block maternal 
factors, if the recovery rate of embryos from transplanted oocytes can be improved. 
The milder zygotic phenotypes of many zebrafish genes compared to their mouse counterparts 
enables zebrafish researchers to study the role of those genes in developmental processes, which 
cannot be studied in the more severe mouse ko phenotypes. On the other hand it is very likely 
that many zygotic mutant phenotypes are not full LOF-phenotypes. Because only maternal 
mRNA, not maternal protein, can be efficiently targeted with MOs, the same might be true for 
many morphants. This is a major problem for studies where phenotypes for different zebrafish 
genes are compared to each other, like in our MO-screen (see chapter 3). Without assessing 
maternal contribution it is not clear, whether differences, especially in the severity of phenotypes, 
are due to differential maternal contribution, or due to differential gene function. Methods to 
interrogate maternal contribution to development, easily applicable to all genes, would help to 
resolve such issues. The early stage oocyte transplantation protocol might be developed into such 
a method. 
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6.5 Conclusions 
1. Using a novel transplantation protocol we demonstrated that stage I-II oocytes derived from 
donor females can be transplanted into surrogate mothers. 
2. Some of the transplanted oocytes fully integrate into the ovary of the surrogate mothers and 
continue with oogenesis. With a very low frequency, viable, normal developing embryos were 
recovered from transplanted oocytes. 
3. The recovery rate of embryos from transplanted oocytes needs to be improved to develop the 
transplantation protocol further, into a method to study maternal gene function in oocyte and 
embryonic development. 
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7 Appendices 
7.1 Tables from microarray analysis 
The results from the enrichment analysis of the microarray data using the DAVID functional 
annotation tool can be retrieved as tables. Those tables contain following information: 
1. Category 
The category is the term-based annotation system (database, resource) within which the 
enrichment analysis is performed by the tool. 
2.  Term 
In this column the enriched terms associated with the analysed gene lists are listed. 
3. Count 
The number in this column is the number of genes in the analysed list, which are involved 
in the respective term. 
4. % 
This is the percentage of genes in List Total which are involved in the respective term. 
5. Genes 
Here the individual genes involved in the respective term are listed. Because of space 
limitations they were not included into the tables of this thesis. 
6. List Total 
The number in this column is the total number of genes which are involved in at least one 
of the terms in the category. 
7. Pop Hits 
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Pop Hits contains the number of genes involved in the respective term within the specific 
background for the analysis. 
8. Pop Total 
The DAVID tool applies a dynamic background. The background for microarray analysis 
using DAVI Functional Annotation tool was all genes on the microarray. Pop Total is the 
specific background for calculations within the specific category. For example all genes 
on the microarray which are involved in at least one of the terms in the category KEGG 
pathways. 
9. P-value 
The p-value is derived from a modified Fisher Exact test (EASE Score) to test the 
significance of the enrichment of terms within gene lists. The cut-off applied by the 
default setting to include a term is ≤0.1. The p-value is calculated by comparing the 
enrichment of Count in List Total to the enrichment of Pop Hits in Pop Total using the 
modified Fisher Exact test. 
10. Fold Enrichment 
The fold enrichment is the observed enrichment over the enrichment by chance. 
11. Bonferroni, Benjamini(-Hochberg) and FDR (False Discovery Rate) 
These are additional standard statistics provided for the assessment of the significance of 
the results from the enrichment analysis. 
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Table 7.1 – Anatomical terms enriched in Taf8down 
Term Count % P-value 
List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment Bonferroni Benjamini FDR 
intestinal bulb 16 15.1 2.80E-10 70 173 6366 8.4109 2.66E-08 2.66E-08 3.08E-07 
pancreas 12 11.3 4.47E-08 70 119 6366 9.170708 4.25E-06 2.12E-06 4.92E-05 
exocrine pancreas 6 5.7 1.77E-06 70 20 6366 27.28286 1.68E-04 5.59E-05 0.001941 
liver 22 20.8 2.42E-06 70 646 6366 3.097125 2.29E-04 5.74E-05 0.002655 
pronephric proximal 
straight tubule 3 2.8 0.004926 70 10 6366 27.28286 0.374456 0.089559 5.283444 
pronephric proximal 
convoluted tubule 3 2.8 0.005979 70 11 6366 24.8026 0.434297 0.09058 6.379048 
gut 10 9.4 0.024315 70 391 6366 2.325904 0.903528 0.283998 23.7062 
lens 8 7.5 0.04881 70 309 6366 2.354508 0.991383 0.448021 42.30857 
retinal photoreceptor 
layer 4 3.8 0.057136 70 81 6366 4.491005 0.996262 0.462604 47.62288 
lens vesicle 7 6.6 0.060716 70 259 6366 2.457915 0.997396 0.448468 49.76781 
fat cell 2 1.9 0.06332 70 6 6366 30.31429 0.997999 0.431604 51.27763 
 
Table 7.2 – Anatomical terms enriched in Taf6down 
Term Count % P-value 
List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment Bonferroni Benjamini FDR 
intestinal bulb 37 19.8 4.35E-26 142 173 6366 9.588129936 9.05E-24 9.05E-24 5.49E-23 
liver 44 23.5 1.13E-11 142 646 6366 3.053503685 2.36E-09 1.18E-09 1.43E-08 
retinal photoreceptor 
layer 14 7.5 1.83E-08 142 81 6366 7.748565467 3.81E-06 1.27E-06 2.31E-05 
retinal cone cell 7 3.7 1.07E-06 142 17 6366 18.45981773 2.24E-04 5.59E-05 0.001356 
gut 25 13.4 4.00E-06 142 391 6366 2.866431325 8.31E-04 1.66E-04 0.005041 
pancreas 13 7.0 1.09E-05 142 119 6366 4.897502663 0.0022615 3.77E-04 0.01373 
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retinal outer nuclear 
layer 6 3.2 5.89E-05 142 20 6366 13.44929577 0.0121727 0.0017481 0.074248 
eye 25 13.4 7.69E-04 142 544 6366 2.060247514 0.1479221 0.0198108 0.966112 
exocrine pancreas 5 2.7 8.48E-04 142 20 6366 11.20774648 0.1617303 0.0194108 1.064191 
pronephric proximal 
straight tubule 4 2.1 0.001139 142 10 6366 17.93239437 0.21101 0.0234215 1.427047 
pronephric proximal 
convoluted tubule 4 2.1 0.001541 142 11 6366 16.3021767 0.274343 0.0287317 1.926003 
YSL 19 10.2 0.002831 142 398 6366 2.140172694 0.4455317 0.0479574 3.513385 
epiphysis 16 8.6 0.003625 142 312 6366 2.299024919 0.5302103 0.0564568 4.478274 
retina 30 16.0 0.017006 142 882 6366 1.524863467 0.9717759 0.2249494 19.4555 
intestine 8 4.3 0.029788 142 135 6366 2.656651017 0.9981452 0.3425139 31.71389 
gill 8 4.3 0.059054 142 157 6366 2.284381448 0.9999968 0.5467454 53.5982 
stratum fibrosum et 
griseum superficiale 2 1.1 0.064996 142 3 6366 29.88732394 0.9999992 0.5605647 57.16199 
 
Table 7.3 – Anatomical terms enriched in Taf8up 
Term Count % P-value 
List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment Bonferroni Benjamini FDR 
musculature system 6 17.1 7.86E-04 27 185 6366 7.646847 0.090727 0.090727 0.899598 
pharynx 5 14.3 0.002885 27 149 6366 7.912006 0.295013 0.160365 3.266868 
sternohyoid 2 5.7 0.016241 27 4 6366 117.8889 0.862106 0.483367 17.15891 
gut 6 17.1 0.019195 27 391 6366 3.618073 0.904175 0.443622 19.97469 
epidermal superficial 
stratum 2 5.7 0.028255 27 7 6366 67.36508 0.968822 0.50023 28.07228 
liver 7 20.0 0.042052 27 646 6366 2.554868 0.994474 0.579532 38.97629 
pharyngeal arch 5 14.3 0.044214 27 333 6366 3.540207 0.995796 0.542367 40.54164 
proliferative region 3 8.6 0.04557 27 84 6366 8.420635 0.99646 0.506109 41.50375 
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somite 7 20.0 0.087047 27 774 6366 2.132357 0.999984 0.706065 64.90111 
fast muscle cell 2 5.7 0.089983 27 23 6366 20.50242 0.999989 0.68048 66.17728 
epidermis 4 11.4 0.096562 27 271 6366 3.480115 0.999995 0.672747 68.88397 
 
Table 7.4 – Anatomical terms enriched in Taf6up 
Term Count % P-value 
List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment Bonferroni Benjamini FDR 
mesoderm 5 45.5 2.35E-05 7 230 6366 19.770186 0.0011051 0.0011051 0.0223423 
presumptive blood 3 27.3 1.00E-04 7 17 6366 160.48739 0.004692 0.0023488 0.0949993 
sternohyoid 2 18.2 0.003765 7 4 6366 454.71429 0.1624855 0.0573927 3.5199407 
intermediate cell 
mass of mesoderm 3 27.3 0.005534 7 126 6366 21.653061 0.2295839 0.0631257 5.1344804 
blood 3 27.3 0.006424 7 136 6366 20.060924 0.261327 0.0587815 5.9377038 
nucleate erythrocyte 2 18.2 0.008455 7 9 6366 202.09524 0.3290894 0.0643557 7.7490721 
fast muscle cell 2 18.2 0.021491 7 23 6366 79.080745 0.6398004 0.1357308 18.645411 
blood island 2 18.2 0.027033 7 29 6366 62.719212 0.7242 0.1487164 22.918529 
axial chorda 
mesoderm 2 18.2 0.061533 7 67 6366 27.147122 0.9494535 0.2822625 45.294682 
hypaxial myotome 
region 2 18.2 0.069552 7 76 6366 23.932331 0.9662317 0.2873915 49.577162 
 
Table 7.5 – Pathways enriched in Taf8down 
Term Count % P-value 
List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment Bonferroni Benjamini FDR 
dre03320:PPAR 
signaling pathway 4 3.8 0.006083 27 36 2439 10.03704 0.1923 0.1923 5.261333 
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Table 7.6 – Pathways enriched in Taf6down 
Term Count % P-value 
List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment Bonferroni Benjamini FDR 
dre03320:PPAR 
signaling pathway 6 3.2 9.86E-04 55 36 2439 7.3909091 0.059351 0.0593511 0.990947 
dre00982:Drug 
metabolism 4 2.1 0.003867 55 15 2439 11.825455 0.213576 0.1131946 3.835134 
dre00980:   
Metabolism of 
xenobiotics by 
cytochrome P450 4 2.1 0.004686 55 16 2439 11.086364 0.252651 0.0925115 4.629537 
dre00591:Linoleic 
acid metabolism 3 1.6 0.023287 55 11 2439 12.094215 0.767977 0.3059632 21.16306 
dre00520:Amino 
sugar and nucleotide 
sugar metabolism 4 2.1 0.040761 55 35 2439 5.0680519 0.924237 0.4031151 34.29281 
dre00260:Glycine, 
serine and threonine 
metabolism 3 1.6 0.070900 55 20 2439 6.6518182 0.989532 0.5322925 52.39002 
dre00140:Steroid 
hormone biosynthesis 3 1.6 0.077280 55 21 2439 6.3350649 0.993171 0.5095257 55.58808 
dre00250:Alanine, 
aspartate and 
glutamate 
metabolism 3 1.6 0.083835 55 22 2439 6.0471074 0.995611 0.4926658 58.67100 
 
Table 7.7 – Pathways enriched in Taf8up 
Term Count % P-value 
List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment Bonferroni Benjamini FDR 
dre04115:p53 
signaling pathway 3 8.6 0.006307 8 44 2439 20.786932 0.096284 0.096284 4.3939237 
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dre04110:Cell cycle 3 8.6 0.024537 8 89 2439 10.276685 0.328002 0.180245 16.173748 
dre04010:MAPK 
signaling pathway 3 8.6 0.067443 8 154 2439 5.9391234 0.672805 0.310921 39.094802 
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